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The experimental work described in this Thesis has been mainly focused on 
the study of the regulation of viral gene expression, in two different 
members of the Retroviridae family, namely the lentivirus HIV-1 and the 
gammaretrovirus MoMLV.  
The results are divided into two parts, Part A and Part B.  
 
The work reported in Part A gives critical clues for the  comprehension of 
the still obscure mechanisms that regulate function of the HIV-1 
transactivator Tat in the initiation and elongation of HIV-1 transcription. In 
particular, we exploited a proteomic screening aimed at characterizing 
novel Tat partners. This approach allowed us to identify the cellular histone 
chaperone NAP-1 (Nucleosome Assembly Protein-1) as a Tat-binding 
protein. We found that this interaction exerts a positive role on Tat-driven 
LTR transactivation and on HIV-1 infection. To our knowledge, this is the 
first demonstration of an interaction between Tat and a cellular histone 
chaperone. We propose a mechanism by which Tat benefits from this class 
of proteins to relieve the repression imposed by chromatin conformation on 
proviral transcription.  
 
The findings described in Part B are part of an ongoing project, that we 
derived from our previous observation that HIV-1 transcription is also 
regulated by long-range chromatin interactions. In particular, we originally 
found that a gene loop structure is imposed on the provirus upon 
transcriptional activation. We now show that MoMLV also adopts a 
transcription-dependent LTR-LTR gene loop conformation. This observation 
leads us to hypothesize that gene looping might be a general hallmark of 
retroviral transcription. Moreover, we also demonstrate that  an aberrant 
loop might form between the retroviral MoMLV LTRs and regulatory regions 
of the host cell genome. We suggest that this event might be at the basis 
of the phenomenon of  insertional mutagenesis observed in some of the 
gene therapy clinical trials that so far have exploited members of the 

















1A.  INTRODUCTION 
 
 
1.1 REPLICATION CYCLE OF HIV-1: AN OVERVIEW 
 
All viruses belonging to the Retroviridae family are characterized by an RNA 
genome that is converted to a cDNA intermediate during the viral life cycle. 
The reverse transcription of the viral RNA is the defining hallmark of the 
retroviruses, the step from which these viruses owe their name. The 
genome contains three essential genes common to all the members of the 
family, gag, pol and env, encoding for both structural and enzymatic 
proteins required for the whole viral life cycle. Seven genera of Retroviridae 
family have been defined on the basis of genome structure and nucleotide 
sequence relationships.  
The Human Immunodeficiency Virus type 1 (HIV-1) belongs to the 
Lentivirus genus. Since the isolation and the identification of HIV-1 as the 
etiologic agent of the Acquired Immuno-Deficiency Syndrome in the early 
‘80s (Barre-Sinoussi et al., 1983; Popovic et al., 1984), a remarkable body 
of knowledge has accumulated about the mechanisms of retroviral 
infections and pathogenesis of the retrovirus-induced diseases. 
Nothwistanding this progress, HIV-1 still remains a major threat to public 
health and a challenge for drug and vaccine development, due to several 
reasons related to the biology of the cells that are the target of HIV-1 and 
to the life cycle of the virus itself. 
The viral genome consists of two RNA molecules, each approximately 10 
kb-long (Alizon et al., 1984), harboring, besides the gag, pol and env 
genes, a number of genes that are specific for HIV-1:  the two regulatory 
genes tat and rev, and four other accessory genes, namely vif, vpr, vpu 
and nef.  
The gag, pol and env gene products are synthesized as single polyproteins 
and later processed, the first two by the viral protease and the last by a 
cellular protease. The gag gene encodes for the structural core proteins 
(capsid, nucleocapsid) and the matrix protein of the viral particle; the env 
gene encodes for the glycoproteins gp120 and gp41, that are embedded in 
the phospholipidic viral envelope; the pol gene encodes for the enzymes 
Reverse Transcriptase, Integrase and Protease, crucial for viral replication. 
The auxiliary genes render HIV-1 a very complex and sophisticated virus, 
allowing it to exhibit a vast number of regulatory pathways and remarkable 















Figure 1.1  Structure of the HIV-1 genome and functions of its 
encoded proteins (Adapted from Trkola, 2004). 
 
 
In recent years, the interplay between HIV-1 and its host cells has been 
extensively studied, unraveling the importance of several host factors for 
different steps in the viral life cycle. At the same time, strategies adopted 
by host cells to counteract the infection have been described, contributing 
to the view that the manifestation of a productive infection is the result of 
the balance of both pro-viral and anti-viral mechanisms. 
 
1.1.1  A road to the nucleus: entry, uncoating and reverse 
transcription 
HIV-1 infects primarily T helper lymphocytes, macrophages and, to some 
extent, microglial and dendritic cells. Entry into the host cells requires the 
expression of the CD4 receptor and fusion co-receptors, that are strain- 
and cell type specific (Kwong et al., 1998). Several chemokine receptors  
function as co-receptors for HIV-1, the best charachterized of which are the 
CC-chemokine receptor 5 (CCR5) and the CXC-chemokine receptor 4 
(CXCR4), expressed by T cells, mononuclear phagocytes and dendritic cells. 
Based on the ability to bind these molecules, HIV-1 can be divided into 
different strains: R5 strain (CCR5), X4 strain (CXCR4) or R5X4 (CCR5 and 
CXCR4). While R5 strain can be isolated throughout the natural course of 
human infection, X4 (which, of note, are ony 1-2% of the dualtropic X4R5) 
and X4R5 emerge later during disease progression (Doms and Trono, 
2000). Interestingly, and relevant for the mucosal transmission of the 
infection, the lectin-like receptor DC-SIGN (Dendritic Cell-Specific 
Intercellular adhesion molecule-3-Grabbing Non-integrin) was shown to be 
involved in the viral uptake from mucosal and skin dendritic cells, that can 
then vehicle the virus to T cells in the lymphnodes (Geijtenbeek et al., 
2000). 
The conformational change induced by the first interaction between gp120 
and CD4 promotes the binding to the co-receptor, eventually leading to 
viral entry by direct fusion with the plasma membrane (mediated by gp41) 
(Chan and Kim, 1998) or by endocytosis followed by glycoprotein- and 
dynamin-dependent fusion with intracellular compartments (Miyauchi et al., 
2009). 
The process leading from viral entry to uncoating is not completely 
understood, and apparently involves viral proteins, including p17 Matrix, 
Nef, Vif, as well as host proteins (Dvorin and Malim, 2003). Upon 
completion of uncoating, the reverse transcription complex is formed, 
composed of viral RNA, Reverse Transcriptase, Integrase, p17 Matrix, P7 
Nucleocapsid, Vpr and many cellular proteins. The course of reverse 
transcription is highly ordered and quite well-established, starts in the 
cytoplasm being completed in the nucleus, and involves the translocations 
of DNA intermediates resulting in the duplication of identical sequences 
(U3, R, U5) at both 5’ and 3’ ends of the final cDNA, the so-called “Long 
Terminal Repeats” (LTRs) (Gilboa et al., 1979). Products of reverse 
transcription are actively transported into the nucleus through the nuclear 
pores, consistent with the ability of the virus to also infect non-dividing 
cells, which is a hallmark of all lentiviruses (Bukrinsky, 2004). Double-
stranded viral DNAs are complexed with both viral (Integrase, 
Nucleocapsid, Matrix, Reverse Transcriptase and Vpr) and cellular proteins, 
in the Pre-Integration Complex (PIC). The molecular processes underlining 
the PIC entry into the nucleus remain elusive, nevertheless it seems 
reasonable that a redundancy of mechanisms exists, at least in part 
mediated by the Nuclear Localization Signals (NLS) that have been 
identified in most of the viral proteins of the PIC. Cellular protein partners, 
namely BAF (Barrier-to-Autointegration Factor), LEDGF (Lens Epithelium-
Derived Growth Factor)/p75, LAP2  (Lamin-Associated Polypeptide 2 ), 
importins, Ku helicase, HMG (High Mobility Group) proteins, TNPO3 
(Transportin-SR2) (Christ et al., 2008) are also involved in nuclear entry of 
the PIC and viral integration (for a comprehensive review, see (Suzuki and 
Craigie, 2007) and references therein).  
 
These early steps of viral replication appear to be the main targets for 
those host proteins, generally termed as “restriction factors”, that elicit an 
innate anti-viral response. Among these, TRIM5  was identified as the 
factor that blocks HIV-1 infection in simian cells (Stremlau et al., 2004). 
Since its discovery, many studies have tried to address the molecular 
mechanisms by which TRIM5  restricts HIV-1. It has been suggested that 
the blocks are at reverse transcription and nuclear import steps, 
nevertheless the anti-viral activity of TRIM5  still remains poorly 
understood. Interestingly, TRIM5  action was found to be dependent on 
the peptidyl-prolyl isomerase Cyclophilin A (and even a TRIM5-Cyp A fusion 
gene was cloned, created by retrotransposition of a CypA cDNA into the 
TRIM5 locus, (Sayah et al., 2004). Cyclophilin A has previously been 
reported to bind and to induce a conformational change of the HIV-1 
capsid protein, thus affecting its interactions with uncoating factors, with 
nuclear pore components as well as with restriction factors such as TRIM5  
(for comprehensive reviews, see (Luban, 2007; Towers, 2007). 
Another mechanism that can suppress HIV-1 replication is mediated by the 
apolipoprotein B mRNA-editing enzyme 3 family (APOBEC3) (Sheehy et al., 
2002). These are cytidine deaminases that hypermutate the viral genomes 
(although a deaminase-independent inhibition by APOBEC was also 
reported (Nguyen et al., 2007; Sasada et al., 2005), causing replication 
defects at multiple steps. In particular, APOBEC3G and APOBEC3F are 
those responsible for the pre-integration complex restriction.. HIV-1 Vif 
protein counteracts incorporation of APOBEC3G into viral particles mainly 
by recruiting an E3 ubiquitin ligase complex that targets APOBEC3G to 
proteasomal degradation (recently reviewed in (Goila-Gaur and Strebel, 
2008). 
 
1.1.2  HIV-1 in the nucleus: integration and transcription 
Once inside the nucleus, integration of the double-stranded viral DNA into 
the cellular genome is mediated by the Integrase protein, which binds the 
end of the viral DNA and catalyzes the subsequent joining reaction that 
establishes the HIV provirus within the host chromosome (Miller et al., 
1997). To accomplish its functions, both the tethering to chromatin and the 
completion of its enzymatic activity, Integrase requires several host factors, 
most of them already included in the PIC, such as LEDGF/p75 (Maertens et 
al., 2003), emerin (Jacque and Stevenson, 2006; Shun et al., 2007), BAF 
(Lin and Engelman, 2003), INtegrase Interactor 1 (INI1) (Kalpana et al., 
1994), HMGA1 (Farnet and Bushman, 1997). Interestingly, Integrase was 
also shown to be subject to different Post-Translational Modifications 
(PTMs), that variously affect its properties: acetylation mediated by the 
cellular Histone Acetyl-Transferase (HAT) p300 increases its affinity for 
DNA template (Cereseto et al., 2005), while ubiquitination reduces the 
stability of the protein (Mousnier et al., 2007); moreover, ubiquitination is 
prevented by phosphorylation and subsequent isomerization (Manganaro et 
al., submitted paper). 
Alternatively, if the viral DNA does not get integrated, it may follow three 
different fates: the ends of the viral DNA might be joined to form a 2-LTR 
circle; the viral genome might undergo homologous recombination resulting 
in a single LTR circle; viral DNA might auto-integrate into itself producing a 
rearranged circular structure. Notwithstanding that none of these variants 
produce infectious virus, they seem to be transcriptionally active, leading to 
selected transcription of tat and nef genes before integration (Wu and 
Marsh, 2001). Finally, it is worth mentioning that generation of these forms 
of circular DNA before integration, that can persist inside the cells, are 
related to the phenomenon referred to as pre-integration latency (Coiras et 
al., 2009; Lassen et al., 2004); (Zack et al., 1990). 
 
Although HIV-1 integration is not site-specific, several lines of evidence 
indicated that it is not completely random. Early in vitro studies using either 
purified Integrase protein or PICs isolated from freshly infected cells, 
revealed that not only the primary sequence of the acceptor DNA, but also 
its conformation altered by protein binding, might at least in part dictate 
the preference for certain sites of integration (Bor et al., 1995; Bor et al., 
1996). However, major insights into the study of retroviral integration, 
derived from the in vivo studies, which took advantage of Linker-Mediated 
PCR to amplify and then sequence hundreds of junctions between viral and 
human DNA in cultured cells upon acute infection with retroviruses or 
retroviral vectors. First, Carteau and collegues showed that in an acutely 
infected T cell line (SupT1), HIV-1 strongly disfavored centromeric alphoid 
repeats (Carteau et al., 1998), although it has been later demonstrated 
that integrations into heterochromatic regions can occur, and might be 
responsible of post-integration latency (Lewinski et al., 2005). Several 
other high-throughput studies, exploiting a broad range of cellular models, 
such as different T- and non T-cell lines, primary lymphocytes and resting 
CD4+ cells from infected individuals, revealed that HIV-1 preferentially 
integrates within active transcriptional units. This might turn to be an 
advantage for the virus, which can thus better exploit the cellular 
transcriptional machinery for the transcription of its own genes (Han et al., 
2004; Huang et al., 2007; Mitchell et al., 2004; Schroder et al., 2002). 
Interestingly, comparative analysis of integration sites of HIV-1 and other 
oncoretroviruses demonstrated that the mechanisms for integration site 
selection are peculiar for each retrovirus. In particular, Moloney Murine 
Leukemia Virus (MoMLV) integrates preferentially near the start site of 
transcriptionally active genes and near CpG islands, and targets Common 
Integration Sites (CISs) such as proto-oncogenes and growth-controlling 
genes, in a number of cellular models (Bushman et al., 2005; Cattoglio et 
al., 2007; Mitchell et al., 2004; Recchia et al., 2006; Wu et al., 2003). 
 Although the scenario is not still completely defined, and the viral 
determinants of the selection still remain elusive (even if a crucial role in 
tethering to chromatin has been ascribed to LEDGF/p75, (Maertens et al., 
2003)), what is clearly emerging is that the selection of sites for integration 
is strongly dependent on chromatin structure. Interestingly, the chromatin 
milieu encountered by the provirus also influences the levels of basal HIV-1 
gene expression, although this effect is by-passed upon Tat transactivation 
(Jordan et al., 2003; Jordan et al., 2001). Thus, chromatin environment at 
the site of integration might be one of the possible mechanisms underlying 
the establishment of post-integration latency, which refers to the lack of 
expression after the insertion of viral DNA into the host genome. In 
particular, one form of latency might result from proviral integration into 
regions of heterochromatin, where transcription is repressed (Coiras et al., 
2009; Han et al., 2004; Marcello, 2006; Williams and Greene, 2007).  
 
Once integrated into the host genome, the provirus acts as any human 
RNA Pol II-transcribed gene, with transcription proceeding from the 
promoter and enhancer elements present in the 5’ LTR, to the 
polyadenylation site comprised within the 3’ LTR. Regulation of HIV-1 gene 
expression involves a complex interplay between the local chromatin 
environment, cellular transcription factors, and the viral-encoded trans-
activating protein Tat. Early phases of transcription are mostly mediated by 
host transcription factors bound to the LTR, and allow the production of 
Tat, which in turn promotes an efficient initiation and a processive 
elongation of viral transcription. To fulfill its functions, Tat binds a hairpin 
structure present at the 5’ end of the nascent viral RNA, named Trans-
Activation-Responsive region (TAR), and establishes interactions with a 
vast amount of cellular partners, that eventually determine a stimulation of 
transcription. 
The mechanisms that underlie the control of HIV-1 gene expression are 
described in details in the Section 1.2 of this Thesis. 
 
Tat-mediated transcription leads to the generation of approximately thirty 
different viral transcripts from the provirus; 2 kb-long multiply spliced 
transcripts are predominant in the early phases of infection (encoding for 
Tat, Rev and Nef), while singly spliced RNAs of 4 kbs, and unspliced RNAs 
of 9 kbs become leading species later in infected cells. The first short 
transcripts are rapidly transported into the cytoplasm following the same 
pathway as cellular mRNAs (Cullen, 1998), while export to the cytoplasm of 
unspliced and partially spliced depends on the expression of the virally-
encoded Rev protein. This protein shuttles between nucleus and cytoplasm 
and binds the viral transcripts through the interaction with an RNA stem-
loop structure named RRE (Rev Responsive Element) located in the env 
gene (Malim et al., 1990). Rev binding to RRE determines the 
multimerization of the protein, and the following association with the 
cellular CRM-1 and Ran GTPase proteins. The nucleo-cytoplasmic gradient 
of GTP/GDP determines the translocation of the transcripts; indeed, the 
Rev/Crm-1/Ran-GTP complex, associated with viral RNA in the nucleus, 
interacts with the nuclear pore complex thus allowing nuclear export. Once 
in the cytoplasm, hydrolysis of GTP to GDP occurs, and causes the 
dissociation of the transcript, while  Rev returns into the nucleus by binding 
importin and Ran-GDP, for subsequent round of export (Cullen, 1998; 
Suhasini and Reddy, 2009). 
 
1.1.3  Late phases of HIV-1 infection: assembly, budding and 
maturation 
The late phases of HIV-1 life cycle are characterized by the assembly of 
new viral particles, their release from the plasma membrane and their 
maturation. HIV-1 assembly and release are triggered by the viral Gag 
precursor p55, from which the structural components of the viral core 
derive. Following its synthesis, p55 traffics to the host cell plasma 
membrane, and the pre-assembled virion buds from the lipid rafts, specific 
membrane sub-domains enriched in cholesterol. Interestingly, this is the 
same compartment in which the myristoylated form of the Nef protein is 
incorporated, being this a prerequisite for the biological activity of the 
protein itself (Geyer et al., 2001). Furthermore, it is worth mentioning the 
exception of primary macrophages, where HIV-1 buds into large 
intracellular vacuoles proposed to be late endosomes. In this way, HIV-1 
can be retained in an infectious state for prolonged period of times, being 
released in a delayed manner similarly to secretion of exosomes, and thus 
being important for pathogenesis (Morita and Sundquist, 2004). 
Several lines of evidence have suggested that HIV-1 requires different host 
factors to orchestrate its assembly and budding, such as components of the 
Endosomal Sorting Complex Required for Transport (ESCRT) (Garrus et al., 
2001; Martin-Serrano et al., 2001) and the apoptosis-linked-gene 2 
interacting protein (Alix) (Strack et al., 2003; von Schwedler et al., 2003). 
It is worth mentioning that cellular restriction factors inhibiting viral release 
(Tetherin and Calcium-modulating cyclophilin Ligand 1, CAML-1) have also 
been identified, and seem to be counteracted by the action of viral Vpu, 
through a still poorly understood mechanism (Neil et al., 2008; Varthakavi 
et al., 2008). 
Finally, the budding virion is subject to cleavage of the Gag precursor by 
the viral protease; the proteolytic activity ends when the virion is already 
detached from the host plasma membrane, and results in the formation of 





















Figure 1.2  A schematic overview of HIV-1 life cycle (Adapted from 













1.2  CONTROL OF HIV-1 GENE EXPRESSION 
 
The regulation of HIV-1 transcription is a complex event of significant 
pathological relevance, which recapitulates general concepts of cellular 
transcription with some peculiarities. The process of HIV-1 transcription can 
be subdivided into one of two distinct phases. The first phase is dependent 
on the HIV-1 LTR, since it contains a wide spectum of cis-acting consensus 
sites for several cellular transcription factors, that mediate early stages  of 
viral transcription (explained in details in Section 1.2.1). The second phase 
immediately follows, and relies on the Tat protein, encoded by the virus 
itself, synthesized in the course of the first phase. By the interaction with 
the TAR element and through a multiplicity of different mechanisms and 
interactors, Tat promotes efficient initiation and elongation of viral 
transcription (Section 1.2.2). In addition, a further level of HIV-1 
transcription regulation is related to the framework that controls general 
transcription of the host cells, both in terms of cellular factors distribution 
and availability, and in terms of nuclear positioning and/or long-range 
chromatin interactions established within viral sequences as well as 
between the provirus and host chromosomes (Section 1.2.3).   
 
 
1.2.1  The HIV-1 Long Terminal Repeat (LTR) promoter 
 
Cis-acting cellular factors binding the LTR 
LTRs are generated in their symmetrical configuration during the process of 
reverse transcription and so they appear as “repeats” only in the viral DNA. 
In the context of integrated viral DNA, the major function of the LTR is the 
regulation of viral RNA synthesis. Different experimental approaches, such 
as mutagenesis of LTR-driven reporter genes in transfection experiments, 
as well as DNA footprinting and Electrophoretic Mobility Shift Assays 
(EMSAs), have led to the identification of several binding sites for nuclear 
proteins within the LTR (Gaynor, 1992) and reviewed in (Pereira et al., 
2000). 
HIV-1 expression relies on a single transcript, which can be multiply spliced 
or left unspliced, that is initiated from the 5’ LTR region, at a single 
Transcription Start Site (TSS). Indeed, the HIV-1 promoter and adjacent 
regulatory elements, both involved in the recruitment of RNA Pol II at the 
TSS, are located within the U3 region and function in the context of the 5’ 
LTR. In addition, important regulatory motifs within the TAR (Du et al., 
1993; Montano et al., 1996) as well as the U5 (el Kharroubi and Verdin, 
1994; Van Lint et al., 1997) regions have also been described. 
Nevertheless, it is worth mentioning that several studies have addressed 
the possible existence of transcripts initiating at other positions, starting 
from the identification of a protein, the Anti-Sense Protein (ASP) on the 
antisense strand (Miller, 1988). Although the question has always been 
controversial, recently an unbiased antisense transcription-specific RT-PCR 
approach detected antisense transcripts in infected cells. Furthermore, a 
novel poly(A) signal was identified within the pol gene in the antisense 
strand, and antisense transcription was shown to be positively modulated 
by Tat (Landry et al., 2007). 
From a functional point of view, the LTR can be divided into one of four 
main regions: (i) the core promoter region, encompassing the TSS, which 
exerts a positive basal effect on transcription; (ii) the enhancer region, 
which increases the effect of the basal region; (iii) the modulatory region, 
formely called “negative regulatory element”, containing several positive 
and negative regulatory elements, critical for modulating HIV-1 gene 
expression in response to various stimuli; (iv) the Trans-Activation-
Responsive region (TAR), found within the R region in the 5’ of all viral 
transcripts. 
A schematic representation of LTR regions is given in Figure 1.3. 
 
Figure 1.3  HIV-1 Long Terminal Repeat (LTR) promoter (Adapted 
from “Retroviruses”, Coffin, Hughes and Varmus, CSHL press). 
 
(i) The core (or basal) promoter contains the TATA box and three 
tandemly arranged binding sites for the constitutively expressed Sp1 
transcription factors (Jones et al., 1986). Both elements are necessary for 
basal level of LTR-driven RNA synthesis. 
As in other eukaryotic cellular promoters, the TATA box is specifically 
bound by the TBP (TATAA-Binding Protein) subunit of TFIID; mutations of 
this region resulted in a marked decrease of both basal transcription and 
viral replication. Once bound, TFIID constitutes a scaffold upon which other 
General Transcription Factors (GTFs) can assemble a functional 
transcription complex, the so-called pre-initiation complex (Orphanides et 
al., 1996), similarly to what happens for cellular genes. Indeed, TFIIB is 
recruited, and in turn recruits RNA Pol II to the promoter, definitively 
establishing the location of the TSS. To allow promoter clearance and 
transcription initiation, TFIIH is also incorporated (Goodrich and Tjian, 
1994), and its kinase subunit (Cyclin-Dependent Kinase, CDK7) 
phosphorylates the C-Terminal Domain (CTD) within the largest Pol II 
subunit Rpb1 (Serine 5) (Akoulitchev et al., 1995). This modification 
renders RNA Pol II an elongation-competent enzyme able to escape from 
the promoter region (Orphanides and Reinberg, 2002). Besides CDK7, also 
CDK8 (Maldonado et al., 1996) and the CDK9 subunit of P-TEFb (Positive 
Transcription Elongation Factor b) (Mancebo et al., 1997) phosphorylate 
the RNA Pol II CTD thus regulating transcriptional initiation and elongation 
(for further details, see Section 1.2.2 “Role of Tat in HIV-1 transcription”).  
The sites  for Sp1 are located upstream of the TATA element: mutagenesis 
studies demonstrated that Sp1 control basal transcription, even though its 
effect is markedly higher on Tat-mediated transcription. Indeed, Sp1 was 
shown to be necessary and sufficient to recruit Cyclin T1 to the LTR, 
allowing P-TEFb-mediated transcription in a Tat/TAR-independent manner  
(Harrich et al., 1989; Yedavalli et al., 2003).  
Finally, also LBP-1/YY1 (Leader Binding Protein-1/Yin Yang 1) binding sites 
can be found in the core promoter region: in particular, high affinity sites 
close to the TSS and low affinity sites close to the TATA box were 
described, and proved to exert a positive and a negative effect on 
transcription, respectively (Coull et al., 2000; Kato et al., 1991). 
 
(ii) The enhancer region mediates the transcriptional inducibility of the 
provirus in response to a variety of stimuli which trigger cellular activation 
and proliferation (Chinnadurai, 1991; Lusic et al., 2003; Siekevitz et al., 
1987). Located upstream of the core promoter, the enhancer encompasses 
two partially overlapping binding sites for the inducible transcription factors 
NF- B (Nabel and Baltimore, 1987) and for STAT5 (Signal Tranducer and 
Activator of Transcription 5) (Selliah et al., 2006), respectively. Noteworthy, 
also NF-AT members can bind in the same region of the NF-B  consensus 
sites, and likely play an important role particularly in T cells (Kinoshita et 
al., 1998). Full-length STAT5 was shown to exert a direct positive effect on 
activation of viral transcription (Selliah et al., 2006), while the naturally 
occurring C-terminally truncated STAT5 form (expressed by HIV-1 infected 
cells, (Bovolenta et al., 1999) acts as negative regulator of HIV-1 
expression in a chronically infected cell line (U1) and in CD4+ PBMCs 
(Peripheral Blood Mononuclear Cells) of HIV-1-positive individuals cultivated 
ex vivo (Crotti et al., 2007).  
The NF- B/Rel family regulates expression of numerous genes involved in 
processes such as growth, development, apoptosis, and inflammatory and 
immune responses. The most abundant form of NF- B is a p50/p65 dimer, 
being p50 the DNA binding and p65 the transactivating domain (altough 
also p65 was shown to carry a DNA binding domain in its N-terminus, as 
reported by (Toledano et al., 1993) whose activity is tightly controlled by 
intracellular localization. Indeed, in the cytoplasm, NF- B dimers are 
complexed with the I B inhibitor and cannot be imported into the nucleus. 
Following activation of T cells by a variety of extracellular stimuli, the 
bound I B is phosphorylated and subsequently degraded, while free NF- B 
is translocated into the nucleus where it activates transcription of target 
genes (for a comprehensive review, see (Vallabhapurapu and Karin, 2009).  
A further degree of complexity is added by the fact that NF- B p65 is also 
regulated by interactions with cellular HATs such as CBP (CREB Binding 
Protein), p300 and P/CAF (p300/CBP Associated Factor), which mediate 
acetylation of several Lysine residues variously affecting binding to I B, 
binding to DNA and transcriptional activity (Chen et al., 2002b; Kiernan et 
al., 2003). In particular, acetylation of Lys 310 appears to be crucial for 
increasing transriptional activity, and is reversed by the nicotinamide 
adenine dinucleotide-dependent class III HDAC (Histone De-ACetylase) 
SIRT1 (Yeung et al., 2004). NF- B has been shown to stimulate both basal 
and Tat-mediated expression in activated T-cells (Nabel and Baltimore, 
1987; Siekevitz et al., 1987),  while mutations in its binding sites affect 
HIV-1 infectivity to an extent that depends on the mutation type and on 
the levels of endogenous NF- B.  
 
(iii) Although the modulatory region was not shown to dramatically affect 
promoter activation neither in vitro nor in reporter assays in transfected 
cells, site-specific mutagenesis studies revealed that it considerably impacts 
viral replication in both some T cell lines and in primary lymphocytes. This 
region is conserved among isolated HIV strains, and it is bound by several 
cellular proteins such as LEF-1, Ets-1, USF, NF-AT, c-Myb and COUP-TF 
(reviewed in (Pereira et al., 2000)). The modulatory region has also been 
proposed to contain a Negative Regulatory Element (NRE), whose deletion 
increases LTR-driven transcription and viral replication (Rosen et al., 1985).  
 
(iv) The HIV-1 TAR encompasses the 5’-terminal (nucleotides +1 to +59, 
numbering the TSS as +1) of all viral RNAs. This region functions as an 
RNA sequence rather than as a DNA element (Muesing et al., 1987). It 
folds into a highly stable, nuclease-resistant stem-bulge-loop structure 
which is essential for Tat-mediated LTR transactivation (Berkhout et al., 
1989), as it is suggested by the fact that mutations that destabilise the 
stem by disrupting base-pairing abolish Tat-stimulated transcription. 
Furthermore, the TAR element was found to be functional only when 
placed in the 3’ to the HIV-1 promoter and in the correct orientation and 
position (Selby et al., 1989).  
  
Interestingly, footprinting analysis revealed binding sites for several 
transcription factors (such as AP-1, Sp1, NF-AT) also in the R/U% junction 
and in the U5 region. 
 
Chromatin conformation at the HIV-1 LTR promoter 
Following integration into the cell genome, and independent from the 
integration site, the proviral DNA, similarly to cellular genes, is organized 
into a chromatin structure. LTR proved to act as a very strong promoter 
when analyzed in vitro as naked DNA (Parada and Roeder, 1996), while it 
is almost silent when integrated into the cellular genome in the absence of 
stimulation (Pomerantz et al., 1990). These findings clearly indicated that 
chromatin conformation plays essentially a repressive role on HIV-1 
transcription. 
Both in vitro (Sheridan et al., 1997; Steger and Workman, 1997) and in 
vivo nuclease accessibility studies of the proviral chromatin structure (El 
Kharroubi et al., 1998; Van Lint et al., 1996; Verdin et al., 1993) showed 
that the 5’ LTR, independent from the integration sites, is incorporated into 
two distinct nucleosomes, namely nuc-0 and nuc-1, precisely positioned 
with respect to cis-acting regulatory elements, and separated by a 
nuclease-hypersensitivity region. In the transcriptionally silent provirus, 
nucleosome positioning defines two large nucleosome-free areas, one 
spanning the core promoter/enhancer in the U3 region (nucleotides -265 to 
-3) and the other encompassing the primer-binding site immediately 
downstream to the 5’ LTR (nucleotides +141 to +265). A single 
nucleosome called nuc-1 is located between these two open regions, and it 
has been shown to be specifically and rapidly destabilized concomitant with 
transcription activation induced by HDAC inhibitors, cytokines or by the 
viral transactivator Tat (Van Lint et al., 1996; Verdin et al., 1993).  
Interestingly, several genome-wide studies of nucleosome positioning 
conducted both in yeast and in human cells revealed that most RNA Pol II-
transcribed genes carry a similar chromatin conformation, with 
nucleosomes precisely positioned at promoters that are remodeled 
concomitant with transcription activation (Bernstein et al., 2004; Hartley 
and Madhani, 2009; Schones et al., 2008).  
The position of nuc-1 in close proximity of the TSS and its displacement 
during transcription activation clearly suggest that chromatin exerts a 
crucial repressive role on proviral expression, and that disruption of nuc-1 
is necessary for transcriptional activation (Figure 1.4). To further reinforce 
the chromatin-mediated repression of HIV-1 expression, it is worth 
mentioning that genomic footprinting studies performed either in activated 
or in silently infected cells, have indicated that most of the binding sites in 
the promoter are occupied by cellular transcription factors despite of the 
activation state (Demarchi et al., 1993). This is consistent with the view 
that the transcriptional activation of the integrated LTR is not mainly 
impaired by DNA target site accessibility, but instead occurs through the 
modulation of chromatin conformation. 
Figure 1.4  Chromatin conformation at the HIV-1 LTR promoter 
(Adapted from (Marcello et al., 2001b). 
1.2.2 The Tat protein of HIV-1 
 
Structure of the Tat protein 
Viral replication in vivo requires the virally-encoded Tat protein, a 14 kDa 
protein conserved in the genomes of all primate lentiviruses. It is translated 
from multiply spliced transcripts, and its gene is located in the 3’ portion of 
the viral genome. The tat gene is made up of two exons (first exon: 
residues 1-72, second exon: residues 73-101) and in most primary isolates 
encodes for a 101 amino acid-long polypeptide, although one of the most 
widely utilized laboratory strains (HIV-1HXB2) produces a shorter albeit fully 
functional protein of 86 amino acids, generated from a point mutation that 
creates a premature stop codon (Jeang et al., 1999). No crystal structure of 
the protein has been obtained so far, and the best information about the 
three-dimensional structure of Tat, based on Nuclear Magnetic Resonance 
(NMR) spectroscopy, indicate that it possesses a highly flexible structure 
and does not exhibit obvious secondary structure elements (Bayer et al., 
1995). 
 
Figure 1.5  Structure of HIV-1 Tat protein. 
 
On the basis of its amino acidic composition, the Tat sequence has been 
subdivided into several distinct regions, each of which is essential for Tat 
function: an N-terminal acidic region (aa 1-19), a cystein-rich domain (aa 
20-31), a core region (aa 32-47), a basic region (aa 48-57), and a C-
terminal region (aa 72-101) (Figure 1.5). The generation of a wide 
collection of mutants allowed the definition of a detailed structure-function 
map of Tat, with different roles ascribed to each domain. The best studied 
region is the arginine-rich basic domain, highly conserved among HIV 
isolates, responsible for binding to TAR (Weeks and Crothers, 1991) and for 
the nuclear localization of the protein (Hauber et al., 1989). The core 
domain also contributes to TAR binding, while the cystein-rich region is 
believed to be involved in metal ion binding and, more relevant, is 
necessary for Cyclin T1/CDK9 binding (Garber et al., 1998). The C-terminal 
region appears to be dispensable for transactivation, although it retains a 
still unrecognized role in viral pathogenesis in vivo, and is less conserved 
than the other domains in the different isolates (Smith et al., 2003).  
  
 
Post-translational modifications of Tat 
Tat is also subjected to various PTMs by host cellular proteins, including 
acetylation (i), phosphorylation (ii), methylation (iii), ubiquitination (iv), 
which affect its transactivating properties, adding complexity to the 
transcriptional scenario at the viral promoter.  
 
(i) The best charachterized Tat modification is acetylation, mediated by 
cellular HATs and occurring on lysine residues in the basic and in the 
cystein-rich domains of the protein. The association between Tat and HAT 
activity has been described by three groups almost at the same time, who 
showed that: Tat interacted with p300 (Hottiger and Nabel, 1998); Tat-
driven LTR transactivation was defective when p300 and P/CAF expression 
was reduced (Benkirane et al., 1998); Tat recruited p300 and the closely 
related CBP to the LTR promoter as well as p300 overexpression increased 
LTR transactivation both in rodent and in human cells (Marzio et al., 1998). 
In addition, Tat was found to be itself a substrate of several HATs, namely 
p300, P/CAF and GCN5, and different publications identified the modified 
lysines: Lys50 and Lys51 are acetylated by p300 and GCN5, while P/CAF 
acetylates Lys28 (Col et al., 2001; Deng et al., 2000; Deng et al., 2001; 
Kiernan et al., 1999; Ott et al., 1999). How acetylation at Lys28 and Lys50 
might modulate Tat activity has been controversial. Despite the finding that 
acetylation affects Tat transactivation and viral replication (Bres et al., 
2002b), the exact manner by which these PTMs impact Tat functions is still 
not completely understood (Bres et al., 2002a; Dorr et al., 2002; Kaehlcke 
et al., 2003; Mujtaba et al., 2002). Nevertheless, a model has been 
proposed, based on all the previous evidence, in which unmodified Tat first 
binds P/CAF (Kiernan et al., 1999), which in turns acetylates Lys28 thus 
promoting association of Tat with Cyclin T1. Then the Tat/P-TEFb complex, 
bound with high affinity to TAR, phosphorylates RNA pol II CTD, while 
p300 recruited by RNA Pol II acetylates Lys50. Lys50Ac induces the 
dissociation of Tat/P-TEFb from the TAR RNA (Kaehlcke et al., 2003; 
Kiernan et al., 1999), allowing the formation of the ternary complex Tat/P-
TEFb/P/CAF that associates to the elongation complex during the whole 
elongation phase. Interestingly, D’Orso and collegues recently analyzed the 
role of Tat acetylation using Tat chimeras containing basic domains of 
lentiviruses in which Lys28 is not conserved (such as Bovine 
Immunodeficiency Viruses, BIVs) and measured affinity for TAR binding. 
They demonstrated that Lys28 acetylation increases the affinity and 
stability of the HIV-1 Tat/Cyclin T1/TAR complexes; conversely, BIVs have 
evolved different mechanisms to achieve high-affinity RNA binding, having 
a high Tat/TAR affinity that does not require neither Cyclin T1 nor Tat 
acetylation (D'Orso and Frankel, 2009). 
The requirement for Lys28/Lys50 acetylation in ternary complex 
assembly/disassembly might allow for additional steps of transcriptional 
regulation, likely involving cycles of acetylation/deacetylation. Indeed, the 
nicotinamide adenine dinucleotide-dependent class III HDAC SIRT1 was 
shown to specifically de-acetylate Lys50 both in vitro and in vivo. Tat and 
SIRT1 sinergistically activated the LTR and, conversely, Tat transactivation 
was defective upon SIRT1 knock-down, suggesting that this reversible 
acetylation allows Tat to be recycled to TAR for susequent rounds of HIV 
transcription (Pagans et al., 2005). Interestingly, the same authors 
reported that Tat blocked the ability of SIRT1 to deacetyate Lys310 in the 
p65 subunit of NF- B (likely competing with p65 for SIRT1 binding), 
leading to a hyperactivation of expression of NF-kB-responsive genes and 
eventually to immune cell hyperactivation (Blazek and Peterlin, 2008). 
 
(ii) Phosphorylation of Tat has been initially reported only in vitro, 
involving the interferon-induced, double stranded-RNA-activated protein 
kinase PKR (Brand et al., 1997) and the CDK2/Cyclin E complex (Deng et 
al., 2002). Surprisingly, in spite of the interaction of Tat with P-TEFb, no 
evidences of CDK9-mediated HIV-1 Tat phosphorylation has been reported 
so far (on the contrary, HIV-2 Tat was found to be phosphorylated by 
CDK9 in vivo) (Herrmann and Rice, 1993). More recently, Tat was shown to 
be phosphorylated on Serines 16 and 46 (two highly conserved residues) in 
the context of the integrated HIV-1 provirus. In vivo phosphorylation is also 
likely to be CDK2-mediated, and be important for HIV-1 tanscription, since 
mutants in Serine residues proved to be greatly impaired in viral replication 
(Ammosova et al., 2006). Although two serine-threonine phosphatases, 
namely protein phosphatase 2A (PP2A) and protein phosphates-1 (PP1) 
were found implicated in the regulation of HIV-1 transcription (Ammosova 
et al., 2003; Bharucha et al., 2002; Faulkner et al., 2003), they were so far 
reported to only dephosphorylate CDK9.  
 
(iii) Both Arginine and Lysine methylation of Tat was described. Arginine 
methylation by the Protein Arginine Methyl-Transferase 6 (PRMT6) onTat  
Arg52/Arg53 residues of Tat was found to negatively regulate HIV-1 
transcription by disrupting the Tat/TAR/Cyclin T1 complex (Boulanger et 
al., 2005; Xie et al., 2007). More recently, methylated Tat was found to be 
more stable compared to the unmodified protein, due to the prevention of 
Tat degradation by the proteasome. Once stabilized, Tat can persist both 
within the cell and in the extracellular milieu, and this might be relevant for 
AIDS pathogenesis because Tat can thus exerts its functions beyond the 
infected cells, with possible involvement in the pathogenesis of AIDS-
related cancer, neurodegeneration and T cell death (Sivakumaran et al., 
2009).  
In addition, Tat was shown to associate with and to be modified by two 
histone methyltransferases of the SUV39 family of SET domain-containing 
proteins (SETDB1 and SETDB2) in vitro. Reporter assays after SETDB1/2 
knock-down revealed that Lys50 and Lys51 methylation exerts an inhibitory 
effect on viral transcription, likely competing with Lysine acetylation (Van 
Duyne et al., 2008). 
 
(iv) Ubiquitination of Tat has been described by Benkirane and collegues 
who identified Hdm2 as the E3 ligase for ubiquitination of Lys71 both in 
vitro and in vivo. Interestingly, ubiquitination proved to enhance Tat 
transactivating properties (Bres et al., 2003). The mechanism by wich 
ubiquitination of Tat affects its transcriptional activity was further 
investigated, and insights came from the discovery that the proteasome 
regulates both basal and Tat-induced transcription, by a proteolytic and a 
non-proteolytic mechanisms, respectively. In particular, in the absence of 
Tat, both the 19S and 20S subunits of the proteasome are associated with 
the LTR and the coding regions, and negatively modulate basal 
transcription. This conclusion is drawn from the increase in HIV-1 
expression observed after either treatment with the proteasome inhibitor 
MG132 or proteasome subunit knock-down. Conversely, when ubiquitinated 
Tat is present, it recruits additional 19S proteasome subunit at the HIV-1 
promoter, stimulating transcriptional elongation. This occurs through Tat 
interaction with the protein PAAF1 (Proteasomal ATPase-Associated Factor 
1), which in turns favors the proteasome dissociation into 19S and 20S 
particles (Lassot et al., 2007). According to this model, a growing body of 
evidence has indicated that the 19S proteasome functions in the epigenetic 
regulation of gene expression, both in yeast and mammals, apparently 
associating with highly transcribed genes (Bhat et al., 2008; Koues et al., 
2009; Lee et al., 2005). It is worth mentioning that PAAF1 seems to be 
required for efficient transcriptional elongation from the LTR via regulation 
of the histone chaperone hSpt6. Indeed, PAAF knock-down, as well as 
hSpt6-knock-down, led to a depletion of core histones as detected by ChIP 
and to an accumulation of aberrant short transcripts, suggesting that 
PAAF1 and hSpt6 cooperate to favor efficient transcriptional elongation by 
promoting the nucleosome reassembly after RNA Pol II passage (Nakamura 
et al., Retrovirology Volume 6 Suppl 2 “Frontiers of Retrovirology: Complex 
retroviruses, retroelements and their hosts”, meeting abstracts). 
 
Role of Tat in HIV-1 transcription 
Transcription driven by the LTR is several hundred-fold higher in the 
presence of Tat than in its absence. Without Tat, the HIV-1 provirus cannot 
transcribe efficiently, due to a defect in elongation that leads to an 
accumulation of short transcripts (Kao et al., 1987). Tat is unique among 
eukaryotic transcriptional activators because it functions via RNA (TAR) 
rather than DNA promoter elements (Berkhout et al., 1989).  
Interestingly, although most Tat interactions are TAR-mediated, also TAR-
independent modes of Tat transactivation have also been described. 
Indeed, provided that the enhancer region of the LTR is intact (Berkhout et 
al., 1990), Tat induces transcription from the LTR basically because it is an 
activator of NF- B. Several pathways have been proposed to participate in 
Tat-mediated NF- B activation. First, Tat induces nuclear translocation of 
NF- B acting through the degradation of I B, via the cellular interferon-
inducible protein kinase PKR (Demarchi et al., 1996; Demarchi et al., 
1999); second, Tat induces activation of NF- B through the Tumor 
Necrosis Factor alpha (TNF- )-mediated signaling pathway, since it both 
alters the redox state of the infected cells and induces the expression of 
the TNF-  gene (Kalantari et al., 2008; Schreck et al., 1991). 
Through its interaction with TAR RNA and a variety of protein-protein 
interactions, Tat activates HIV-1 transcription by promoting the assembly of 
a transcriptionally competent complex at the LTR. For instance, Tat binds 
directly Sp1, and moreover several GTFs, including TFIID, TFIIB, TFIIH and 
RNA Pol II itself, recently confirmed by Raha and co-workers by Chromatin 
Immuno-Precipitation (ChIP) experiments (Raha et al., 2005).  
The most well-charachterized Tat interaction is that with the Cyclin T1 
subunit of the P-TEFb complex (Wei et al., 1998). P-TEFb is composed of 
the cyclin-dependent kinase CDK9 associated with Cyclin T1 or with one of 
the other C-type cyclins (for comprehensive reviews on P-TEFb see (Bres et 
al., 2008; Chen et al., 2006; Peterlin and Price, 2006). As a consequence of 
this binding, P-TEFb and Tat bind TAR cooperatively. The formation of the 
P-TEFb/Tat/TAR ternary complex is an essential step towards the assembly 
of the processive RNA Pol II machinery at the LTR promoter (Bieniasz et 
al., 1998; Garber et al., 1998; Zhou et al., 1998). Studies in murine cells, 
where the introduction of the human Cyclin T1 restores Tat function, gave 
the final proof that P-TEFb is the cellular cofactor for Tat. Indeed, mouse 
cells are not permissive to HIV-1 infection, due to a single Cystein-to-
Tyrosine mutation at position 261 in the Cyclin T1 gene, however restoring 
Tyrosine 261 renders murine cells subscetible to HIV-1 infection (Garber et 
al., 1998). 
Studies performed using RNA interference as well as highly specific 
inhibitors have demonstrated that,  besides being a cellular cofactor for 
HIV-1, P-TEFb is required for efficient expression of most of cellular genes. 
Notwithstanding, HIV-1 genes are the most sensitive to the availability of 
P-TEFb, as it is demonstrated by the fact that Tat-driven LTR 
transactivation is blocked by concentrations of P-TEFb inhibitors that do not 
exert any effect on transcription of cellular genes (Chao and Price, 2001). 
It has been proposed that at the beginning of the transcription cycle, 
CDK7-mediated phosphorylation on Serine 5 of RNA Pol II CTD facilitates 
promoter clearance, but shortly after initiation, the progression of Pol II is 
stalled by two negative elongation factors, namely NELF  (Negative 
Elongation Factor) and DSIF (Dichloro-1- -D-RibofuranosylBenzimidazole 
riboside (DRB)-Sensitivity-Inducing Factor). To overcome this checkpoint, 
Tat recruits P-TEFb to the stalled Pol II, forming the stable ternary complex 
with Tat/TAR/Cyclin T1 (which in turn is regulated by Tat acetylations, as 
previously described). P-TEFb phosphorylates DSIF, NELF and Serine 2 on 
RNA Pol II CTD, thus causing NELF dissociation and the conversion of DSIF 
into a positive elongation factor, finally allowing the production of full-
length transcripts (reviewed in (Barboric and Peterlin, 2005).  
 
Figure 1.6  Activation of HIV-1 transcription by Tat (Adapted from 
Barboric et al., 2005). 
 
It is worth mentioning that P-TEFb activity is regulated by different 
mechanisms. First, regulation is accomplished by controlling the expression 
levels of both Cyclin T1 and CDK9 (Zhou et al., 2000); second, a number of 
CDK9 PTMs have been described so far, namely phosphorylation (Fong and 
Zhou, 2000), ubiquitination (Kiernan et al., 2001) and acetylation (Sabo et 
al., 2008), affecting CDK9 properties; third, nucleo-cytoplasmatic shuttling 
of CDK9 could also be modulated finely tuning P-TEFb transactivating 
activity (Napolitano et al., 2002).  
In addition, several lines of evidence have indicated that activity of P-TEFb 
is tightly controlled by its associations with both positive and negative 
regulators, such as Brd4 (Bromodomain-containing protein-4) and HEXIM1 
(Hexamethylene bis-acetamide Inducible) proteins/7SK small nuclear RNA 
(snRNA), respectively. 
Brd4 and HEXIM1/7SK exist in two mutually exclusive CycT1/CDK9-
containing complexes: about half of cellular P-TEFb associates with Brd4, 
resulting in an active, low-molecular-weight complex. Generally, Brd4 
recruits P-TEFb to chromatin through its interaction with acetylated 
histones, but it proved to be dispensable for HIV-1 transcription, since it 
can be functionally substituded by Tat (Yang et al., 2005). In addition, Brd4 
has been recently correlated with HIV-1 transcriptional inhibition: indeed, it 
inhibits CDK9 inducing its phosphorylation, and as a matter of fact ChIP 
experiments detected phospho-CDK9 at the silent HIV-1 promoter 
(Bisgrove et al., 2007; Zhou et al., 2009). 
The other half of cellular P-TEFb exists in an inactive high-molecular-weight 
complex with the 7SK snRNA and the HEXIM proteins (Nguyen et al., 2001; 
Yang et al., 2001; Yik et al., 2003). Interestingly, HEXIM1 binds the same 
region of Cyclin T1 that is involved in Tat binding; indeed, both GST pull-
down experiments and size exclusion chromatography revealed a mutually 
exclusive binding of the two effectors to Cyclin T1, suggesting a model 
where Tat and HEXIM1 compete for Cyclin T1 binding (Schulte et al., 
2005). Furthermore, the 7SK-binding motif in HEXIM1 contains clusters of 
positively charged residues, highly homologous to the basic TAR-binding 
domain of Tat. A similar RNA-protein recognition mechanism might regulate 
the formation of both the Tat/TAR/P-TEFb and the HEXIM1/7SK/P-TEFb 
ternary complexes, which might help convert the inactive HEXIM1/7SK-
bound P-TEFb into an active complex for Tat-activated and TAR-dependent 
HIV-1 transcription (Michels et al., 2004; Yik et al., 2004). Therefore it has 
been speculated that the TAR RNA/Tat lentiviral system has evolved to 
subvert the cellular 7SK RNA/HEXIM1 system. Interestingly, Ott and co-
workers recently reported that acetylation of Cyclin T1 regulates the 
equilibrium of active and inactive P-TEFb, by triggering the dissociation of 
CyclinT1/CDK9 from 7SK RNA/HEXIM1; nevertheless, either an acetylation-
defective mutant of Cyclin T1 or the wild type protein synergize with Tat in 
LTR transactivation at the same levels (Cho et al., 2009). 
 
Figure 1.7  The Brd4/P-TEFb, the Tat/TAR/P-TEFb and the 
HEXIM1/7SK/P-TEFb complexes (Adapted from Zhou et al., 
Microbiol. Mol. Biol. Rev. 2006)(Zhou and Yik, 2006). 
 
 
Further insights into Tat transactivation come from the work of K. Jones 
and collaborators, which highlighted the role of the Ski-Interacting Protein 
SKIP as a positive regulator of Tat/P-TEFb-mediated transcription. 
Depending upon the cellular context, SKIP can function either as a co-
activator or as a co-repressor, and it also has a still obscure function in 
splicing. It has been shown to associate with the active form of P-TEFb and 
be required for Tat transactivation both in vitro and in vivo, as assessed by 
both over-expression and knock-down reporter assays. SKIP is recruited 
together with Tat and P-TEFb at the HIV-1 promoter and, since it also 
favors transcription elongation in vitro, it is likely that it acts through 
nascent RNA to overcome pausing by RNA Pol II (Bres et al., 2005). 
Recently, by RNAi-ChIP approaches, SKIP was shown to act downstream of 
Tat/P-TEFb to recruit both c-Myc and its partner TRAPP (a scaffold for 
HATs), and the Menin subunit of the MLL1 histone methyltransferase 
complex (TriMethH3K4) (Bres et al., 2009; Zhou et al., 2004). 
 
Interestingly, also the co-repressor CTIP2 (COUP-TF Interacting Protein 2) 
also clearly emerged as a negative regulator of the P-TEFb complex. This 
protein co-purifies with the inactive P-TEFb, and inhibits the enzymatic 
activity of CDK9. Tat expression redirected CTIP2 occupancy from 7SK to 
TAR RNA, but did not impact the recruitment of the P-TEFb complex. (Rohr 
et al., Retrovirology Volume 6 Suppl 2 “Frontiers of Retrovirology: Complex 
retroviruses, retroelements and their hosts”, meeting abstracts 2009). 
 
Tat and chromatin dynamics in transcription activation 
Besides activating HIV-1 gene expression by increasing transcriptional 
processivity, Tat exerts a crucial role in relievieng the block in 
transcriptional activation imposed on the LTR by chromatin structure. That 
chromatin asociated with the HIV-1 promoter undergoes a structural 
rearrangement concomitantly with transcriptional activation is a well-
established notion (El Kharroubi et al., 1998; Verdin et al., 1993). 
Numerous studies aimed at unraveling the mechanisms by which Tat 
remodels chromatin structure to allow efficient transcription accumulated in 
recent years. Understanding how chromatin is modified and governs HIV 
expression is also critical for understanding proviral latency with the final 
goal of developing new therapeutical strategies (Richman et al., 2009)(see 
Discussion of this Thesis). 
The epigenetic regulation of HIV-1 transcription occurs by covalent 
modifications of the N-termini of the core histones in nucleosomes (i) and 
by the action of ATP-dependent chromatin remodeling complexes (ii). 
Altough it is primarily directed by Tat in conjunction with various cellular 
proteins, it is worth mentioning that also other viral proteins, such as Vpr 
and Integrase, also participate in chromatin control of HIV-1 expression, 
interacting with histone modifiers or ATP-dependent chromatin remodeling 
complexes (reviewed in (Suzuki and Craigie, 2007). 
 
(i) HAT-mediated histone acetylation at gene promoters has been shown 
to be necessary, although not sufficient, for transcriptional activation, by 
directly altering chromatin structure, and by acting as a molecular tag for 
the recruitment of chromatin-modifying complexes (for recent reviews, see 
(Choi and Howe, 2009; Li et al., 2007). Each HAT has its own lysine 
specificity within the tails of H3 and H4, according to the “histone code” 
hypothesis that dictates the epigenetic regulation of transcription 
(Jenuwein and Allis, 2001).  
Tat has ben extensively shown to target several HATs, including p300/CBP 
(Hottiger and Nabel, 1998; Marzio et al., 1998), P/CAF (Benkirane et al., 
1998), GCN5 (Col et al., 2001), Tip60 (Kamine et al., 1996)  and TAFII250 
(Weissman et al., 1998), which are likely responsible for nuc-1 
destabilization and displacement occurring at LTR upon transactivation 
(Van Lint et al., 1996; Verdin et al., 1993). ChIP assay has been explored 
to demonstrate that, both in cells containing the sole LTR or the entire HIV-
1 provirus (latently infected cell lines), cellular HATs, namely CBP, P/CAF 
and GCN5, are all recruited to the LTR upon Tat activation. Once recruited, 
these HATs acetylate histones H3 and H4 of nuc-1, relieving chromatin 
repression, prior to the onset of productive viral transcription (Lusic et al., 
2003). Of notice, knock-down of P/CAF and p300 dramatically reduced Tat 
transactivation of an integrated HIV-1 promoter (Bres et al., 2002b). 
Histone acetylation might promote transcription also because acetylated 
histones are more easily transferred from nucleosomes to histone 
chaperones, thus contributing to create a histone-depleted environment, 
which correlates with increased gene expression (Ito et al., 2000). 
In addition, Tat has been shown to modulate the enzymatic activity of 
HATs, as it induces a conformational change in p300/CBP that significantly 
increases the HAT activity of p300 on histone H4 (Deng et al., 2001). 
While histone hyperacetylation results in increased chromatin accessibility 
and transcriptional activation, conversely HDAC-mediated removal of acetyl 
groups leads to transcriptional repression. Several lines of evidence have 
demonstrated that distinct LTR-bound complexes recruit HDACs at the HIV-
1 promoter where they inhibit viral expression. TFs YY1 and LSF (Late SV40 
transcription Factor) cooperatively recruit HDAC1, and this is paralleled by 
a reduced nuc-1 acetylation and by LTR down-regulation (Coull et al., 
2000). Conversely, Tat counteracts chromatin repression by displacing 
HDAC1 thus increasing histone acetylation in nuc-1 (He and Margolis, 
2002).  
Furthermore, in latently infected cells NF- B p50/HDAC1 complexes have 
been shown to constitutively bind the silent LTR, where histones proved to 
be hypoacetylated, while synthesis of full-length transcripts could be 
rescued by Tat expression (Williams et al., 2006). Recently, also CBF-1 (C-
promoter Binding Factor-1) has also been described to potently inhibit LTR 
transcription via histone deacetylation; since this protein is over-expressed 
in quiescent or unstimulated cells, its involvement in the establishment of 
latency was postulated (Tyagi and Karn, 2007). Consistent with the crucial 
role of chromatin structure and dynamics for the control of proviral 
expression, multiple studies have indicated that HDAC inhibitors, including 
TSA (Thricostatin A), trapoxin, valproic acid and sodium butyrate, lead to 
transcriptional activation in latently infected cells, holding an important role 
as potential therapeutics (Savarino et al., 2009; Van Lint et al., 1996)}. 
However, taking into account that transcription factors involved in HIV1 
activation, namely NF- B and Sp1, are also acetylated, whether the effect 
of inhibitors is due to the inhibition of HDACs or of factor deacetylases is 
still not clear. 
 
Although histone acetylation has been the prominent covalent modification 
of histones described so far, other modifications, such as phosphorylation 
or methylation on specific residues, have also been identified at the 
induced LTR to be marks of active transcription. 
For example, phosphorylation of Serine 10 in the tail of the histone H3 
could be mediated by either NF- B or the mitogen-activated protein kinase 
pathways via I -B kinase-  or MSK1/2, respectively. 
In addition, trimethylation of lysine 4 of histone H3 (TriMethH3K4) has 
been detected upon TNF -induction of latently infected cells. A drop in this 
modification has been appreciated upon treatment with flavopiridol, an 
inhibitor of the kinase activity of CDK9, and this is consistent with the 
observation that the P-TEFb-associated SKIP protein also associates with 
the Menin component of the MLL1 histone methyltransferase complex (Bres 
et al., 2009; Zhou et al., 2004). 
 
Generally, besides histone deacetylation, another histone covalent 
modification that correlates with heterochromatin assembly and gene 
silencing is trimethylation of Lys9 of histone H3 (TriMethH3K9) (Grewal and 
Moazed, 2003). It is mediated by the methyltransferase Suv39H1 and it 
recruits HP1 proteins, proving to be crucial for heterochromatin 
establishment (Cheutin et al., 2003). Once TriMethH3K9-bound, HP1s in 
turn recruit more Suv39H1, ensuring heterochromatin maintenance and 
spread (Maison and Almouzni, 2004). 
Elegant Suv39H1 and HP1  knock-down experiments performed in several 
systems, including cell lines carrying silent proviruses, infected T-cell lines 
and PBMCs from infected individuals, showed that Tat-mediated 
transcription was greatly increased in cells in which the proteins had been 
silenced compared to control cells. Accordingly, ChIP experiments revealed 
that both SUV39H1 and HP1  occupancy of the LTR was significantly 
reduced upon Tat activation, along with a decrease in TriMethH3K9. 
Collectively, these findings clearly suggested that Suv39H1, HP1 , and 
TriMethH3K9 exert a crucial role in chromatin-mediated repression of HIV-1 
gene expression and, moreover, that Tat-mediated transactivation of the 
HIV-1 promoter, besides co-activator recruitment, involves chromatin 
derepression (du Chene et al., 2007). However, it is worth mentioning that 
the role of HP1 proteins in heterohromatin establishment at the HIV-1 
genome has been controversial. Indeed, Marban and collegues reported 
that all the three isoforms ( ,  and ) were detected in the silent HIV-1 
genome and released concomitant with transcriptional activation (Marban 
et al., 2007). Moreover, an experimental approach similar to that used by 
Benkirane and collegues, consisting in a combination of siRNA-mediated 
knock-down of HP1s and ChIP analysis of proviral occupancy of HP1s and 
RNA Pol II, recently showed that the  isoform, but not the  isoform, of 
HP1, and the non-processive RNA Pol II are present at the silent LTR where 
they function as negative regulators. Upon activation, the  isoform is 
released, concomitant with histone H3 phosphorylation and acetylation, 
and replaced by HP1 , both at the promoter and at the coding regions, 
together with the processive RNA Pol II. These results are suggestive of a 
positive role of the  isoform (Mateescu et al., 2008). 
 
Figure 1.8  A model for chromatin dynamics in the regulation of 
Tat-mediated HIV-1 expression (adapted from du Chéné et al., 
EMBO J 2007). 
 
Interestingly, a role in the repressive chromatin establishment at the LTR 
promoter has also been ascribed to the co-repressor CTIP2: in microglial 
cells, Sp1- and COUP-TF-bound CTIP2 recruit both HDACs (1 and 2) and 
SUV39H1, thus contributing to heterochromatin establishment and proviral 
silencing (Marban et al., 2005; Marban et al., 2007). 
However, the mechanisms by which Tat relieves chromatin repression still 
remain elusive: it has been hypothesized that either it associates with an 
enzymatic activity that directly modifies TriMethH3K9, or that it decoys 
SIRT1 HDAC activity, leading to an accumulation of hyperacetylated 
histones (Pagans et al., 2005).  
 
(ii) Several lines of evidence have recently underlined the necessity of the 
SWI/SNF family of ATP-dependent chromatin remodeling complexes in Tat 
transactivation of HIV-1 promoter.  
First, Henderson and collaborators, using an immobilized-template assay 
with a probe spanning the 3’ boundary of nuc-1, reported that, following 
PMA (Phorbol Myristate Acetate) treatment, BRG-1 (the ATPase subunit of 
human SWI/SNF) is targeted to the LTR, and that this recruitment is 
dependent on the transcription factor ATF-3 (Henderson et al., 2004). 
Accordingly, BRG-1 knock-down, as well as INI-1 (INtegrase Interactor-1, 
another ATPase) knock-down, greatly impaired Tat-mediated 
transactivation (Mahmoudi et al., 2006), while both in vitro and in vivo 
BRG-1 was detected in the same complex with acetylated Tat (Agbottah et 
al., 2006).  
The Brm SWI/SNF ATPase was also shown by ChIP assay to be recruited at 
the HIV-1 promoter in a Tat-dependent manner. Interestingly, this 
interaction is disrupted by Tat acetylation at Lys50, suggesting that Tat 
recruits Brm before the p300-mediated dissociation from TAR RNA (Treand 
et al., 2006).  
 
Beyond HIV-1 transcription: additional activities of Tat 
Besides its critical function in the control of HIV-1 expression, Tat also 
affects other steps of viral life cycle (i), as well as different host cell 
functions (ii) and host gene expression (iii).  
 
(i) Over 10 years ago, it was reported that Tat might play a role in reverse 
transcription of viral RNA, as it was demonstrated by the fact that HIV-1 
variants carrying mutated tat genes were unable to retrotranscribe their 
genome efficiently upon PBMC infection (Harrich et al., 1997). The 
mechanisms by which Tat regulates reverse transcription still remain 
elusive, since Tat has never been shown to be incorporated into virions; 
however, it has been suggested that a few Tat molecules might be 
incorporated, likely binding the two copies of genomic RNA, even if they 
are undetectable by the current available techniques. Hence, Tat might 
conceivably be associated with the reverse transcription complex and 
directly participate in the process of viral DNA synthesis, probably 
promoting loading of tRNA primer onto viral RNA or suppressing non-
specific DNA elongation (Kameoka et al., 2002). 
 
(ii) A more robust set of evidences suggest that Tat affects a remarkable 
number of host cell functions.  
For example, Tat-mediated induction of apoptosis has been first described 
more than a decade ago (Li et al., 1995; Westendorp et al., 1995). Multiple 
evidence has demonstrated that Tat pro-apoptotic effect is accomplished 
through a multiplicity of mechanisms, including the up-regulation of Fas 
ligand, TRAIL (Tumor necrosis factor-Related Apoptosis-Induced Ligand), 
Bax and Caspase-8, and the down-regulation of Bcl2 (reviewed in (Romani 
et al., 2009). Of notice, Tat induces apoptosis by also altering the dynamics 
of microtubule polymerization inside the cell (Chen et al., 2002a). Besides 
binding -tubulin dimers, Tat physically associates also with the 
polymerized microtubules, both in vitro and in vivo, resulting in microtubule 
stabilization and enhancement of tubulin polymerization (de Mareuil et al., 
2005). Interfering with microtubule polymerization and depolymerization 
finally results in an alteration of the permeability of the mitochondrial 
membrane and the release of cytochrome c from mitochondria, a critical 
event in triggering apoptosis (commented in (Giacca, 2005)). Moreover, in 
the course of a biochemical fractionation assay of T cell extracts searching 
for Tat-associated kinases that phosphorylate RNA Pol II CTD, the 
microtubule-associated LIS1 protein, known to regulate microtubule 
dynamics by interacting with dynein, was identified (Epie et al., 2005).    
Interestingly, Tat was shown to affect translation: in a yeast two-hybrid 
screening aimed at identifying cellular partners of the second exon of Tat, 
the human translation elongation factor-1  (EF-1 ) was characterized, and 
this interaction proved to impact translation of cellular, but not viral mRNAs 
(Xiao et al., 1998). 
Finally, a growing body of evidence has recently suggested that a further 
level of complexity in the virus-host interplay is related to the RNA 
interference (RNAi) pathway, and in particular Tat has emerged as a 
suppressor of the RNAi machinery (reviewed in (Kumar and Jeang, 2008). 
Relationships between HIV-1 infection and microRNAs (miRNAs) are very 
complex and still remain elusive, notwithstanding mechanisms have begun 
to be unraveled: cellular miRNAs control HIV-1 replication and latency 
targeting viral mRNAs (Huang et al., 2007); viral genomes produce viral 
interference RNAs (viRNAs) that can target both viral and cellular mRNAs 
(Bennasser et al., 2004); HIV-1 infection can alter the expression of cellular 
miRNAs that target factors involved in HIV-1 replication (Triboulet et al., 
2007). In this scenario, Tat physically interacts with Dicer, causing the 
partial repression of the ability of Dicer itself to process precursor dsRNAs 
into small interfering RNAs (siRNAs) (Bennasser and Jeang, 2006; 
Bennasser et al., 2005). Furthermore, the TAR RNA has been shown to 
function as an RNAi-decoy, which sequesters the Dicer-interacting protein 
TRBP2 (TAR RNA-Binding Protein 2), thus preventing the formation of a 
functional RISC (RNA-Induced Silencing Complex) (Bannwarth and 
Gatignol, 2005; Christensen et al., 2007).  
 
(iii) The activation of transcription exerted by Tat is not limited to the HIV-
1 provirus, since expression of a number of genes has been found to be 
transactivated, even though to a less extent, by Tat itself. For example, Tat 
up-regulates the expression levels of several cytokines, including IL-2, IL-6, 
IL-8, IL-10 and TNF-  through the activation of the PKR-NF- B pathway 
(Chang et al., 1995; Demarchi et al., 1999). Of interest, the IL-2 promoter 
is bound by the T-cell specific global gene regulator SATB1 (Special AT-rich 
sequence Binding protein 1), which in turn recruits HDAC1 leading to 
transcriptional repression. Tat was also found to bind SATB1, thus, Tat-
mediated IL-2 up-regulation was apparently due to a competitive 
displacement of HDAC1 bound to SATB1, leading to increased acetylation 
of IL-2 promoter (Kumar et al., 2005). 
Recently the Tat-mediated up-regulation of Matrix Metallo-Proteinase-9 
(MMP-9) in astrocytes has been demonstrated to be dependent on the 
activation of the MAP kinase-NF- B pathway (Ju et al., 2009).  
Conversely, genome-wide expression profiling in T cell lines revealed that 
several cellular genes, mostly transcription factors or mediators involved in 
pathways that control cellular proliferation and differentiation, were down-
regulated upon Tat transactivation (de la Fuente et al., 2002; Gibellini et 
al., 2002). Recently, De Marco and collaborators exploited single cell 
quantitative Fluorescent in situ RNA hybridization (RNA FISH) to 
demonstrate that, in a cell line harboring a Tat-inducible HIV-1 vector 
integrated within the HMBOX1 gene, Tat induced LTR trans-activation and 
repressed HMBOX1 expression independent from vector integration, in both 
alleles. The authors suggested that HIV-1 might target for integration 
genes that are repressed by Tat, taking an advantage for the virus during 
transcriptional activation (De Marco et al., 2008). 
A different mechanism has been described for the Tat-mediated down-
modulation of MHC II (Major Histo-Compatibility Complex class II) genes, 
since Tat has been reported to compete with the MHC II transactivator 
CIITA for the binding to Cyclin T1 (Kanazawa et al., 2000). 
 
Finally, it is worth mentioning that HIV-1 transcription can be influenced by 
cellular transcription, and viceversa, through transcriptional interference. 
The preference of HIV-1 to integrate into actively transcribed regions 
(Lewinski et al., 2005; Schroder et al., 2002) raises the possibility that 
transcription of provirus might be positively or negatively affected by 
transcription of host neighbouring genes. Indeed, this has been extensively 
investigated (Greger et al., 1998). Recently, the Peterlin’s group took 
advantage of T cell lines carrying silent HIV-1 integrations within actively 
transcribed genes to describe this event (Jordan et al., 2003). In particular, 
they showed that the elongating RNA Polymerase, originating from the host 
gene promoter, confers transcriptional interference on HIV-1 expression 
because it physically excludes pre-initiation complex formation on the LTR. 
Accordingly, this effect could be counteracted by inhibition of the host gene 
promoter or by activation of provirus with Tat (Lenasi et al., 2008). In 
addition, Han and co-workers developed an elegant system in a colon 
carcinoma cell line to monitor the effect of read-through activity on HIV-1 
integrated into an actively transcribed gene, and they surprisingly found 
that it inhibited HIV-1 expression for convergent orientated provirus but 
enhanced HIV-1 expression when provirus was in the same orientation as 
the host gene (Han et al., 2008). How these controversial findings might be 





Plenty of literature has indicated that Tat might contribute to HIV disease 
as an extracellular protein, and several groups have shown that it 
possesses the unusual property to traffic between cells, being secreted by 
infected cells and internalized by cells when present in the extracellular 
milieu, depending on the integrity of its basic domain (Frankel and Pabo, 
1988; Green and Loewenstein, 1988). Extracellular Tat has been reported 
to exert a number of pleiotropic activities when present in the extracellular 
environment, the most well-known of which is its pro-angiogenic activity on 
endothelial cells, assessed both in vitro and in vivo, likely occurring by its 
interaction with the Flk-1/KDR receptor for VEGF-1 (Vascular Endothelial 
Growth Factor-A) (Albini et al., 1998; Albini et al., 1996; Mitola et al., 
1997). Furthermore, Tat has been shown to interact also with chemokyne 
receptors (Albini et al., 1998; Albini et al., 1996; Mitola et al., 1997). 
Besides activating intracellular signal transduction pathways through its 
binding with surface receptors, Tat is also rapidly internalized by cells. 
Internalization occurs through the interaction with the cell surface Heparan 
Sulphate ProteoGlican (HSPG) receptors (Tyagi et al., 2001), followed by 
different endocytic routes, the most prominent of which is the caveolar 
endocytosis (Ferrari et al., 2003). In addition, Tat is also released by cells 
constitutively expressing the protein (Fittipaldi and Giacca, 2005; Tasciotti 
and Giacca, 2005), as well as a detectable amount of Tat is found attached 
to HSPGs in infected cells, suggestive of the importance of extracellular Tat 
of HIV-1 pathogenesis in vivo. Although it has become apparent that Tat is 
secreted through a non-canonical ER-Golgi pathway - export is not 
sensitive to drugs that disrupt these organelles – the mechanisms 
underlying Tat release still remain elusive.  
 
 
1.2.3 Nuclear organization of HIV-1 Transcription 
 
Besides the transcriptional control exerted by the elements that are 
encrypted within the viral genome, the LTR promoter and the Tat trans-
activating protein, HIV-1 transcription is susceptible to a further, epigenetic 
level of regulation, related to the nuclear distribution and availability of the 
host factors required for viral transcription, and to the spatial arrangement 
that the provirus adopts inside the cell nucleus, establishing both intra- and 
inter-chromosomal interactions which variously affect its expression. 
 
Nuclear distribution of proteins controlling HIV-1 expression 
Thanks especially to the recent development of powerful in vivo-imaging 
approaches, a growing body of evidence has contributed to create the 
emerging view of large macromolecular complexes formation, such as the 
transcription machinery, as a highly dynamic process which involves 
transient and stochastic protein-protein and protein-DNA interactions 
(Dundr et al., 2002; Misteli, 2007). This model might be also applied to the 
regulation of HIV-1 transcription, and several publications have addressed 
the issue of studying the subnuclear localization of viral transcription and 
the dynamics of the proteins necessary for mRNA synthesis.  
Fluorescent In Situ Hybridization (FISH)-based studies performed more 
than a decade ago, highlighted the proximity between HIV-1 transcription 
and nuclear speckles, being the latter sites where viral multi-spliced RNA 
accumulate (Boe et al., 1998). Nuclear speckles are irregularly shaped 
compartments enriched in splicing-related factors, such as small nuclear 
ribonucleoprotein complexes (snRNPs) and SR proteins (Lamond and 
Spector, 2003), likely involved in the co-transcriptional RNA processing of 
active genes (Brown et al., 2008). Accordingly, our laboratory, by FRET 
(Fluorescence Resonance Energy Transfer) and immunofluorescence 
techniques, demonstrated that Cyclin T1, when over-expressed, assumes a 
dotted distribution, with foci appearing juxtaposed to nuclear speckles. 
Furthermore, when the direct interaction between Tat and Cyclin T1 was 
visualized inside the cells, it was found that Tat determines the re-
localization of Cyclin T1 outside of the dots (Marcello et al., 2001a). 
Interestingly, Cyclin T1 foci were found to co-localize with other sub-
nuclear structures, namely the ProMyelocytic Leukemia (PML) bodies, either 
when PML was over-expressed, or at the levels of expression of 
endogenous proteins (Marcello et al., 2003).  
Besides the PML protein itself, several other proteins have been described 
to locate into the PML bodies, both when expressed at the endogenous 
levels (for example, SUMO and Sp100), and, especially when PML was 
over-expressed (for example, p300/CBP, GCN5, p53, pRb, Sp1) (Negorev 
and Maul, 2001). PML bodies have been implicated in a wide variety of 
cellular processes. It has been proposed that they are sites of post-
translational modifications and degradation of proteins, and in several 
cases they have been shown to localize to gene-dense regions and actively 
transcribed chromatin regions, including the MHC I gene cluster (for a 
comprehensive review, see (Torok et al., 2009). New insights into the 
mechanisms by which PML regulates transcription, comes from the work of 
Kumar and collaborators, which shows that at the MHC I locus PML, 
together with the Matrix Attachment Region (MAR)-binding protein SATB1, 
mediates the formation of chromatin loop structures, that proved to be 
highly dynamic concomitantly with transcription activation (Kumar et al., 
2007).  
Several findings suggest that PML bodies might be involved in the 
regulation of HIV-1 expression as well. Notably, PML directly binds Cyclin 
T1, targeting it to the bodies, as detected by FRET experiments (Marcello 
et al., 2003). The GCN5-acetylated, transcriptionally-inactive form of CDK9 
has also been reported to co-precipitate and to co-localize with PML, upon 
PML over-expression, both in biochemical fractionation assays (both 
proteins were found in the insoluble nuclear matrix) and in 
immunofluorescence stainings (Fogal et al., 2000; Sabo et al., 2008). Upon 
Tat trans-activation, AcCDK9 is displaced, as assessed by ChIP assay 
(Marcello et al., 2003; Sabo et al., 2008). Collectively, these observations 
support the view of nuclear bodies as depots where proteins such as 
transcription factors, co-activators and co-repressors are accumulated and 
released upon specific signals. Thus, PML bodies most likely modulate HIV-
1 expression by regulating the availability of several factors that are 
required for efficient transcription, such as Cyclin T1, CDK9, p300, RNA Pol 
II, PML itself. These structures are highly dynamic, and equilibrium can be 
easily perturbed, either by Tat, that re-localizes factors in the periphery of 
the bodies, or by protein over-expression (PML, Cyclin T1, p300), that 
mediates formation of larger bodies that do not participate in transcription 
(Marcello et al., 2003; Marcello et al., 2004).  
 
Spatial arrangement of HIV-1 within the cell nucleus 
That chromatin organization inside the nucleus is not random and that 
nuclear architecture can influence gene regulation are widely accepted 
notions (Cremer et al., 2006; Fraser and Bickmore, 2007; Gondor and 
Ohlsson, 2009). Heterochromatin is distributed at the nuclear periphery, 
under the inner surface of the nuclear envelope, while the transcriptionally 
active euchromatin is dispersed in the nuclear interior. In this scenario, 
genes move to the periphery to switch off their expression, and move 
internally into euchromatin to switch them on. Accordingly, artificial 
tethering of a locus to the nuclear envelope resulted in gene silencing, both 
in yeast and in mammalian cells (Dillon, 2008). 
Recently, Dieudonné and collaborators addressed the issue of how the 
subnuclear localization of an HIV- provirus might affect its expression, and 
studied positioning of the provirus in several cell lines, all harboring silent 
but inducible copies of HIV-1, before and upon activation. Combining 4C 
(Lomvardas et al., 2006) and FISH techniques, they identified a region in 
the proximity of the centromere of the chromosome 12 that physically 
interacted with the silent provirus. Upon cell induction with phorbol esthers, 
this association was lost, although the transcribing provirus remained 
localized at the nuclear periphery (Dieudonne et al., 2009). Overall, these 
findings strongly support the idea that nuclear positioning to the periphery 
and moreover long-range chromatin interactions with pericentric 
heterochromatin, correlate with HIV-1 transcriptional repression. 
 
Besides inter-chromosomal associations, recently intra-chromosomal 
interactions have also been shown to be crucial in the regulation of HIV-1 
expression. In particular, elegant 3C – Chromosome Conformation Capture 
– experiments (Dekker et al., 2002), extensively described in Section 1.6) 
revealed the existence of a juxtaposition of the two LTRs in the HIV-1 
provirus, reminiscent of gene-loop structures, already detected both in 
yeast and human genes (Perkins et al., 2008). 
Chromatin loops are ubiquitous structural elements of chromatin, 
implicated at all levels of chromatin organization and function, from kb-
sized loops involved in the interaction between promoters and upstream 
regulatory elements, to giant loops involved in the extrusion of a locus from 
the chromosome body (Cremer et al., 2006; Fraser, 2006; Misteli, 2007). 
Notably, gene loops have also been described, in which RNA Pol II-
transcribed genes bridge together their 5’ and 3’ ends (Ansari and 
Hampsey, 2005; Martin et al., 2005; O'Sullivan et al., 2004; Singh and 
Hampsey, 2007; Tan-Wong et al., 2008), according to the well-established 
notion that the 3’-end processing and RNA-processing complexes physically 
interact with the transcription machinery (Bentley, 2005).  
Perkins and co-workers combined 3C and ChIP approaches, and further 
developed a plasmid-3C assay, to demonstrate that a specific gene loop 
conformation is imposed on the HIV-1 provirus upon transcriptional 
activation (Perkins et al., 2008). As a model, they used the promonocytic 
U1 cell line, carrying two copies of integrated HIV-1, almost silent due to 
defective production of Tat. Upon activation with TPA, the provirus adopted 
a circular conformation - detected by 3C - with the 5’ and the 3’ LTRs 
juxtaposed, and this was paralleled by an increase of phosporylated RNA 
Pol II (Serin 2 and Serin 5) as well as CDK9 at both proviral ends, as 
detected by ChIP analysis. In addition, another conformational change was 
revealed, between the 5’ LTR and the MSD (Major Splice Donor) site, likely 
reflecting the functional interplay existing between these sequences to 















Figure 1.9  Transcription-dependent HIV-1 gene looping. 
 
Interestingly, treatment with flavopiridol abolished loop formation, 
suggestive that LTR juxtaposition was dependent on ongoing transcription. 
Plasmid-3C experiments performed with variously modified LTRs showed 
that mutations of the MSD or of the 3’ LTR poly(A) determined a significant 
drop in looping as well, while substitution with functional heterologous 
promoter or poly(A) elements resulted in the maintenance of HIV-1 looping 
properties. Taken together, these findings indicated that both ongoing 
transcription and pre-mRNA processing are essential for HIV-1 loop 
formation, and predict that these structures might be a general hallmark of 



















1.3 THE HISTONE CHAPERONE NUCLEOSOME ASSEMBLY 
PROTEIN-1 (NAP-1) 
 
1.3.1 Histone chaperones: classification and functions 
 
Histone chaperones bind free histones and prevent their improper and 
premature interactions with DNA or other factors, thus controlling histone 
supply and incorporation into chromatin (Loyola and Almouzni, 2004; Park 
and Luger, 2008; Polo and Almouzni, 2006). 
Althought a universally accepted classification of histone chaperones is still 
lacking, different criteria can be exploited to group them according to 
common features. Since chaperones which preferentially interact with H2A-
H2B can be distinguished from those that prefer H3-H4, histone binding 
selectivity is considered one of those criteria. Interestingly, histone 
chaperones that bind linker histones as well as H2A and H3 histone 
variants have also been described (De Koning et al., 2007; Shintomi et al., 
2005). Another useful criterion to classify histone chaperones is taking into 
account their way of action, so that three categories can be defined: 
chaperones that can bind and transport or transfer histones without 
necessarily involving additional partners (i); multichaperone complexes that 
combine several histone chaperone subunits (ii); chaperones that provide 
histone-binding capacity within large enzymatic complexes (iii). An 































Table 1.10  Classification of histone chaperones (Adapted from De 
Koning et al., Nat. Struct. Mol. Biol. 2007). 
 
Histone chaperones can play a broad range of functions in vivo in 
regulating histone metabolism. Soon after their synthesis, histones interact 
with chaperones, either to be stored or to be translocated into the cell 
nucleus. Once in the nucleus, histone chaperones gain access to chromatin 
and play a role in all DNA transactions in which chromatin assembly is 
required, including de novo DNA replication, DNA repair and/or 
recombination and transcription.  
DNA Replication: Three fundamental steps are necessary for duplication of 
nucleosome organization during replication (Polo and Almouzni, 2005, 
2006): the transient disruption of parental nucleosomes (i), the transfer of 
parental histones onto nascent DNA (ii), the deposition of newly 
synthesized histones (iii). 
Histone chaperones, together with ATP-dependent chromatin remodeling 
enzymes, act as histone acceptors during nucleosome disruption. Moreover, 
several works have described the central role of histone chaperones in 
depositing newly synthesyzed histones onto replicating DNA (Shibahara and 
Stillman, 1999; Tyler et al., 1999). 
DNA Repair and/or recombination: Coordination of DNA repair and histone 
dynamics is required to preserve genetic and epigenetic information in 
response to a double strand break (DSB) within chromatin (Altaf et al., 
2007; Bao and Shen, 2007; Downs et al., 2007). Phosphorylation of H2AX 
is induced very rapidly in quite large adjacent chromatin domains upon DSB 
formation. Phosphorylated H2AX is thought to provide a docking platform 
not only for repair factors, but also for histone modifiers and chromatin-
remodeling complexes, often in concert with different histone chaperones. 
Furthermore, histone chaperones are involved in the subsequent steps of 
removal and restoration of chromatin structure; histone eviction and 
exchange are key mechanisms underlying these events, responsible for 
incorporation of newly synthesized histones and for the recycling of the 
evicted ones (De Koning et al., 2007; Green and Almouzni, 2002; Groth et 
al., 2007; Peterson and Cote, 2004). 
Transcription: During transcription, histones are thought to be partially or 
totally evicted from the transcribed DNA (Li et al., 2007; Park and Luger, 
2008). The evicted histones may then be recycled after passage of RNA Pol 
II or, alternatively, newly synthesized histones might be incorporated, and 
this cycle of eviction/deposition requires histone chaperone participation 
(De Koning et al., 2007; Kim et al., 2007; Workman, 2006). In order to 
affect histone eviction and deposition, histone chaperones need to reach 
transcription sites: direct  interaction with elongating polymerase (Endoh et 
al., 2004), binding to general transcription factors (Chimura et al., 2002) as 
well as interaction with the chromatin remodeling machinery (Simic et al., 
2003) have all been shown to promote recruitment of histone chaperones 
to their site of action. Furthermore, in yeast gene expression is also 
modulated by incorporation of histone variants, which involves histone 
chaperones as well (Raisner et al., 2005; Thambirajah et al., 2009). Finally, 
histone chaperones can alter chromatin structure during transcription also 
through the links with  histone modifications, in particular histone 
acetylation: HAT complexes might require to act in complex with a histone 
chaperone (Tsubota et al., 2007), or acetylation of histones might 




















1.3.2 Characterization of Nucleosome Assembly Protein-1  
 
Nucleosome Assembly Protein-1 (NAP-1) was first identified in extracts 
from human (HeLa) and mouse cells as a protein associated with facilitated 
assembly of nucleosome-like structures in vitro (Ishimi et al., 1984; Ishimi 
et al., 1983). NAP-1 is conserved among all eukaryotes (Ishimi and Kikuchi, 
1991; Ito et al., 1996; Simon et al., 1994; Steer et al., 2003), and its 
deletion in Drosophila and in mouse has been shown to lead to embryonic 
lethality, suggestive of its central role inside the cells (Lankenau et al., 
2003; Rogner et al., 2000).  




















Mouse  Expressed in brain, 















Mouse  Smith, 2003 
SET/TAF-I  Human, Mouse Stimulates elongation of 
DNA replication, inhibitor 
of HATs 
Von Lindern, 1992 
Matsumoto, 1993 
CINAP Mouse Widely expressed in 
different tissues, 3-fold 
higher in brain 
Lin, 2006 
TSPY Human Expressed in testis, 




Table 1.12  NAP family of proteins (Adapted from Park et al.,  
2006). 
 
NAP-1 belongs to the NAP family of proteins, which are characterized by   
sequence homology and their common ability to assemble histones into 
nucleosomes on DNA templates in vitro (Park and Luger, 2006a). While 
only one NAP-1 member is present in yeast, higher eukaryotes contain 
multiple NAP-1 homologues. The expression of many of the family 
members is cell- or tissue-specific, as indicated in Table 1.12. 
NAP-1 is a highly acidic protein ( 25%), with three clusters of acidic amino 
acidic residues, the longest and the most conserved of which is located in 





Figure 1.13  The NAP-1 protein (Adapted from Park et al., PNAS 
2006). 
 
The crystal structure of yeast NAP-1 (yNAP-1) has recently been 
determined (Park and Luger, 2006b) and revealed the presence of two 
domains, namely an N-terminal dimerization domain (domain I in Figure 
1.13), and a four-stranded antiparallel –sheet domain (domain II) 
responsible for the interaction with other proteins (previously  known to 
bind the KIX domain of p300, (Asahara et al., 2002). Althought the protein 
crystallized as a dimer, in physiological salt conditions it is in equilibrium 
between dimeric and octameric forms (Toth et al., 2005). 
Both a Nuclear Localization Signal (NLS) (Mosammaparast et al., 2005; 
Mosammaparast et al., 2002) and a Nuclear Export Signal (NES) (Miyaji-
Yamaguchi et al., 2003) can be identified in NAP-1 sequence, nevertheless 
the exact mechanisms by which NAP-1 is shuttled between nucleus and 
cytoplasm are still unclear. Intracellular localization of NAP-1 is 
controversial, since its predominant cytosolic distribution cannot apparently 
be conciled with its role in chromatin assembly (Marheineke and Krude, 
1998). It might be conceived that NAP-1 is only transiently nuclear and 
regularly exported to the cytosol, althought the static subcellular 
localization of NAP-1 is cytoplasmic. Furthermore, some evidence suggest 
that NAP-1 localization changes during cell cycle progression, being mostly 
nuclear in S phase and mostly cytoplasmic in G1 and G2 phases (Ito et al., 
1996; Miyaji-Yamaguchi et al., 2003; Rodriguez et al., 2000).  
In particular, yNAP-1 has been shown to be phosphorylated at 11 sites in 
vivo (three serines by Caseine Kinase 2), and this modification increases 
nuclear import of the protein, thus affecting the progression through S 
phase (Calvert et al., 2008).  
Besides phosphorylation, NAP-1 is also subjected to other PTMs. For 
example, acetylation of NAP-1, imparted by p300, occurs in a cell-cycle 
dependent manner: in particular, it increases during the S phase, most 
likely regulating cell cycle progression (Asahara et al., 2002). Two 
additional uncommon PTMs of NAP-1 have been described, namely 
polyglutamylation and polyglycylation. Polyglutamylation, originally 
identified on tubulin, consists in the addition of side chains composed of 
several glutamyl units; this modification reversibly changes the total 
negative charge of the C-terminus of the protein, and is thought to play a 
role in the regulation of the oligomeric states and in NAP-1 nucleo-
cytoplasmatic transport (Regnard et al., 2000). Polyglycylation of NAP-1  
occurs on residues that are close to the polyglutamylation sites, and is 
supposed to block the further acidification of the C-terminus by preventing 
polyglutamylation itself (Ikegami et al., 2008). In this way, this PTM also 




1.3.3 NAP-1 functions and interactors 
 
NAP-1 acts as a nucleo-cytoplasmatic shuttling factor that delivers H2A/H2B 
histone dimers from the cytoplasm to the chromatin assembly machinery in 
the nucleus (Mosammaparast et al., 2005; Mosammaparast et al., 2002). 
In addition to its histone binding and nucleosome assembly activity, NAP-1 
is implicated in transcriptional regulation (extensively described in section 
1.3.4) and in the regulation of cell cycle (interacting with B-type cyclines, 
as described in (Altman and Kellogg, 1997; Kellogg and Murray, 1995).  
Furthermore, both traditional and proteome-wide approaches combined 
with mass spectrometry identified NAP-1 as a protein involved in a large 
variety of cellular functions, such as mRNA processing and translation or 
cell membrane or lysine biosynthesis,  with a vast number of interactors 
(Calvert et al., 2008; Krogan et al., 2006; Moshkin et al., 2009; Titz et al., 
2006); reviewed in (Zlatanova et al., 2007). Whether all the found 
interactions are physiologically significant still remains to be determined. 
Discussing the whole spectrum of NAP-1 functions and interactors inside 
the cell is beyond the aim of this Thesis; therefore, in the next section I will 
focus on the roles exerted by NAP-1 during transcription. 
 
1.3.4 NAP-1 and nucleosome dynamics during transcription 
 
Chromatin structure poses significant obstacles on RNA Pol II-mediated 
transcription at the levels of both initiation and elongation. The 
participation of histone chaperones in modulating chromatin fluidity and 
accessibility during transcription initiation and elongation has been 
described in several reports, although further investigation especially 
concerning the roles of these proteins in vivo, is still needed.  
Suggestive of the crucial role exerted by NAP-1 in transcriptional 
regulation, is a finding obtained from a microarray-based genome-wide 
expression analysis in nap-1 yeast cells. This analysis revealed that in the 
knock-out cells, about 10% of all yeast open reading frames changed their 
transcription levels more than 2-fold when compared to the wild type strain 
(Ohkuni et al., 2003). In a more recent screening performed in yeast NAP-1 
was also found among the transcriptional activators (Titz et al., 2006). 
Besides, both in vitro and in vivo studies using reconstituted nucleosomal 
arrays or reporter constructs respectively, indicated that NAP-1 has a 
stimulatory effect on transcription, which could be further enhanced in the 
presence of activator or co-activator proteins (Asahara et al., 2002; 
Rehtanz et al., 2004; Shikama et al., 2000).  
Recently, several lines of evidence have suggested a role of NAP-1 in 
develpmental gene regulation. Indeed, a proteomics survey of the protein 
interaction networks of several histone chaperones, including NAP-1, was 
performed in Drosophila embryos, and revealed the interaction of this 
protein with the RLAF (RPD3 LID-Associated Factors) complex. This 
complex possesses both histone deacetylase and TriMethH3K4-
demethylase activities, and it is therefore implicated in gene silencing; in 
particular, a cooperation between RLAF and NAP-1 was shown to mediate 
repression of Notch–regulated genes (Moshkin et al., 2009). In addition, in 
a study aimed at characterizing the chromatin changes associated to the 
reprogramming of mouse Primordial Germ Cells (PGCs) to totipotency, 
NAP-1 was shown to accumulate in the nuclei of reprogramming cells 
(while being almost completely cytoplasmatic in the neighbouring somatic 
cells). Collectively, these findings strongly support the view of histone 
chaperones, such as NAP-1, as key regulators of the global tuning of gene 
expression occurring during development (Hajkova et al., 2008). 
 
Chromatin dynamics is tightly regulated by a multiplicity of mechanisms 
including histone modifications, chromatin remodeling, histone variant 
incorporation and histone eviction. The concerted action of all these 
mechanisms is required to displace nucleosomes at promoters 
concomitantly with gene activation (Bernstein et al., 2004; Cairns, 2009; Li 
et al., 2007; Workman, 2006), and references therein). Numerous literature 
data have shown that histone chaperones assist in both the deposition and 
the removal of promoter nucleosomes.   
That transcriptionally active chromatin is depleted in H2A/H2B histones is a 
well-known notion (Baer and Rhodes, 1983). In this respect, NAP-1 forms a 
complex with H2A/H2B dimers enhancing their release, and induces a 
topologically-dependent H3/H4 release from in vitro-transcribed templates 
(Levchenko and Jackson, 2004). NAP-mediated removal of H2A/H2B dimers 
also facilitates nucleosome sliding along DNA in an ATP-independent 
manner (Park et al., 2005), and recruitment of transcription factors to gene 
promoters (Walter et al., 1995). Recently NAP-1 has also been shown to 
remove the histone H1 from chromatin fibers, suggesting that it might 
regulate transcription by modulating the local linker histone amount as well 
(Kepert et al., 2005).  
Histone variants have also been associated with nucleosome displacement 
(Thambirajah et al., 2009). In particular, H2A.Z is concentrated on the 
promoters of genes that are poised for activation and is more easily 
released from chromatin than canonical H2A. In yeast, NAP-1 is part of the 
SWR1 chromatin remodeling complex, which acts by either facilitating H2A-
H2B dimer removal or delivering the variant histone complex (Mizuguchi et 
al., 2004).  
Many histone chaperones also cooperate with chromatin remodeling 
complexes to modulate nucleosome assembly and disassembly (Angelov et 
al., 2006). Indeed NAP-1, together with RSC complex, disassembles 
nucleosomes in vitro (Lorch et al., 2006), while in vivo it cooperates with 
CHD (Chromo-Helicase/ATPase DNA binding) remodelers to displace 
nucleosomes at promoters and coding regions in an ATP-dependent 
manner upon gene transcription (Walfridsson et al., 2007). 
Both physical and functional interactions between histone chaperones and 
co-repressors/co-activators (especially HATs) have also been described 
(Eckey et al., 2007). In particular, besides being a target of p300 itself, 
previous evidence has demonstrated that NAP-1 is a functional component 
of a complex comprising the co-activator p300, and that it increases the 
activity of different p300 targets, including p53 and E2F (Rehtanz et al., 
2004; Sharma and Nyborg, 2008; Shikama et al., 2000). Furthermore, 
p300-mediated histone acetylation helps transfer H2A/H2B from 
nucleosomes to NAP-1 (Ito et al., 2000).  
If the mechanisms described so far mainly concern the involvement of 
NAP-1 in transcriptional nucleosome dynamics at the level of gene 
promoters, it is worth mentioning that NAP-1 plays an important role 
during transcription elongation as well. Evidence suggests that it functions 
in chromatin reassembly after the passage of RNA Pol II, and that its 
recruitment to the coding region of actively transcribed genes is dependent 
on the Yra1 subunit of the TREX mRNA transcription and export complex 
(Del Rosario and Pemberton, 2008). 
1.3.5 NAP-1 and viral infection 
 
Increasing evidence indicate that viruses exploit human NAP-1 (hNAP-1) for 
several purposes. For example, Rehtanz and collegues demonstrated that 
the transcriptional activator E2 of Papillomavirus forms a ternary complex 
with hNAP-1 and p300, that is efficient in the activation of viral 
transcription (Rehtanz et al., 2004). Similarly, the Tax protein of the 
Human T cell Leukemia Virus type 1 (HTLV-1) recruits the coactivators 
CBP/p300 to the viral promoter, and hNAP-1 has been shown to cooperate 
in eviction of the acetylated histones from the chromatin template 
concomitant with transcription activation (Sharma and Nyborg, 2008). 
Interestingly, also EBNA1 protein of Epstein-Barr Virus also directly binds 
hNAP-1 and this interaction is crucial for viral gene expression (Holowaty et 
al., 2003; Wang and Frappier, 2009). Finally, in a screening aimed at 
identifying new interactors of HIV-1 Rev protein, hNAP-1 has been reported 
to bind Rev, resulting in altering Rev oligomerization state and increasing 













AIM OF THE STUDY 
 
The work described in PART A of this Thesis is aimed at characterizing 
novel interactors of the Tat transactivating protein of HIV-1. In particular, 
exploiting a proteomic approach, we identify the cellular histone chaperone 
NAP-1 (Nucleosome Assembly Protein-1) as a Tat-binding protein and we 
further investigate the role that this interaction exerts in the context of viral 
infection. We propose a mechanism by which Tat benefits from this class of 
proteins to relieve the repression imposed by chromatin conformation on 















2A. RESULTS  
 
 
2.1 Identification of cellular factors binding to HIV-1 Tat by 
proteomic analysis 
In order to shed light on Tat functions, we exploited  a proteomic approach 
directed at identifying novel cellular partners that are involved in the 
regulation of HIV-1 transcription by Tat. To this aim, we used an 
expression vector encoding the open reading frame of full length Tat (101 
aa) fused with a C-terminal Flag tag (Ott et al., 1999). The Flag epitope did 
not interfere with the transactivating activity of Tat on the HIV promoter 
(data not shown). HEK 293T cells were transfected either with Tat101-Flag, 
or with a plasmid encoding for the Flag epitope alone as a negative control, 
and cell extracts were immunoprecipitated with M2 Flag antibody 
conjugated to agarose beads. Affinity purified Tat-Flag protein and co-
purifying cellular factors were subsequently subjected to a DNase/RNase 
treatment, which proved to be essential to avoid the purification of a vast 
number of RNA-binding proteins unspecifically co-immunoprecipitating with 
Tat (mainly ribosomal proteins, data not shown). After elution with an 
excess of Flag peptide, purified proteins were separated on a 6-10% 
gradient SDS-PAGE gel and stained with silver stain (Figure 2.1 panel A). 
Individual bands that were apparent in the sample from the Tat-Flag-
transfected but not in the Flag-transfected cells were excised, and the 
corresponding proteins were identified by mass spectrometry. ESI-MS/MS 
(Electrospray tandem Mass Spectrometry) analysis of peptides obtained by 
trypsin digestion led to the identification of four proteins, as listed in Figure 
2.1, panel B. Apart from Tat-Flag itself, as expected we recognized 
previously described Tat partners, such as the p32 subunit of the ASF/SF2 
splicing factor (Petersen-Mahrt et al., 1999) and B23/nucleophosmin (Chan 
et al., 1997). p32 is also known as Tat-Associated Protein (TAP) due to its 
well-known ability to bind Tat both in vitro and in vivo; (Yu et al., 1995); 
acetylated Tat was shown to bind p32 thus inhibiting splicing and 
promoting the production of full-length transcripts (Berro et al., 2006). 
B23/nucleophosmin is a nucleolar protein possibly associated with ribosome 
assembly and/or transport, which binds Tat when both proteins are 
overexpressed (Li, 1997) and is required for Tat nucleolar localization but 
not for promoter transactivation (Stauber and Pavlakis, 1998).  
Furthermore, we identified a few novel potential Tat interactors, among 
these, ribosomal protein S4 and hNAP-1 (human Nucleosome Assembly 
Protein-1), a histone chaperone that plays multiple roles during chromatin 
transactions (see Section 1.3 of this Thesis). The proteomic analysis was 
repeated and the results were also  confirmed by sequencing proteins 
directly from the Flag beads, instead than from gel-excised bands. 
Since overexpressed Tat is known to accumulate in the nucleoli due to its 
unspecific RNA binding capacity (e.g. (Marcello et al., 2001a)), and given 
the observation that the same proteomic assay resulted in the identification 
of a number of other ribosomal proteins when performed in the absence of 
RNAse, no further work was performed on the ribosomal S4 protein.  
Of notice, hNAP-1 was identified by several peptides (as indicated in Figure 
2.1 panel C), in three independent preparations, with P=7.8 x 10-19, 
indicating highly specific and reproducible interaction. Therefore, further 




























2.2 hNAP-1 specifically binds HIV-1 Tat in vivo 
 
To confirm the interaction between Tat and hNAP-1 found in the proteomic 
assay, we performed a co-immunoprecipitation analysis exploiting two 
C 
A B 
Figure 2.1  Identification of Tat-interacting proteins by mass 
spectometry. 
A. Flag-immunopecipitated material from Tat-Flag- and Flag- (indicated as 
mock) transfected HEK 293T cells was resolved by 6-10% gradient SDS-
PAGE gel, followed by silver staining. Protein bands present exclusivelyin the 
sample transfected with Tat-Flag were excised from the gel and their 
identification attempted by ESI-MS/MS. The identified proteins, in addition to 
Tat-Flag, are indicated with numbers. B. Identified proteins are listed in the 
table, together with their accession numbers to NCBI or SwissProt 
databases, and with their molecular mass expressed in kDa. C. Amino acid 
sequence of the human NAP-1 protein. The underlined amino acid 
sequences correspond to peptides obtained from MS/MS analysis of three 
independent preparations. 
epitope-tagged versions of both proteins. When expression vectors for Tat-
Flag and for an N-terminal hemagglutinin (HA)-tagged version of hNAP-1 
(HA-NAP-1, (Rehtanz et al., 2004)) were transfected into HEK 293T cells, 
HA-NAP-1 was co-immunoprecipitated with Tat using an anti-Flag antibody 
(Figure 2.2, upper panels). Furthermore, the specificity of the interaction of 
the two proteins is underlined by the observation that no co-
immunoprecipitation was observed neither when HA-NAP-1 was co-
expressed with a Flag-tagged luciferase expressing plasmid, nor when Tat 
was co-expressed together with HA-tagged SET/TAF-I (Pegoraro et al., 
2006), another member of the NAP family, despite its high sequence 
homology with hNAP-1 (further discussed in the Section 3.1 of this Thesis) 
Of note, the EBNA1 protein of EBV binds both of them, as described in 












Figure 2.2  Co-immunoprecipitation of Tat with transfected hNAP-
1. 
The plasmids indicated on top of the figure were transfected into HEK 293T 
cells. The upper two panels show western blots with the indicated antibodies 
after immunoprecipitation using an anti-Flag antibody; the lower two panels 
show western blotting controls from from whole cell extracts (WCL) from 
transfected cells to show the levels of expression of the transfected proteins. 
The same extracts were run on an SDS-PAGE gel and immunoblotted with 
anti-Flag and anti-HA antibodies to verify protein expression levels. 
Interestingly, the levels of Tat protein were significantly higher in cells also 
expressing hNAP-1 or hSET/TAF-I (Figure 2.2, lower panels). Whether this 
observation argues for a stabilizing effect that histone chaperones exert on 
small highly basic proteins, such as histones or Tat itself, or it is solely an 
artefact due to protein overexpression, is still to be determined. The same 
co-immunoprecipitation experiment was repeated omitting the treatment of 











Figure 2.3  Co-immunoprecipitation of Tat with transfected hNAP-1 
in the absence of DNase/RNase treatment. 
The plasmids indicated on top were transfected into HEK 293T cells. 
Twenty-four hours after transfection, cell lysates were immunoprecipitated 
with an immobilized anti-Flag antibody without treatment with DNase I and 
RNase A. Immunoprecipitated proteins were resolved by SDS-PAGE along 
with input whole cell lysates (WCL; upper panel, left side) and revealed by 
anti-HA antibody. The arrow shows  transfected hNAP-1 co-
immunoprecipitated with Tat-Flag. 
The same membrane as above was stripped mildly and exposed to an anti-
Flag antibody to monitor the efficiency of transfection and 
immunoprecipitation. The bands indicated by an asterisk correspond to 
residual HA-hNAP-1 not removed by stripping. 
 
A 
As shown in Figure 2.3, the binding between Tat and hNAP-1 was 
confirmed, and these data are even more convincing because they exclude 
the possibility that treatment with nucleases might have exposed the basic 
domain of Tat allowing its interactions with other proteins otherwise 
inaccessible to them. Of note, hNAP-1 overexpression resulted in a 
remarkable higher expression of Tat, as in the previous experiment. 
To further validate our data we performed another co-immunoprecipitation 
experiment, in which extracts of HEK 293T cells transfected with a GFP-
tagged-Tat-encoding plasmid (Marcello et al., 2001a) and with GFP-
encoding plasmid as a negative control, were immunoprecipitated with an 
anti-GFP antibody. The antibody (Ishimi et al., 1985) detected hNAP-1 in 
samples of Tat-GFP-transfected but not GFP-tranfected cells, thus 
indicating that HIV-1 Tat binds specifically also the endogenous hNAP-1 
protein (Figure 2.4 panel A).  
Finally, bacterially expressed and purified GST-Tat recombinant protein, but 
not recombinant GST, was also able to pull-down endogenous hNAP-1 from 
a HEK 293T cell extract, as shown in Figure 2.4 panel B. It is worth 
mentioning that both GFP- and GST-Tat retain full transcriptional and 
trafficking capacities as the wild-type protein, as demonstrated elsewhere 
(Demarchi et al., 1996; Fittipaldi et al., 2003; Marcello et al., 2001a; 


























2.3 hNAP-1 binds HIV-1 Tat through its C-terminal domain 
 
Once established that hNAP-1 and HIV-1 Tat interact in vivo, we sought to 
dissect the regions that mediate this interaction. 
To map the Tat-interacting domain in the hNAP-1 protein, full-length (aa 1-
391) and several deletion mutants of hNAP-1 were expressed as GST-
fusion recombinant proteins (Rehtanz et al., 2004). In particular, the 
following deletion mutants were produced, as shown in Figure 2.5 panel A: 
three mutants lacking progressively longer N-terminal portions (aa 92-391; 
aa 162-391; aa 290-391, respectively); three mutants lacking progressively 
longer C-terminal portions (aa 1-290; aa 1-162; aa 1-92); three mutants 
lacking both N- and C-termini, and containing different parts of the central 
domain (aa 162-290, aa 92-162, aa 92-290). GST pull-down experiments 
with these fragments were performed using in vitro translated 35S-labeled 
HIV-1 Tat. GST-hNAP-1 fragments immobilized on beads were incubated 
with 35S-Tat and, after extensively washing, proteins were resolved by SDS-
B 
Figure 2.4  Co-immunoprecipitation of Tat with endogenous hNAP-
1. 
A. Co-immunoprecipitation of endogenous hNAP-1 with GFP-Tat. Extracts 
prepared from HEK 293T cells transfected with plasmids encoding for GFP-
Tat or GFP alone were immunoprecipitated with an anti-GFP antibody and 
immunoblotted with anti-hNAP-1 antibody. Whole cell extracts (WCE) were 
run on an SDS-PAGE gel and immunoblotted with anti-GFP and anti-hNAP-1 
antibodies to verify amounts of expressed proteins. B. GST-pulldown 
experiment using GST-Tat or GST alone recombinant proteins; Gst-Tat, but 
not control GST protein, pulled down endogenus hNAP-1 from HEK 293T 
whole cell extracts. 
 
A 
PAGE. Figure 2.5 panel B shows the gel either stained with Coomassie Blue 









Figure 2.5  Mapping of the Tat-interacting domains in the hNAP-1 
protein. 
A. Schematic representation of hNAP-1 protein and of its deletion mutants 
obtained as GST fusion proteins. The capacity of binding to Tat (panel B) is 
indicated on the right side of each mutant. The two dotted boxes indicate 
the hNAP-1 domains interacting with Tat. B. Representative GST pull-down 
experiment using the indicated hNAP-1 mutants and radiolabeled Tat full-
length protein. The autoradiography shows the amount of Tat binding to 
each mutant; the histogram on top shows densitometric quantification of 
data, expressed as fold binding with respect to background binding to GST 
alone (set as 1). The lower panel shows the Coomasssie stained gel at the 
end of the binding experiment. The experiment was repeated at least three 
times with similar results. 
 
B 
As expected, labeled HIV-Tat was found to bind GST-hNAP-1 but not GST 
alone. All deletants lacking the N-terminus of the protein up to aa 161 
bound Tat as efficiently as the full length protein. In contrast, binding was 
greatly impaired when the hNAP-1 domain from residues 163 to 289 as well 
as the C-terminal region from residues 290 to 391 were deleted. These 
results indicate that Tat binds two separable domains within the hNAP-1 
protein, one internal from amino acid 162 to 290 and one C-terminal from 
residues 290 to 391 (Figure 2.5 panel B). The former encompasses the 
four-stranded antiparallel –sheet previously shown to act as the protein 
interaction domain (Park and Luger, 2006b) interacting with other cellular 
factors, without compromising histone binding (Mosammaparast et al., 
2002; Shikama et al., 2000). The latter domain corresponds to the long 
acidic region which is also involved in the binding of other cellular proteins 
such as the histone acetytransferase p300 (Shikama et al., 2000). 
 
 
2.4 The basic domain of HIV-1 Tat binds the C-terminal domain of 
hNAP-1 
 
Conversely, next we analyzed the domains of Tat responsible for the 
interaction with hNAP-1. For the expression of both full-length and mutated 
Tat derivatives we used the 86 aa-long form of Tat, present in the widely 
studied HXB2 strain, which is transcriptionally active as well as Tat 101 
(Jeang et al., 1999). A few deletion mutants were produced, one lacking 
the second exon (aa 1-72) and one lacking the N-terminal acidic domain 
(aa 22-86). Also point mutation mutants were employed in the assay, 
namely a derivative of Tat86 carrying cystein to alanine mutations at 
positions 22, 25 and 27 in the cystein-rich domain or arginine to alanine 





(Tat86 C(22-27)A and Tat86 R(49-57)A, respectively) (Marzio et al., 1998) 
(Figure 2.6A). These proteins, obtained as C-terminal fusions to GST, were 
used to pull-down 35S-methionine-labelled hNAP-1 obtained by in vitro 
transcription/translation.  
 
Figure 2.6  Mapping of the hNAP-1-interacting domains in the HIV-
1 Tat protein. 
A. Schematic representation of HIV-1 Tat protein and of its mutants 
obtained as GST fusion proteins. The capacity of binding to hNAP-1 (panel 
B) is indicated on the right side of each mutant. The dotted box correspond 
to the basic domain of Tat, which binds hNAP-1. B. Representative GST pull-
down experiment using the indicated Tat derivateves and in vitro transcribed 
and translated hNAP-1 protein. The autoradiography shows the amount of 
hNAP-1 binding to each mutant; the histogram on top shows densitometric 
quantification of data, expressed as fold binding with respect to background 
binding to GST alone (set as 1). The lower panel shows the Coomasssie 
stained gel at the end of the binding experiment. The experiment was 
repeated at least three times with similar results. 
 
The results obtained demonstrated that the interaction of Tat with hNAP-1 
strongly depended on the integrity of the arginine-rich region of Tat, clearly 
indicating that Tat binds hNAP-1 through its basic domain. Similar of our 
observations with Tat, interactions of hNAP-1 with HIV-1 Rev and EBNA1 of 
EBV occur through arginine-rich regions (Cochrane et al., 2009; Holowaty 
et al., 2003). 
 
 
2.5 hNAP-1 and Tat cooperate in the activation of HIV-1 gene 
expression 
It is well known that one of the main biological functions of Tat is the 
transcriptional transactivation of LTR and, moreover, that one of the 
essential molecular events that parallel Tat-driven transcriptional activation 
is the modification of chromatin structure that essentially represses 
transcription from the integrated HIV-1 promoter (Easley et al., 2009; Lusic 
et al., 2003; Van Lint et al., 1996; Verdin et al., 1993). 
hNAP-1 acts as a histone chaperone operating in both transcription and 
DNA replication (reviewed in (Park and Luger, 2006a; Zlatanova et al., 
2007). Nucleosomes are displaced at promoters during gene activation in a 
process that involves histone modifications, ATP-dependent chromatin 
remodeling complexes, histone variants and histone eviction (Li et al., 
2007). Several findings indicated that hNAP-1 participates in the regulation 
of dynamics of chromatin structure through a multiplicity of mechanisms 
(See Section 1.3.4 of this Thesis). 
Based on these evidences, and in order to gain insights into the mechanism 
of the cooperativity between hNAP-1 and Tat proteins, we analyzed their 
roles in the LTR transactivation exerted by HIV-1 Tat. To this aim, a 
reporter construct containing the U3 and R sequences of the HIV-1 LTR 
upstream of the firefly luciferase reporter gene was co-transfected into 
HeLa cells, together with vectors for HA-tagged hNAP-1 and HIV-1 Tat. As 
shown in Figure 2.7, Tat determined a 200- to 250-fold increase in the 
levels of gene expression, depending on the amount of transfected vector. 
The expression of hNAP-1 alone did not stimulate promoter activity (same 
activation as the basal promoter). However, the co-expression of hNAP-1 
together with increasing amounts of Tat increased luciferase activity 520- 
and 620-fold respectively, suggesting that hNAP-1 is able to enhance Tat-
mediated transactivation of LTR promoter. Part of the lysates not subjected 
to the luciferase assay were loaded on a SDS-PAGE gel and immunoblotted 





Figure 2.7  hNAP-1 cooperates with Tat in LTR transactivation. 
HeLa cells were co-transfected with a reporter construct containing the HIV-
1 LTR upstream of the luciferase gene, and with vectors expressing HA-
tagged hNAP-1 and HIV-1 Tat, as indicated. The histogram shows mean ± 
standard deviation for at least three independent experiments; the results 
are shown as fold transactivation over LTR-luciferase reporter alone. The co-
expression of hNAP-1 significantly increased Tat transactivation of the LTR 
promoter. The wester blot at the bottom shows the levels of transfected 
hNAP-1 protein in a representative experiment. 
To test the requirement for endogenous hNAP-1 protein in Tat-mediated 
HIV-1 LTR transactivation, we performed luciferase assays with HeLa cells 
in which expression of hNAP-1 was down-regulated by RNAi. A specific 
anti-hNAP-1 siRNA oligonucleotide was designed which was able to silence 
up to 80% of the expression of its target from forty-eight hours after 










After thirty-six hours from the beginning of siRNA treatment, cells were 
transfected with the reporter plasmid LTR-luciferase together with 
increasing amounts of HIV-1 Tat-encoding plasmid. Thirty-six hours later, 
luciferase assays on cell lysates were performed. As expected, in control 
siRNA-transfected cells we observed a dose-dependent increase in LTR 
Figure 2.8  hNAP-1 knock-down greatly impaired Tat-mediated LTR 
transactivation. 
HeLa cells were transfected with a specific siRNA against hNAP-1 or a 
control siRNA, and then transfected with the LTR-luciferase reporter 
together with Tat. The histogram shows mean ± standard deviation for at 
least three independent experiments; the results are shown as fold 
transactivation over LTR-luciferase reporter alone. The western blot at the 
bottom shows the levels of endogenous hNAP-1 protein and of tubulin as a 
control in a representative experiment. 
transactivation in response to Tat, while luciferase activity was greatly 
impaired in cells in which the expression of hNAP-1 had been silenced,  
compared to control cells.
Collectively, the results of these experiments strongly indicate that hNAP-1 
participates in Tat-mediated control of HIV-1 gene expression. 
 
2.6 Effect of hNAP-1 on HIV-1 infection 
 
To examine the effect of hNAP-1 on HIV-1 expression, we used an HIV-1 
vector in which a portion of nef gene had been replaced by the firefly 
luciferase gene; two frameshifts inactivate vpr and env genes, thus 
blocking subsequent rounds of viral replication (pNL4.3 R- E-). Infectious 
virus, pseudotyped with the Vesicular Stomatitis Virus pantropic envelope 














Figure 2.9  Effect of hNAP-1 overexpression on HIV-1 infection. 
Overexpression of hNAP-1 enhances LTR transcription upon HIV-1 infection. 
HeLa cells were transfected with an expression vector for HA-hNAP-1 or with 
a control vector, and then infected with VSVG-luciferase HIV-1 vector. 
Luciferase activity was measured 24 hours after infection. The mean ± 
standard deviation of at least three different experiments is shown. The 
panel on the right side shows anti-HA immunoblotting to assess HA-hNAP-1 
expression in a representative experiment.  
Pseudotyped virus was used to infect HeLa cells in which hNAP-1 had been 
either overexpressed or knocked-down by RNAi.  As shown in Figure 2.9, 
the overexpression of hNAP-1 (as assessed by western blot analysis) 
resulted in a 5-fold increase of luciferase activity in HA-hNAP-1-transfected 
cells compared to mock-transfected cells.  
Conversely, we tested what was the effect of knocking-down the 
expression of endogenous hNAP-1. HeLa cells were treated with a control 
siRNA and with a siRNA directed against hNAP-1, and infected with the 
luciferase reporter virus. Twenty-four hours later we performed luciferase 
assay on cell lysates: consistent with the previous overexpression 
experiment, luciferase activity was significantly decreased in cells in which 
the expression of hNAP-1 had been silenced, compared to control cells 
(Figure 2.10). 
Taken together, these results strongly support the conclusion that hNAP-1 
also plays an important activating role in the context of HIV-1 expression. 
Figure 2.10  Effect of hNAP-1 knocking-down on HIV-1 infection. 
Silencing of hNAP-1 impairs LTR transcription upon HIV-1 infection. HeLa 
cells were treated with an siRNA directed against hNAP-1 or a control siRNA. 
48 hours after the beginning of siRNA treatment, cells were infected with 
the luciferase reporter virus, and luciferase assays were performed on cell 
lysates 24 hours later. The mean ± standard deviation of at least three 
different experiments is shown. The panel on the right side shows anti-
hNAP-1 immunoblotting to assess the levels of endogenous hNAP-1 and 
tubulin expression in a representative experiment. 
Taken together, these results strongly support the conclusion that hNAP-1 
also plays an important activating role in the context of HIV-1 infection. 
 
 
2.7 p300, hNAP-1 and Tat synergistically activate HIV-1 
transcription 
 
Previous work has indicated that hNAP-1 interact with the cellular 
transcriptional co-activator and histone acetyltransferase p300 . Similar to 
Tat, the binding of p300 to hNAP-1 involves two domains, one from 
aminoacids 123 to 230 and a second one C-terminal to aminoacid 290 
(Asahara et al., 2002; Ito et al., 2000; Shikama et al., 2000). Since it has 
been demonstrated that Tat protein directly interacts with p300, and that 
p300 ia also an essential co-factor for Tat-driven HIV-1 expression (Marzio 
et al., 1998), we investigated the effects of hNAP-1 and p300 on Tat-
mediated transactivation.  
For this purpose, HeLa cells were transfected with an LTR-luciferase 
reporter plasmid and expression vectors for p300 and hNAP-1 together with 
Tat. According to our previous observations (Marzio et al., 1998), p300 
enhanced Tat-driven transcriptional activation ( 2 folds over Tat alone), as 
well as hNAP-1 enhanced Tat-mediated transactivation  2.5 folds over Tat 
alone (see Figure 2.7). Neither p300 nor hNAP-1 alone, nor hNAP-1 plus 
p300 had any significant effect on transcription.  However, when all the 
three proteins were overexpressed, transcription was further increased 














To sought out which could be the mechanism underlying the cooperativity 
between Tat, hNAP-1 and p300 in LTR transactivation, we performed a co-
immunoprecipitation assay in the same experimental conditions as reported 
for the luciferase assay described in Figure 3.11. In cells overexpressing 
p300, the amount of hNAP-1 protein co-immunoprecipitating with Tat was 
markedly increased, as shown in the upper panel of Figure 3.12. Since  
overexpression of p300 did not affect the levels of expression of hNAP-1 or 
Tat proteins (immunoblots on whole  cell lysates, Figure 2.11), our findings 
are consistent with the possibility that p300 might stsbilize the formation of 





Figure 2.11  hNAP-1, Tat and the acetyltransferase p300 
sinergistically activate viral transcription. 
HeLa cells were co-transfected with LTR-luciferase reporter plasmid and with 
vectors for HIV-1 Tat, HA-hNAP-1 and p300, as indicated. The histogram 
shows the mean ± standard deviation of at least three independent 
experiments; results are expressed as fold transactivation over LTR-
luciferase reporter alone. 
 
Figure 2.12  p300 enhances Tat.hNAP-1 interaction in vivo. 
The plasmids indicated on top of the figures were transfected into HEK 293T 
cells. The upper panel shows immunoblot with anti-HA antibody after 
immunoprecipitation using an anti-Flag antibody. The lower three panels 
show western blotting controls from whole cell lysates (WCL) from 






Activation of the HIV-1 LTR is a complex event involving the coordinated 
function of several cellular proteins acting by both releasing the negative 
inhibition that chromatin imposes on the promoter and inducing the 
recruitment of elongation-competent RNA Pol II-containing complexes. Tat 
appears to exert an essential activatory role for both these processes. Tat 
function is highly dependent on specific interactions with a variety of 
cellular proteins. In the last decade, a number of laboratories have 
reported the identification of various cellular factors that mediate Tat 
function. These factors fall in several broad categories, including members 
of the basal transcriptional machinery, among which RNA Pol II itself, 
ubiquitous transcription factors, transcriptional co-activators, histone-
acetyltransferases, and others (Brady and Kashanchi, 2005; Gautier et al., 
2009; Giacca, 2004; Marcello et al., 2004). Overall, these factors only 
partially account for the complexity of the molecular mechanisms 
underlying Tat-mediated transactivation, and the overall process of proviral 
gene expression into the host cells still remains only partially explained. 
 
 
3.1 HIV-1 Tat and the cellular histone chaperone hNAP cooperate 
in the activation of HIV-1 gene expression 
 
Our proteomic screening led to the identification of yet another cellular 
partner, the histone chaperone hNAP-1, that appears to be involved in 
mediating Tat function. Full length hNAP-1 protein is 391 amino acid long, 
contains three acidic domains and has a long KIX-binding domain (Park and 
B 
A 
Luger, 2006b) (Figure 3.1 panel A). NAP-1 belongs to the NAP family of 
proteins, whose members are characterized by an elevated sequence 
homology (for a recent review, see (Park and Luger, 2006a)). In particular, 
the KIX-binding domain (Asahara et al., 2002) and the long C-terminal 
acidic domain are the most conserved among NAP histone chaperones, as 
it is demonstrated by 47% and 68% amino acid homology in the two 
regions respectively between hNAP-1 and hSET-TAF-I, another member of 
the NAP family (Kawase et al., 1996; von Lindern et al., 1992)(Figure 3.1 
panel B). Crystal structures of both yNAP1 and hSET/TAF-I were 
determined and  their comparison revealed that the two proteins were 








Interaction between Tat and hNAP-1 was confirmed both in vitro and inside 
the cell, and the domains that are involved in the binding were mapped, in 
both hNAP-1 and in Tat proteins. The basic region of Tat was found to bind 
two separable domains within hNAP-1, one internal from aminoacids 162 to 
Figure 3.1  Schematic representation of hNAP-1 and sequence 
homology between hNAP-1 and hSET/TAF-I. 
A. The acidic domains of hNAP-1 are rapresented as black boxes, with the 
indication of their boundary amino acids. The NLS, NES and KIX-binding 
domains are marked. B. The most conserved regions between hNAP-1 and 
hSET/TAF-I are shown by grey boxes, and the percentage of homology is 
indicated. 
290 and one C-terminal from residues 291 to 392. These domains 
correspond to a series of alternate  - helix/ -sheet regions that are known 
to be involved in the interaction with histones and other cellular proteins 
(see (Park and Luger, 2006a, b) and references therein). Of notice, the 
observation that Tat does not bind the highly homologue C-terminal acidic 
domain of hSET/TAF I, argues in favor of a specific interaction between Tat 
and hNAP-1 which is not merely based on electrostatic interactions. 
The relevance of the detected interaction between Tat and hNAP-1 was 
further reinforced by the observations that the over-expression of hNAP-1 
stimulated Tat-mediated transactivation of the LTR in a dose-dependent 
manner, as well as HIV-1-expression in the context of viral infection. 
Conversely, the down-regulation of the protein by RNAi greatly impaired 
viral expression.  
To our knowledge, this is the first demonstration of an interaction between 
Tat and a histone chaperone and a first proof of the involvement of this 
class of proteins in the regulation of proviral transcription. Of interest, the 
recent finding that Rev also binds hNAP-1, resulting in an alteration of the 
oligomerization state of the protein and in a consequent increase in Rev 
aviability, suggests that hNAP-1 can modulate HIV-1 infection exerting its 
positive role at several steps of the viral life cycle (Cochrane et al., 2009). 
Furthermore, it is worth mentioning that interactions between hNAP-1 and 
other viral transactivators, such as the E2 protein of HPV (Rehtanz et al., 
2004), the Tax protein of HTLV-1 (Sharma and Nyborg, 2008) and the 
EBNA1 (Holowaty et al., 2003; Wang and Frappier, 2009) protein of EBV, 
have also been described. 
 
Of notice, and in contrast to our expectations, the proteins we identified in 
our proteomic screening did not detect several of the cellular proteins 
previously reported to associate with Tat and to mediate some of its 
functions. Several possible reasons might explain this outcome.  
Our proteomic screening was conducted by immunoprecipitating a Flag-
epitope tagged version of Tat (which was fully active transcriptionally) 
followed by RNase/DNase treatment, elution with a Flag peptide and 
resolution of Tat-associated proteins by gradient gel electrophoresis. In 
particular, we found that RNase treatment was essential to avoid the 
purification of a vast number of RNA-binding proteins unspecifically co-
immunoprecipitating with Tat (data not shown). It might well be envisaged, 
however, that this clearing step might also affect the binding of Tat to 
some of its known partners, the interaction of which is strengthened by 
RNA bridging. In addition, RNA removal also frees the basic domain of Tat, 
thus rendering this region available for the interaction with hNAP-1 
(although we also demonstrated that the binding of the two proteins 
occurred even in the absence of the DNase/RNase treatment).  
An additional explanation for the lack of other known Tat partners in our 
screening relates to the relative abundance of hNAP-1 in the cells, 
compared to other proteins such as p300 or P/CAF HATs, or Cyclin T1. 
Since our method relied on the identification of protein bands in silver-
stained gels, a likely possibility is that we missed the detection of lower 
abundance proteins.  
Finally, it is worth however noting that other proteomic screening aimed at 
the identification of cellular partners to other proteins also failed in 
identifying obvious candidates, while successfully discovered new factors 
essential for the function of the investigated proteins (Berro et al., 2006; 
Cochrane et al., 2009; Janardhan et al., 2004). 
 
 
3.2 p300, hNAP-1 and Tat synergistically activate HIV-1 
transcription 
 
There is growing evidence that hNAP-1 plays important roles during 
transcriptional activation (Ohkuni et al., 2003; Rogner et al., 2000; Steer et 
al., 2003; Walfridsson et al., 2007). In particular, hNAP-1 and other histone 
chaperones both cooperate with ATP-dependent chromatin remodeling 
complexes (Asahara et al., 2002; Nakagawa et al., 2001) and participate in 
the formation of protein complexes also containing p300/CBP (Asahara et 
al., 2002; Ito et al., 2000; Rehtanz et al., 2004; Shikama et al., 2000). 
Taken together, these observations clearly suggest that hNAP-1 may serve 
as an interaction hub between transcriptional co-activators and chromatin. 
As far as p300/CBP is specifically concerned, p300 has been shown to 
directly bind the C-terminus of hNAP-1, namely the same region that is also 
involved in binding to Tat. Since the basic domain of Tat is also involved in 
binding to p300 (Marzio et al., 1998), we cannot rule out the possibility 
that p300 might act as a scaffold for the simultaneous interaction with the 
two proteins. While further biochemical studies are clearly needed to 
ascertain this possibility, it is of interest to observe that the over-expression 
of all the three proteins together determined an increase in the levels of 
LTR transcription that is higher than those obtained by over-expression of 
either p300 or hNAP-1 alone together with Tat. In addition, expression of 
p300 did not affect the levels of hNAP-1 or Tat proteins, but markedly 
increased their binding in vivo. This observation is again in favour of the 
view that p300 might exert a stabilizing role on the Tat-hNAP-1 interaction. 
This possibility would be consistent with the proposed function for hNAP-1 
in regulating transcription in all p300-dependent promoters (Rehtanz et al., 
2004; Sharma and Nyborg, 2008; Shikama et al., 2000).  
3.3 Models for hNAP-1-mediated chromatin dynamics and 
transcriptional activation at HIV-1 promoter 
 
What might be the actual mechanism by which hNAP-1 might facilitate Tat 
transactivation?  
(i) First, over-expression of hNAP-1 significantly increases the overall levels 
of Tat inside the cells. This result is consistent with the possibility that the 
positive effect exerted by hNAP-1 on HIV-transcription is due to a hNAP-1-
mediated stabilization of the Tat protein itself. 
(ii) Second, and more relevant to a specific and direct role of hNAP-1 on 
the LTR promoter, we envision that hNAP-1 might play a positive role on 
HIV-1 transcription because it relieves repression exerted by chromatin at 
the HIV-1 promoter. Earlier results have indicated that the acetylation of 
histones by p300 helps transfer histones H2A and H2B from nucleosomes 
to hNAP-1 (Ito et al., 2000) and that, at least in vitro, the absence of 
histones H2A and H2B correlates with increased gene activity, probably by 
decreasing the level of chromatin folding (Baer and Rhodes, 1983; Chan 
and La Thangue, 2001). On the basis of these findings and of previous 
observations made at the level of the HTLV-1 promoter (Sharma and 
Nyborg, 2008), we can speculate that hNAP-1 and p300, brought to the 
LTR promoter through their interaction with Tat,  might cooperate in the 
creation of an open-chromatin environment, favorable for gene expression. 
In addition, it is likely that histone loss results from a process of 
nucleosome eviction rather than nucleosome sliding, as oserved for the H3-
H4 histone chaperone Asf1 (Anti-Silencing Factor 1) in yeast (Adkins et al., 
2004).  
Supporting this model, a recent genome-wide analysis in fission yeast has 
revealed that chromatin remodeling factors and NAP-1 co-localize within 
promoter regions, and cooperate to disassemble nucleosomes near the 
TSS, an event that is linked to changes in the levels of histone acetylation 
(Walfridsson et al., 2007). SWI/SNF ATP-dependent chromatin remodeling 
complexes and acetylated histones have been shown at the LTR promoter 
upon transcriptional activation as well (Agbottah et al., 2006; Henderson et 
al., 2004; Lusic et al., 2003; Treand et al., 2006). 
 
Figure 3.2  A proposed model for Tat and hNAP-1 synergy in the 
LTR promoter transactivation (see text for details). 
 
Further understanding into this model might arise from ChIP experiments, 
which would allow one to assess the recruitment of hNAP-1 at the HIV-1 
promoter upon transcriptional activation, as well as from biochemical 
approaches, such as micrococcal nuclease assays, that would address 
nucleosome occupancy on in vitro-chromatinized LTRs. 
 
 
3.4 HIV-1 latency 
 
Our study unraveled a novel mechanism exploited by HIV-1 Tat to 
overcome the repression that the chromatin environment exerts on viral 
gene expression. In this context, it is worth mentioning that highlightening 
the epigenetic mechanisms through which chromatin governs HIV-1 
expression is critical for understanding the phenomenon referred to as 
proviral latency, which  still represents one of the major challenges to find 
a cure for HIV-1 infection (Richman et al., 2009). 
Latent HIV-1 reservoirs are established early during primary infection and 
constitute a major barrier to eradication, even in the presence of HAART 
(Highly Active Anti-Retroviral Therapy). The main reservoir is composed of 
latently infected resting memory CD4+ T lymphocytes that harbour a 
transcriptionally inactive integrated provirus (Chun et al., 1997; Chun et al., 
1995). The extremely long half-life of this cell population, together with a 
tight control of HIV-1 gene expression allows the virus to maintain hidden 
copies of its genome, which are in turn able to trigger a novel systemic 
infection upon interruption of therapy. 
Given the importance of the charachterization of this reservoir in order to 
achieve viral eradication, significant effort has been made to define the 
mechanisms that establish and maintain HIV-1 latency, most of which 
operate at the transcriptional level, thus being influenced both by the 
chromatin environment at the site of viral integration and by the availability 
of viral and host factors.  
Latency was shown to result from transcriptional interference, which 
depends on the integration site and on the orientation of the provirus in 
the cell chromosome (Han et al., 2008; Lenasi et al., 2008), or from 
modification of chromatin conformation and remodeling, especially as far as 
modifications of histone tails are concerned – for example, latently infected 
Jurkat cells show highly deacetylated and trimethylated histones (Pearson 
et al., 2008). Finally, latency might  ensue as a consequence of the 
absence of nuclear host transcription activators or presence of cellular 
transcriptional repressors (Coiras et al., 2007). Comprehensive reviewes on 
HIV-1 latency can be found in the recent literature (Coiras et al., 2009; 
Lassen et al., 2004; Marcello, 2006; Williams and Greene, 2007).  
It will be interesting to understand at what extent the interaction between 
Tat and hNAP-1 might provide new information on the molecular 










4A. MATERIALS AND METHODS 
 
 
4.1 Protein purification and identification  
 
Twenty-four hours after transfection, 2 X 108 HEK 293T cells were washed 
once in phosphate-buffered saline (PBS) and lysed on ice in lysis buffer 
(150 mM NaCl/ 20 mM HEPES pH 7.9/ 0.5% NP-40/ 1 mM EDTA/ 1mM 
DTT/ protease inhibitor cocktail-Roche). The cell extract was sonicated 
once and then centrifuged for 15’ at 14000 rpm at 4°C. An aliquot of the 
cleared extract was kept as input, while the rest was incubated with 100 l 
of packed and pre-equilibrated Flag M2 agarose beads overnight at 4°C. 
Beads were rinsed twice in lysis buffer, then treated with DNAse I 
(Invitrogen, according to manufacturer’s instructions) and RNAse A (150 
mM NaCl/ 10 mMTris HCl pH 7.5/ 5 mM EDTA/ 10 units RNAse A, for 30’ at 
37°C) and then washed in the same buffer three times. Immunocomplexes 
were eluted by adding 500 g/ml Flag peptide (Sigma, St. Louis, Mo.) in 
lysis buffer. The eluate was concentrated by standard trichloroacetic acid 
precipitation and resuspended in 1X sodium dodecyl sulfate- polyacrylamide 
gel electrophoresis (SDS-PAGE) protein loading buffer. Proteins were then 
subjected to 6-12% gradient SDS-PAGE and then stained with silver stain. 
Mass-spectrometry-based protein identification was performed as 
previously described (Wysocka et al., 2003). 
 
 
4.2 Cell cultures, plasmids and siRNAs 
 
HeLa and HEK 293T cells were cultured in Dulbecco’s modified Eagle’s 
medium with Glutamax (Life Technologies, Inc.) supplemented with 10% 
fetal bovine serum (Life Technologies, Inc.) and gentamicin (100 g/ ml) at 
37°C in a humidified 95% air-5% CO2 incubator.  
All hNAP-1 encoding plasmids (wild type and mutants) were a kind gift 
from Prof. G. Steger (Rehtanz et al., 2004). All other plasmids used have 
already been described elsewhere (Dorr et al., 2002; Emiliani et al., 2002; 
Marzio et al., 1998; Pegoraro et al., 2006).  
RNA interference (RNAi) with hNAP-1 was performed against the target 
sequence 5’ AAGGAACACGAUGAACCUAUU 3’. For the control we used 
against the target sequence 5’ GGCTACGTCCAGGAGCGCACC 3’ of the GFP 
protein. Synthetic double-stranded RNA oligonucleotides were purchased 
by Dharmacon (Chicago, IL). 
 
 
4.3 Co-immunoprecipitation  
 
For co-immunoprecipitation analyses, HEK 293T cells where transfected 
with the indicated plasmids using the standard calcium phosphate co-
precipitation method. Twenty-four hours after transfections cells were 
washed once in PBS and lysed on ice in 1 ml/dish lysis buffer (150 mM 
NaCl/ 20 mM HEPES pH 7.9/ 0.5% NP-40/ 1 mM EDTA/ 1mM DTT/ 
protease inhibitor cocktail-Roche). After sonication, cleared  cell extracts 
were incubated with pre-equilibrated Flag M2 agarose beads on a rotating 
wheel for four hours at 4°C. Beads were washed twice with 1 ml of lysis 
buffer, then they are treated with DNAse I (Invitrogen, according to 
manufacturer’s instructions) and RNAse A (150 mM NaCl/ 10 mMTris HCl 
pH 7.5/ 5 mM EDTA/ 10 units RNAse A, for 30’ at 37°C) and then washed 





Anti-hNAP-1 mouse monoclonal antiserum was a kind gift from Y. Ishimi 
(Ishimi et al., 1985). Mouse monoclonal anti-Flag M2 antibody, mouse 
monoclonal anti-tubulin, and mouse monoclonal anti-Flag M2 agarose-
conjugated beads were purchased from Sigma (St. Louis, Mo.). Rat 
monoclonal anti-HA  high affinity (3F10) antibody was purchased from 
Roche diagnostics.  
 
 
4.5 Recombinant proteins 
 
Glutathione S-transferase (GST), GST-Tat, GST-hNAP-1, GST-Tat mutants 
and GST-hNAP-1 mutants were prepared as already described (Demarchi et 
al., 1996). Plasmids pcDNA3-Tat101 and pcDNA3-HA-NAP-1  were used as 
templates to produce the in vitro 35S-labeled Tat and hNAP-1 proteins, 
respectively, by using the TNT Reticulocyte Lysate System (Promega) 
according to the manufacturer’s protocol. 
 
 
4.6 GST pull-down assay 
 
GST and GST-Tat recombinant proteins immobilized on agarose beads were 
pre-treated with nucleases (see “in vitro binding assay”).  HEK 293T cells 
were lysed in 150 mM NaCl/ 20 mM HEPES pH 7.9/ 0.5% NP-40/ 1 mM 
EDTA/ 1mM DTT/ protease inhibitors (Roche). Recombinant proteins and 
HEK 293T extracts were incubated one hour and 30 min at 4°C, and 
washed four times in lysis buffer. 
 
4.7 In vitro binding assay 
To remove contaminant bacterial nucleic acids, recombinant proteins were 
pretreated with nucleases (0.25unit/ l Dnase I and 0.2 g/ l RNase) for 1 
hour at 25°C in 50 mM Tris HCl, pH 8.0/ 5 mM MgCl2/ 2.5 mM CaCl2/ 100 
mM NaCl/ 5% glycerol/ 1 mM DTT. Subsequently, GST fusion proteins 
immobilized on agarose beads were washed and resuspended in NETN 
buffer (20 mM Tris HCl, pH7.5/ 100mM NaCl/ 1 mM EDTA/ 0.5% NP-40/ 1 
mM DTT/ 1 mM phenylmethylsulfonylfluoride) supplemented with 0.2 
mg/ml ethidium bromide to impede the possible formation of nonspecific 
interactions between residual DNA and proteins. 400 cpm of 35S-labeled 
hNAP-1 or Tat101 proteins were added and incubated at 4°C on a rotating 
wheel. After one hour, bound proteins were washed twice with 0.3 ml of 
NETN ethidium bromide added, three times with 0.3 ml of NETN without 
ethidium bromide and once with 0.3 ml of 10 mM Tris HCl pH 8.0/100 mM 
NaCl. Finally bound proteins were separated by electrophoresis in an SDS 
12% polyacrylamide gel. Gels were stained and fixed for one hour with 
10% acetic acid/40% methanol/0.1% Coomassie Brilliant blue G250, and 
destained with 10% acetic acid/ 40% methanol. Dried gels were 
quantitated by Instant Imager (Packard). 
 
4.8 Luciferase assay 
Reporter gene assays were performed using pLTR-luciferase plasmid as a 
reporter and pcDNA3-Tat101 as an effector in the presence or absence of 
plasmids  pcDNA3-hNAP-1 and  pCMV-p300. HeLa cells were transfected 
using Effectene Reagent (Quiagen, according to manufacturer’s protocol), 
with 100 ng of pLTR-luciferase, 50 ng of pcDNA3-hNAP-1 5 or 25 ng of 
pcDNA3-Tat101. A Renilla expression plasmid driven by the CMV promoter 
was cotransfected to standardize each experiment. Cells were harvested 
fourty-eight hours post transfections, and luciferase activity was measured 
with Luciferase assay kit (Promega). The measured activities were 
standardized by the activities of Renilla, and transactivation was expressed 
as fold activation compared with the basal activity of LTR-luciferase without 
effectors. Representetive results of duplicate experiments that were 
repeated at least three times are shown in the figures with the mean and 
standard deviation.  
For the luciferase assays performed after hNAP-1 knock down by RNAi, 
siRNAs were transfected using Oligofectamin Reagent (Invitrogen, 
according to manufacturer’s protocol). After 36 hours from the beginning of 
siRNA treatment, cells were transfected with LTR-luciferase and CMV-
Renilla  plasmids and increasing amounts of pcDNA3-Tat101. Thirty-six 
hours later luciferase assay on cell lysates were performed. 
When cells were infected with VSV-G-luciferase vectors, luciferase assays 
were performed twenty-four hours after the beginning of infection. For the 
gene-silencing experiments, cells were infected fourty-eight hours after 
siRNA transfection. To normalize luciferase measures, lysate concentrations 




4.9 Virus production and infections 
 
To produce VSV-G-luciferase vectors, HEK 293T cells were transfected with 
pNL4.3-luciferase plasmid (Connor et al., 1995; He et al., 1995) and VSV-G 
encoding plasmid at a ratio 3:1, with the standard calcium phosphate co-
precipitation method. Supernatant was collected 48 hours after the 
beginning of transfections, it was centrifuged and filtered with a 45 m 
siringe. Infections with viral supernatant lasted for six hours in the 
presence of polybrene (purchased from Sigma Aldrich) at a final 








































1.4  INTEGRATION OF RETROVIRAL DNA INTO THE HOST CELL 
GENOME AND IMPLICATIONS FOR GENE THERAPY 
 
Although not site-specific, retroviral integration into the host cell genome is 
not a random event. Indeed, a growing body of evidence has accumulated 
in the recent years showing how different members of the Retroviridae 
family exhibit distinct target site preferences (Bushman et al., 2005). In 
this Section, I will focus on the Moloney Murine Leukemia Virus (MoMLV), 
in particular I will summarize the large-scale studies that gave insights into 
genomic site selection for MoMLV integration, and I will describe the 
implications that these studies might have for the use of retroviral vectors 
for gene therapy. 
In this respect, it is important to notice that a mounting interest of the 
scientific community for the issue of retroviral integration is connected to  
the occurrence of serious side effects in patients enrolled in gene therapy 
clinical trials entailing the use of MoMLV-based retroviral vectors. 
 
 
1.4.1 Retroviral vectors and gene thearapy 
 
Since the first therapeutic human gene therapy clinical trial in 1990, for the 
treatment of ADA-SCID (Adenosine DeAminase-Severe Combined Immuno-
Deficiency) (Blaese et al., 1995) over 1300 clinical trials have been 
completed, are ongoing or have been approved, involving 28 different 
countries.  
About one-fourth of these gene therapy experimentations have taken 
advantage of the possibility of transferring genes at high efficiency in 
replicating cells ex vivo using retroviral vectors. Indeed, these vectors 
stably integrate their genome into the host cell chromosomes, thus 
allowing the modification of the target cells. This property is particularly 
desirable when the permanent correction of a genetic defect is sought, as 
in the case of inherited disorders, or whenever gene transfer is required in 
permanently dividing cells, such as stem cells. Over one hundred clinical 
trials have therefore exploited gammaretroviruses, such as the MoMLV, for 
ex vivo transduction of bone-marrow or mobilized hematopoietic precursors 
followed by the reinfusion of the genetically modified cells back into the 
patients. 
SCIDs are a heterogeneous group of inherited disorders that affect the 
development or the activity of the immune system, causing a profound 
reduction or absence of T lymphocyte function. They include ADA-SCID, 
the X-linked Chronic Granulomatous Disease (X-CGD) and the SCID X-
linked 1 (SCID-X1). They all offer reliable models for gene therapy because 
they are lethal conditions that are otherwise curable only by allogenic bone 
marrow transplantation if HLA-matched family donors are available. In the 
past decade, great progress has been achieved in the treatment of SCIDs, 
especially in the gene therapy of ADA-SCID: treated patients exhibited 
transduced hematopoietic stem cells stably engrafted and differentiated 
into myeloid cells containing ADA after a follow-up of four years (Aiuti et 
al., 2009).  
Unfortunately clinical benefit of gene therapy has been obscured by the 
occurrence of severe adverse effects during clinical trials of SCID-X1. 
SCID-X1 is the most common form of SCID (40-50% of all cases), and 
consists in a profound immunodeficiency caused by the mutation of the 
IL2RG gene that encodes for the common cytokine receptor  chain ( c), 
component of the high-affinity IL-2 receptor.  
After successful in vitro experimentation (Candotti et al., 1996; Cavazzana-
Calvo et al., 1996; Hacein-Bey et al., 1998; Taylor et al., 1996), rapidly two 
clinical trials were performed (Cavazzana-Calvo et al., 2000; Gaspar et al., 
2004), entailing the use of a MoMLV vector encoding a IL2RG cDNA to 
transduce autologous CD34+ cells ex vivo which were later re-infused into 
the patients. The number and distribution of T cells increased rapidly, 
achieving normal numbers compared to age-matched control values in 
most of the cases.  
Unfortunately, leukemiac disorders occurred in five (out of twenty) SCID-X1 
treated patients: in four out of the five patients the leukemogenic clone 
carried the vector integrated close to or within the LIM domain-only 2 
(LMO2) proto-oncogene (Nam and Rabbitts, 2006; Royer-Pokora et al., 
1991; Royer-Pokora et al., 1995) and activated its transcription (Check, 
2005; Hacein-Bey-Abina et al., 2008; Hacein-Bey-Abina et al., 2003; Howe 
et al., 2008). Activation of LMO2 promoted clonal T cell proliferation in 
these patients.  
The phenomenon by which expression levels of cellular genes is altered 
upon retroviral integration (as in the case of LMO2) is referred to as 
“insertional mutagenesis”. After the occurrence of these events, several 
studies tried to address  the issue of insertional mutagenesis, and revealed 
that ~20% of genes are up-regulated following retroviral integration in T 
cells (Cattoglio et al., 2007; Maruggi et al., 2009). Of note, retroviral 
integration might also result in the down-regulation of the flanking gene, as 
it has been described in the case of transduction of T-cells with lentiviral 
vectors (Maruggi et al., 2009), and this is likely relied to the frequency of 
intragenic insertion and the strenght of the splice/polyA signal carried by 
the vector, both higher in the case of lentiviral vectors (see Section 1.5 for 
further details). 
However, the outcome of insertional mutagenesis induced by gene vectors 
is still poorly undersood, and might depend on a multiplicity of factors, 
including the architecture of the used vector, intrinsic developmental 
potential of the target cell, as well as on the extrinsic factors that influence 
clonal competition. In this respect it is worth mentioning that in the follow-
ups of both X-CGD and ADA patients treated with ex vivo gene therapy, 
alterations in gene expression of certain genes close to the integration sites 
were detected, but this resulted either in non-malignant clonal expansion 
or  in no clonal expansion at all, respectively (Cassani et al., 2009; Kang et 
al., 2009; Ott et al., 2006; Seger, 2008). Collectively, these findings 
suggest that insertion into certain genes may cause clonal amplification of 
transduced progenitors in vivo. Nevertheless, it is not clear whether clonal 
dominance is entirely the result of in vivo selection, or is favoured by the 
existence of highly preferred regions of retroviral integration that make 
clonal amplification more likely to occur (Cattoglio et al., 2007). 
 
 
1.4.2  MoMLV integration into the host cell genome 
 
The genomic features guiding retrovirus integration site selection have now 
been charachterized in some detail. First, two parallel studies consisting in 
large-scale sequencing of integration sites of MoMLV-based retroviral 
vectors in HeLa cells, revealed that MoMLV integration was favoured near 
the TSSs of genes. In particular, the authors showed that ~20% of the 
integrations were in regions proximal to the TSSs of genes (±5 kb). A 
preference in integration towards the CpG islands was also described 
(Mitchell et al., 2004; Wu et al., 2003).  
An interesting but still controversial issue is that aimed at understanding 
the possible involvement of cellular proteins in determining the specificity 
of the integration site. Several cellular proteins have been implicated in 
anchoring PICs to chromatin, and the fact that some of them are different 
in the MoMLV or HIV-1 PICs, could be suggestive that they might at least in 
part account for the specificity of retroviral and lentiviral integration. In 
particular, several inner nuclear proteins (namely emerin, LAP2 and BAF) as 
well as LEDGF/p75 have been proposed to be involved in the association 
between viral cDNA and the host chromosome, but the evidences reported 
so far are still contradictory (Jacque and Stevenson, 2006; Maertens et al., 
2003; Mulky et al., 2008; Shun et al., 2007). 
Furthermore, it has been hypothesized that the expression program of a 
cell type might be instrumental in directing the pattern of integration. 
Therefore Recchia and co-workers used similar approaches to address 
retroviral integration in  T cells. Indeed, a bias towards the promoters of 
actively transcribed genes has also been described in T cells (Recchia et al., 
2006). Cattoglio and collaborators, beside further confirming these data in 
CD34+ HSCs (Hematopoietic Stem Cells), also identified CISs (Common 
Integration Sites) or hot spots of retroviral integration such as proto-
oncogenes, growth controlling genes and hematopoietic and immune 
system developmental genes (Cattoglio et al., 2007) and personal 
communication by Cattoglio and Mavilio). Interestingly, the same 
conclusions were drawn in a few recent studies, in which integrations of 
retroviral vectors in transduced cells from patients  treated with gene 
therapy were analyzed. In particular, gene-therapy-treated SCID-X1 
patients carried two-thirds of the insertions in or very close to genes (of 
which more than a half were highly expressed in CD34+ progenitor cells), 
and   one-fourth af all integrants were clustered as CISs, suggestive that 
insertion in many gene loci has an influence on cell engrafment, survival 
and proliferation (Deichmann et al., 2007; Schwarzwaelder et al., 2007). 
Similarly, ADA-SCID (a form of SCID resulting from Adenosine DeAminase 
deficiency) patients subjected to gene therapy, also exhibited preferential 
vector integrations into the promoters of transcriptionally active genes, 

























1.5 CHROMATIN ORGANIZATION AND RETROVIRAL 
INTEGRATION  
 
Multiple evidence suggests that chromatin organization inside the cell 
nucleus is not random but rather organized into higher order structures 
that can impact gene regulation (Cremer et al., 2006; Fraser and Bickmore, 
2007; Sexton et al., 2007). The HIV-1 provirus behaves as any RNA Pol II-
transcribed gene, thus it is likely that it is affected by subnuclear 
localization and chromatin interactions, similar to cellular genes.  
As mentioned before, it was demonstrated that positioning to the nuclear 
periphery and long-range chromatin interactions established with 
pericentric heterochromatin, correlate with HIV-1 transcriptional repression 
and latency (Dieudonne et al., 2009). Furthermore, previous work 
performed in collaboration with the Proudfoot’s group in Oxford allowed  
our laboratory to demonstrate that HIV-1 forms a transcription-dependent 
gene loop structure between the 5’LTR promoter and the 3’LTR poly(A) 
signal. This particular conformational structure is also formed between the 
LTRs and the Major Splice Donor (MSD) region adjacent to the 5’LTR in 
HIV-1 provirus (Perkins et al., 2008). The observation that HIV-1 chromatin 
loops during transcriptional activation raised the question whether this is a 
charateristics peculiar to HIV-1 or, conversely, is a more generalized 
feature of all the members of the Retroviridae family. 
Both gammaretroviral (MoMLV) and lentiviral (HIV-1) LTRs contain a 
poly(A) signal entirely located within the R region of the 5’ and 3’ LTRs. 
Potentially, the presence of polyadenylation signals at both ends of the viral 
genomes could pose an obstacle to gene expression, however both viruses 
have evolved a strategy to suppress the promoter-proximal (5’LTR) poly(A) 
signal. 
HIV-1 resolves this “mechanistic dilemma” in several ways: the U3 
sequences that are uniquely transcribed from the 3’ LTR have been shown 
to enhance polyadenylation (Ashe et al., 1995), while suppression of the 5’ 
poly(A) site has been found to depend on the presence of the downstream 
MSD and its interaction with U1 snRNP; in addition, the inactivation of the 
MSD has been shown to result in efficient promoter proximal 
polyadenylation (Ashe et al., 1997). Hence, the capacity of the HIV-1 
genome to form a gene loop structure probably represents a further 
improvement of the virus to effectively inactivate the promoter proximal 
poly(A) site.  
In this respect it is worth mentioning that MoMLV has a much weaker 
poly(A) signal, so that MoMLV did not evolve a mechanism to actively 
suppress the 5’ poly(A), as demonstrated in two previous studies. In one of 
these studies a mutational inactivation of the MSD in the MoMLV-based 
minigene system was shown to have little if any effect on promoter-
proximal poly(A) site usage (Furger et al., 2001). In the second study, 
MoMLV vectors (but not HIV vectors) displayed high frequencies of read-
through of the 3’poly(A) signal (Zaiss et al., 2002). A leaky 3’ poly(A) signal 
has the potential to mobilize cellular sequences due to the frequent 3’ 
poly(A) read-through. This could confer increased probability of activating 
or capturing cellular genes both 5’ and 3’ to the viral integration site by the 
means of long-range chromosomal interactions. 
Collectively, these observations prompted us to investigate the looping 
properties of MoMLV, especially in view of the possibility that formation of 
aberrant chromatin loops between the LTRs and the regulatory elements of 




1.6  CHROMOSOME CONFORMATION CAPTURE (3C) 
 
A powerful manner to detect long-range chromatin interactions is offered 
by a series of methods allowing one to probe physical proximity between 
chromatin elements, albeit without specifically identifying the protein 
components that mediate such interactions. 
Chromosome Conformation Capture (3C) technique, the first technique to 
be developed, allows the analysis of chromatin folding in the native cellular 
environment, at a resolution that is even higher compared to that of the 
current microscopy techniques. It was initially developed by Dekker and co-
workers, who studied the conformation of a complete chromosome in yeast 
(Dekker et al., 2002), but it was afterward modified to  analyze the folding 
of complex gene loci in mammalian cells (Tolhuis et al., 2002). 
An outline of the 3C technology is provided in Figure 1.14. Cells are treated 
with formaldehyde to induce both protein-protein and protein-DNA 
crosslinks, resulting in covalent links between interacting chromatin 
regions. Cross-linked chromatin is then solubilized and digested using an 
appropriate restriction enzyme, and digested chromatin is subsequently 
ligated under diluted DNA concentrations, which strongly promote intra-
molecular over random inter-molecular ligation of cross-linked fragments. 
The cross-links are then reversed, the DNA is purified, and ligation products 
are detected and quantified by PCR using primers across the newly ligated 
ends of fragments. The relative abundance of a particular ligation product 
reflects the frequency with which the two restriction fragments interact 
inside the cell nucleus. 
Plasmid 3C, recently developed by Perkins and collaborators, is based on 
the same principle as chromosomal 3C, but allows the analysis of 
transfected DNA, which is purified using a sucrose gradient; hence, a 
manipulation of sequences required for gene formation is strongly 






Figure 1.14  Outline of Cromosome Conformation Capture (3C) 
technology (Adapted from Ansari et al., 2005). 
 
 
After 3C establishment, other technologies based on the 3C principle have 
been developed, aimed at broadening the 3C potential, and at increasing 
throughput, named 4C (i), 5C (ii), ChIP-loop (iii), 6C (iv) and Hi-C (v). 
(i) While 3C permits one to only detect an interaction between known 
regions, the 4C approaches allow the screening of the entire genome in an 
unbiased manner for DNA segments that physically interact with a DNA 
fragment of choice (referred to as the “bait”), without any prior knowledge 
of their identities. All the DNA fragments captured by the bait are 
simultaneously amplified via inverse PCR, using two bait-specific primers 
that amplify from circularized ligation products (Lomvardas et al., 2006; 
Simonis et al., 2006; Wurtele and Chartrand, 2006; Zhao et al., 2006). 
(ii) 3C-carbon copy (5C), compared to standard 3C, gives the possibility to 
map several hundreds of chromatin interactions for a given locus, thus 
allowing the generation of a complex matrix of interaction frequencies for 
that locus, even though the size of the studied region is quite limited. It 
exploits a multiplex ligation-mediated amplification step to amplify selected 
ligation junctions, which are subsequently analyzed by microarray detection 
or by high-throughput sequencing (Dostie et al., 2006). 
(iii) While neither 3C nor 3C-derived approaches allow the identification of 
proteins, which likely mediate the different DNA interactions, a combination 
of 3C and ChIP was developed (ChIP-loop) to fulfill this requirement. 
Following formaldehyde cross-linking and enzyme digestion, chromatin is 
purified on an urea gradient and then immunoprecipitated using an 
antibody against the protein of interest. Subsequently, the precipitated 
DNA fragments are ligated and junctions are analyzed by PCR, as in a 
standard 3C assay (Kumar et al., 2007). 
(iv) A further evolution of the ChIP-loop is the Combined 3C-ChIP-Cloning 
(6C) technology, which detects all the chromatin regions in the nucleus 
that interact with a given locus of interest, in a specific protein-dependent 
manner. Such information allows the complete mapping of all the 
chromatin interactions mediated by a candidate protein, thus providing an 
important tool to examine the role of specific proteins in nuclear 
organization (Tiwari et al., 2008). 
(v)  Recently, an exciting Hi-C approach was developed, a method that 
identifies in an unbiased manner the chromatin interactions across an 
entire genome, thus allowing the construction of spatial proximity maps of 
human genome at a very high resolution (1 megabase). Cells are cross-
linked with formaldehyde, and DNA is digested with an enzyme that leaves 
5’ overhang, subsequently filled with biotinylated residues. After ligation, 
the resulting DNA sample consists of fragments that were originally in close 
spatial proximity, marked with biotin at the junction. A Hi-C library is 
created by shearing the DNA and precipitating with streptavidin beads to 
select biotin-containing fragments; finally, the library is analyzed by 
massive parallel DNA sequencing, producing a catalog of all the interacting 













AIM OF THE STUDY 
 
 
The work described in PART B of this Thesis is part of an ongoing project 
and it is aimed at assessing the capacity of gammaretroviruses (namely, 
the Moloney Murine Leukemia Virus, MoMLV) to form a transcription-
dependent gene loop stucture as well as lentiviruses (Human 
Immunodeficiency Virus-1, HIV-1). Next we investigate the possibility that 
these higher order chromatin structures, if aberrantly generated between 
viral and host cell regulatory elements, might be at the basis of the 
















2B.  RESULTS 
 
 
2.8 Characterization of a cellular model of retroviral integration 
 
With the aim to develop a cellular system appropriate to study 
gammaretroviral looping, we first produced a MoMLV-derived retroviral 
vector by transfecting an amphotropic HEK 293-based packaging cell line 
with the pLXN plasmid. This plasmid was generated by digestion of pLXSN 
(Clontech) with BamH I and Hind III, in order to excide SV40 promoter, 
thus avoiding the bias related to the presence of an additional promoter, 
and finally obtaining a vector carrying the neomycin resistance gene (neoR) 
under the direct control of the MoMLV LTR (Figure 2.13 panel A). After 
HeLa cell transduction, twenty neomycin-resistent clones were selected and 
assessed for the presence of the MoMLV provirus by real-time PCR (data 
not shown).  
Mapping of integration sites for seven out of twenty clones was obtained 
by inverse PCR, performed according to Chun and co-workers (Chun et al., 
1997). This approach is essentially  based on a nested PCR amplification of 
the  genomic DNA that was first digested with a restriction enzyme and 
then re-ligated, followed by DNA sequencing. The genomic location of the 
integrated MoMLV vectors in HeLa clones is indicated in Figure 2.13, panel 
B, together with the distance from neighboring genes, both 5’ and 3’ with 
respect to the integration sites. Interestingly, most of these clones showed 
integrations in the close proximity of genes, in accordance with previously 
published literature (Bukrinsky, 2006; Bushman et al., 2005; Cattoglio et 
al., 2007; Mitchell et al., 2004; Recchia et al., 2006; Wu et al., 2003). 
Furthermore, two out of seven clones carried the vectors integrated within 
the IGF1R (Insuline-like Growth Factor 1 Receptor) gene (in the fourth and 
in the second intron, in clones 7 and 11, respectively). In this respect, it is 
worth mentioning that IGF1R gene is one of the so-called “hot spots” or 
CISs (Common Integration Sites) of retroviral integration, as revealed in a 
large-scale mapping of thousands of MoMLV integrations in CD34+ 
hematopoietic stem cells (Cattoglio et al., 2007). 
Finally, we verified the copy number of the integrated vectors by Southern 
Blotting, digesting DNA with EcoR I and using a probe that encompasses 
the neoR gene as indicated in Figure 2.13, panel C. Only one major 
restriction fragment was apparent in each clone, indicating that a single 
integration event had occurred; the lenghts of the fragments were 
consistent with the size that had been predicted following the sequence 





Figure 2.13  Characterization of HeLa stable clones harbouring 
retroviral integrations. 
A. Schematic representation of the retroviral vector used to transduce HeLa 
cells. The plasmid pLXSN was digested with Hind III and BamH I in order to 
excise SV40 promoter. The resulting construct was transfected into an 
amphotrofic HEK 293-based packaging cell line, thus obtaining a vector 
which carries the neoR gene under the control of the viral LTR. B. List of 
HeLa clones stably transduced with retroviral vectors and selected by 
Neomicine resistence. The integration sites were determined for 7 clones by 
means of inverse PCR. For each clone, the genomic location and the 
positions of the neighbouring genes are indicated. C. Approximately 20 g 
of genomic DNA extracted from individual HeLa clones were digested with 
EcoR I and analyzed by Southern Blotting using the neoR probe (indicated 
on the lower part ot the panel). Only one major restriction fragment of 
varying size is observed in each clone, indicating single integration event 
had occurred. In the last three lanes on the right, decreasing amounts of the 
linearized pLXN plasmid were used as positive controls. 
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2.9 LTR-LTR  gene looping: 3C analysis of HeLa clone 11 
Next we adapted the 3C methodology in order to render it suitable for the 
study of our model of retroviral integration. In particular, both major and 
minor adjustments were introduced into the previously described protocol 
(Perkins et al., 2008), aimed at adapting the procedure to the analysis of 
relatively short regions, 3 kbs, given the size of the vector used (see the 
Materials and Methods section for details about the 3C protocol). 
We started our analysis with clone 11, harboring the retroviral integration 
within the second intron of the IGF1R gene (see Figure 2.13 panel B). The 
viral vector sequence was found to be integrated in opposite transcriptional 
orientation with respect to IGF1R, in agreement with observations made by 
Recchia and co-workers who detected a significative preference of inverted 
integrations in retrovirally-transduced T cell lines (Recchia et al., 2006). For 
the purposes of 3C, we analyzed the flanking sequences of the integrated 
vector in chromosome 15, and designed PCR primers accordingly. Nuclei 
from HeLa clone 11 were cross-linked, and the chromatin was prepared 
and further digested with the restriction enzymes EcoR I and Dpn II. These 
enzymes met all the requirements of the technique and were tested, being 
the former a 6 bp-cutter with a single site inside the provirus and the latter 
a 4 bp-cutter that cleaves the provirus 14 times, thus providing fine 
mapping of the analyzed interactions. Both EcoR I and Dpn II digestions 
were controlled by quantitative real-time PCR, with primer pairs designed 
across the respective restriction sites; in both cases, the extent of digestion 
was higher than 98% (data not shown). Digested chromatin was then 
ligated under extremely diluted conditions, thus allowing the ligation of 
only those sequences that are physically interacting and disfavoring 
random inter-molecular interactions. Ligated DNA was further purified after 
reversal of cross-linking, and ligation products were detected by PCR using 
appropriate primer sets as indicated in Figure 2.14, panels A and B. 
Critical controls are essential for correct interpretation of 3C data; first, PCR 
amplifications are performed on chromatin that was either cross-linked or 
not cross-linked, and ligated or not ligated. Second, all the 3C primers were 
assessed for amplification of in vitro-generated 3C products (Figure 2.14 
panels A and B, labeled as “controls”). Control template was generated by 
PCR amplification of the sequences surrounding individual EcoR I or Dpn II 
sites, and the PCR products were mixed in equimolar amounts, followed by 
restriction digestion and ligation to include all possible ligation products. 
Third, to verify the amounts of DNA that was used in 3C reactions all the 
chromatin preparations were amplified with the unrelated B13 primers, as 
previously described (Lusic et al., 2003), mapping in the lamin B2 region on 
chromosome 19.  
Representative gels of 3C PCR products are shown in Figure 2.14. Among 
all the tested primer pairs, a specific PCR product was apparent with primer 
pairs 11E3-11E2 and 11D1-11D4, in the cases of EcoR I and Dpn II 
digestions, respectively, and only when chromatin was cross-linked and 
ligated. No evidence for interactions between the MoMLV promoter and 
sequences within the retroviral vector was detected, neither for EcoR I nor 













Primer 11E3 maps in the U3 region of the 5’LTR of MoMLV and amplifies 
the boundary between MoMLV and the upstream sequences; primer 11E2 
amplifies the sequences surrounding the following Eco RI site that is 
positioned 6877 bases downstream  from the MoMLV integration, whereas 
both 11D1 and 11D4 are in close proximity to the insertion site, 107 bp 
upstream and 197 bp downstream, respectively. The detection of a specific 
ligation product using such primers is an indication that the two LTRs are 
physically juxtaposed inside the cell nucleus. This is the first demonstration 
that a looping structure involving MoMLV retrovirus actually exists.  
Figure 2.14  EcoR I and Dpn II 3C analysis on HeLa clone 11 cells. 
A. In the upper part of the panel the integrated provirus and flanking 
chromosomal sequence with restriction sites and primers for EcoR I are 
represented. Numbers denote distance from 5’ (-) or 3’ (+) proviral ends. 
Horizontal arrows indicate primer direction and name; vertical arrows 
indicate restriction sites. In the lower part, EcoR I 3C analysis in clone 11 
cells using either 11E3 or 11E2 primers in combination with one of the other 
EcoR I primers is indicated. Common PCR primers are shown above the 
figure, with the second primer shown above each lane. 3C analysis was 
conducted both on cross-linked and not cross-linked chromatin, before and 
after ligation. In vitro-generated 3C products are labeled as controls. Primers 
B13 (located in the lamin B2 region in chromosome 19) were used to assess 
the amount of starting material. Significant interactions, present only in 
cross-linked and ligated chromatin, are marked by a star. B. In the upper 
part of the panel the integrated provirus and flanking chromosomal 
sequence with restriction sites and primers for Dpn II are represented. 
Primers, resctriction sites and distances from the integration site are 
indicated as in panel A. In the lower part, Dpn II 3C analysis in clone 11 
cells using either 11D1 or 11D4 primers in combination with one of the other 
Dpn II primers is indicated. Primers are indicated as in panel A. 3C analysis 
was conducted both on cross-linked and not cross-linked chromatin, before 
and after ligation. In vitro-generated 3C products are labeled as controls; 
primers B13 were used to assess the amount of starting material. Significant 
interactions, present only in cross-linked and ligated chromatin, are marked 
by a star. 
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2.10 LTR-LTR  gene looping: 3C analysis of HeLa clone 19 
 
In order to confirm data obtained from the analysis of clone 11, we 
extended our studies to another HeLa clone, namely clone 19. As indicated 
in the panel B of Figure 2.13, this clone carries a retroviral integration in 
chromosome 20q13.1, in an intergenic region, with the WISP2 (WNT1 
Inducible Signallilng Protein 2 precursor) gene 18 kb upstream in the same 
transcriptional orientation, and the ADA (Adenosine DeAminase) gene 45 
kb downstream, in an opposite transcriptional orientation.  
To perform 3C analysis on clone 19, we used the same approach as  for 
clone 11, starting from the selection of the suitable restriction enzymes,  
followed by the design of primers spanning the restriction sites. Ban I (a 6 
bp-cutter with 10 sites within the MoMLV provirus) and Dpn II proved to be 
the enzymes of choice; positions of restriction sites and primers for these 
two enzymes, both within the provirus and in the flanking regions are 





























Upon completion of the 3C assay, juxtaposition of the two LTRs was also 
observed in clone 19, as revealed by the specific PCR bands that were 
Figure 2.15  Ban I and Dpn II 3C analysis on HeLa clone 19 cells. 
A. The integrated provirus and flanking chromosomal sequence with 
restriction sites and primers for Ban I are represented. Numbers denote 
distance from 5’ (-) or 3’ (+) proviral ends. Horizontal arrows indicate primer 
direction and name; vertical arrows indicate restriction sites. In the lower 
part of the panel, Ban I 3C analysis in clone 19 cells using either 19B3 or 
19B2 primers in combination with one of the other Ban I primers is 
indicated. Common PCR primers are shown above the figure, with the 
second primer shown above each lane. Significant interactions, present only 
in cross-linked and ligated chromatin, are marked by a star. B. Restriction 
sites, primers for Dpn II and distances from the integration site are indicated 
as in panel A. In the lower part, Dpn II 3C analysis in clone 19 cells using 
either 19D1 or 19B2 primers in combination with one of the other Dpn II 
primers is indicated. Primers are indicated as in panel A. Significant 
interactions, present only in cross-linked and ligated chromatin, are marked 
b
apparent using the primer sets 19B2-19B3 and 19D1-19B2 (Figure 2.15, 
panels A and B). 
 
 
2.11 Aberrant looping involving cellular genes: 3C analysis of 
HeLa clones 11 and 19 
 
The two sets of data obtained on HeLa clone 11 and on HeLa clone 19 
clearly indicate that MoMLV, similar to HIV-1, is able to form a gene-loop 
structure by juxtaposition of its LTRs. Since for HIV-1 looping capacity is 
strictly dependent on the presence of the poly(A) sequence (Perkins et al., 
2008), and since the poly(A) signal of MoMLV is much weaker compared to 
that of HIV-1 (Furger et al., 2001; Zaiss et al., 2002), we envisioned that 
gammaretroviruses might mobilize cellular sequences due to the frequent 
3’ poly(A) read-through, resulting in the formation of aberrant loop 
structures and eventually in  the deregulation of cellular gene expression. 
To test our hypothesis and to evaluate the interactions of retroviral 
sequences with neighboring cellular sequences positioned on the same 
chromosome, we further explored both clones 11 and 19, and we 
performed 3C analysis on larger regions of the human chromosomes 
harboring the proviruses.  
As already mentioned, in clone 11 the vector is integrated in opposite 
transcriptional direction inside the second intron of the IGF1R gene. IGF1R 
is a long gene composed of 21 exons; the  TSS and two different poly(A) 
sites are positioned at a distance of 104 kbs and 210 kbs with respect to 
the integration site. To test the possibility of the involvement of such 
cellular regulatory regions in the formation of atypical loop structures, we 




positioned in close proximity to promoter or poly(A) sequences, and we 

































As indicated in Figure 2.16, several primer sets were assessed, on cross-
linked and not cross-linked (data not shown) chromatin. None of these 
primers detected participation of neighboring cellular sequences in the loop 
formation, neither using EcoR I nor using Dpn II. 
Consistent with the absence of any interaction between retroviral LTRs and 
regulatory elements of IGF1R, no alterations in IGF1R expression were 
observed, as revealed by the quantitative Reverse Trancription-PCR (RT-







Figure 2.16  EcoR I and Dpn II 3C analysis on HeLa clone 11 cells. 
A. The integrated provirus (represented in red) and the IGF1R gene with 
restriction sites, primers for EcoR I and distances from the integration site 
are represented in the upper part of the panel. Horizontal arrows indicate 
primer direction and name, while vertical dashed lines indicate restriction 
sites. In the lower part of the panel, EcoR I 3C analysis in clone 11 cells 
using either 11E3 or 11E2 primers in combination with one of the other EcoR 
I primers is indicated. Common PCR primers are shown above the figure, 
with the second primer shown above each lane. B. Restriction sites and 
primers for Dpn II and distances from the integration site are indicated as in 
panel A. In the lower part, Dpn II 3C analysis in clone 11 cells using either 
11D1 or 11D4 primers in combination with one of the other Dpn II primers 
is indicated. Primers are indicated as in panel A.  
Figure 2.17  Expression analysis of IGF1R gene in clone 11. 
Expression analysis of IGF1R in clone 11 cells was compared to HeLa cells 
and to other clones carrying different retroviral integrations. Total RNA was 
extracted, reverse transcribed and finally amplified by Real Time PCR. 
Expression in HeLa cells was set to 1, while expression in other clones was 
indicated as fold increase over HeLa cells. IGF1R levels were normalized to 
GAPDH used as a housekeeping gene.  
A 
Total RNA was extracted from HeLa and from clones 7, 8, 11, 17, 19, 
reverse-transcribed using random primers, and cDNA was amplified by Real 
Time PCR with primers designed for this purpose. Data were normalized for  
the expression of the housekeeping gene GAPDH (GlycerAldehyde 3-
Phosphate DeHydrogenase). Interestingly, no significant differences in 
IGF1R expression levels were detected between the two clones carrying 
integrations into the IGF1R gene (namely clones 11 and 7) compared to 
untransduced HeLa or clones carrying different integrations (clones 8, 17, 
19). 
Similarly, we analyzed clone 19 for the occurrence of interactions between 
the LTRs and regulatory elements of flanking genes. As described above, 
clone 19 carries a retroviral integration in an intergenic region, between 
WISP2 (located 18 kb upstream in the same transcriptional orientation) and 
ADA (45 kb downstream, in an opposite transcriptional orientation). 
Primers were designed spanning the Ban I and Dpn II restriction sites in 
the proximity of promoters and poly(A) signals of both genes, and used in 
different combinations on cross-linked, digested and ligated chromatin 
(data on not cross-linked chromatin are not shown). As for clone 11, none 
of the tested cellular sequences were found to interact with the MoMLV 





















Next, we analyzed the expression levels of both ADA an WISP2 genes in 
clone 19 cells, and compared them to those obtained either from 
untransduced HeLa cells or from other HeLa clones harboring different 
integrations (clones 7, 8, 11, 17). Primers  were designed across two 
flanking exons, thus allowing the specific amplification of retrotranscribed 
RNA. As expected, the absence of long-range chromatin interactions 
between neighbouring genes and the provirus was in correlation with the  
Figure 2.18  Ban I and Dpn II 3C analysis on HeLa clone 19 cells. 
A. The integrated provirus (represented in red) and ADA and WISP2 genes, 
with restriction sites, primers for Ban I and distances from the integration 
site are represented in the upper part of the panel. Horizontal arrows 
indicate primer direction and name, while vertical dashed lines indicate 
restriction sites. In the lower part of the panel, Ban I 3C analysis in clone 19 
cells using either 19B3 or 19B2 primers in combination with one of the other 
Ban I primers is indicated. Common PCR primers are shown above the 
figure, with the second primer shown above each lane. B. Restriction sites 
and primers for Dpn II and distances from the integration site are indicated 
as in panel A. In the lower part, Dpn II 3C analysis in clone 19 cells using 
either 19D1 or 19B2 primers in combination with one of the other Dpn II 
primers is indicated. Primers are indicated as in panel A.  
 
observation that neither expression of ADA nor tf WISP2 was significantly 
affeected by retroviral integration (Figure 2.19) 
 
2.12 LTR-LTR gene looping and aberrant looping involving cellular 
elements: 3C analysis of HaCaT clones 27 and 28  
 
Retroviral integration induces deregulation of nearby genes in 20% of 
cases, as assessed by large-scale mapping of integration sites performed in 
T cells (Maruggi et al., 2009; Recchia et al., 2006). This observation clearly 
indicates that a higher number of clones should be analyzed in order to 
define in an unbiased manner the involvement of cellular elements in 
atypical MoMLV-mediated chromatin loops. Furthermore, the looping 
properties of MoMLV might be cell type-dependent, in the sense that they 
might be affected by the transcriptional program of the host cell. 
For these reasons, in addition to the analysis on HeLa clones, we further 
applied the 3C technique to another cell line, a keratinocyte-derived HaCaT 
Figure 2.19  Expression analysis of ADA and WISP2 genes in clone 
19. 
Expression analysis of IGF1R in clone 19 cells was compared to HeLa cells 
and to other clones carrying different retroviral integrations. Total RNA was 
extracted, reverse transcribed and finally amplified by Real Time PCR.  
Expression in HeLa cells was set to 1, while expression in other clones was 
indicated as fold increase over HeLa cells. ADA and WISP2 levels were 
normalized to GAPDH used as a housekeeping gene.  
 
cell line obtained from F. Mavilio (Department of Biomedical Sciences, 
University of Modena and Reggio Emilia, Modena, Italy). Mavilio and 
collaborators determined the integration sites for 52 different HaCaT 
clones, and analyzed expression profiles of genes that lie in a region 
spanning 50 kbs upstream and 50 kbs downstream of the integration sites 
(unpublished data, personal communication from Maruggi and Mavilio). Out 
of 83 genes analyzed, only one was observed to be significantly 
upregulated, namely SERPINB5 (SERin Proteinase Inhibitor clade B5) gene, 
in clone 28. HaCaT clone 28 harbors three different integrations, at 
positions 3p24.2, 10q26.13 and 18q21.33. Among the six genes analyzed in 
the 100 kbs across the three integrations in clone 28, three were found not 
to be expressed, two were expressed but their expression was not affected 
by MoMLV integration, and one (SERPINB5) was up-regulated. This cellular 
setting represented an excellent milieu for studying the physical 
interactions between retroviral and cellular regulatory elements.  
Thus, we extended 3C analysis to clone 28 (mentioned above), as well as 
to another HaCaT clone, namely clone 27, carrying two proviruses 
integated in chromosomes 2q37.1 and 15q26.3, in which a slight up-
regulation of the LRRC28 (Leucine Rich Repeat Containing 28) gene 
flanking the integration site has been observed.  
For clone 27, we focused our attention on the retrovirus integrated in 
chromosome 15, and Ban I was the enzyme that met all the requirements 
of the 3C method (with 12 restriction sites within the provirus). Chromatin 
was cross-linked, digested, ligated under proper conditions and purified 
DNA was analyzed by PCR. As shown in Figure 2.20, the only specific band 
that was detected was the one  amplified by the 15B2-15B3 primer set on 
cross-liked and ligated chromatin, indicating that LTR-LTR juxtaposition 
ideed occurred also in HaCaT cells. 
 
 
Figure 2.20  Ban I 3C analysis on HaCaT clone 27 cells. 
In the upper part of the figure the integrated provirus and flanking 
chromosomal sequences, encompassing LRRC28 gene, with restriction sites 
and primers for Ban I are represented. Numbers denote distance from 5’ (-) 
or 3’ (+) proviral ends. Horizontal arrows indicate primer direction and 
name; vertical arrows or dashed lines indicate restriction sites. In the lower 
part of the figure, Ban I 3C analysis in HaCaT clone 27 cells using either 
15B2 and 15B3 primers in combination with one of the other Ban I primers 
is indicated. Common PCR primers are shown above the figure, with the 
second primer shown above each lane. 3C analysis was conducted both on 
cross-linked and not cross-linked chromatin, before and after ligation. In 
vitro-generated 3C products are labeled as controls; primers B13 were used 
to assess the amount of starting material. Significant interactions, present 
only in cross-linked and ligated chromatin, are marked by a star. 
 
The provirus is here integrated within the fifth long intron of the LRRC28 
gene, which is transcribed in the same direction of the retroviral vector. We 
also addressed eventual interactions with flanking cellular elements, and for 
this purpose additional primers were designed along the promoter and the 
poly(A) signal of LRRC28.  
No interactions were detected neither with the LRRC28 promoter nor with 
its poly(A) sequence (Figure 2.20) and, accordingly,  expression of LRRC28 
seemed not to be altered by MoMLV integration. An over-expression of 1.5 
fold was measured over the mean expression level measured in 
untransduced HaCaT and in the other 51 analyzed HaCaT clones; however,  
this was not considered significant (unpublished data, personal 







For clone 28, we analyzed in detail only the provirus integrated in 
chromosome 18q21.33 (close to SERPINB5). Bgl II and Dpn II with 
respectively a single and  13 cleavage sites inside the provirus were used. 
3C was performed according to our previously adapted protocol, with 
Figure 2.21  Expression analysis of LRRC28 gene in HaCaT clone 
27. 
Expression analysis of LRRC28 gene in clone 27 cells was compared to 
untransduced HaCaT cells and to other clones (51) carrying different 
retroviral integrations. Total RNA was extracted, reverse transcribed and 
finally amplified by Real Time PCR. Expression in HaCaT cells was set to 1, 
while expression in other clones was indicated as fold increase over HeLa 
cells. Expression levels were normalized to GAPDH used as a housekeeping 
gene.  
primers designed across the restriction sites, and used in various 
combinations on chromatin purified at the final step of the 3C assay. As 
shown in Figures 2.22 and 2.23, amplification with primers 18Bg2-18Bg3 
(Bgl II digestion) and 18D2-18D3 (Dpn II digestion) resulted in a specific 
band (confirmed by sequencing) on chromatin that was cross-linked and 
ligated, indicative that a LTR-LTR loop has occurred. As a negative control, 
all the combinations between 18Bg2 or 18D2 and internal primers (Bgl1 
and Bgl2 for Bgl II digestion; D3, D4, D5, D6 for Dpn II digestion) did not 
generate any amplification product.  
Next, we investigated the possibility that MoMLV establishes interactions 
with regulatory elements of nearby genes. As shown in Figures 2.22 and 
2.23, the retroviral integration in chromosome 18 is in an intergenic region, 
with the VPS4B (Vacuolar Protein Sorting factor 4B) gene positioned 35 kbs 
upstream, in an opposite transcriptional orientation, and the SERPINB5 
gene 19 kbs downstream, in the same transcriptional orientation of the 
MoMLV vector. Primers were designed across either Bgl II and Dpn II 
restriction sites encompassing the promoters and the poly(A) signals of 
both genes, and tested in PCR reactions together with 18Bg2 and 18D2, 
respectively. Interestingly, we detected a specific PCR band when 18Bg2-
18D9 and 18D2-18D9 sets of primers were used. This result clearly 
suggested that the MoMLV 5’LTR promoter was juxtaposed and physically 




Figure 2.22  Bgl II 3C analysis on HaCaT clone 28 cells. 
In the upper part of the figure the integrated provirus and flanking 
chromosomal sequences, encompassing VPS4B and SERPINB5 genes, with 
restriction sites and primers for Bgl II are represented. Numbers denote 
distance from 5’ (-) or 3’ (+) proviral ends. Horizontal arrows indicate primer 
direction and name; vertical arrows or dashed lines indicate restriction sites. 
In the lower part of the figure, Bgl II 3C analysis in HaCaT clone 28 cells 
using 18Bg2 primer in combination with one of the other Bgl II primers is 
indicated. Common PCR primers are shown above the figure, with the 
second primer shown above each lane. 3C analysis was conducted both on 
cross-linked and not cross-linked chromatin, before and after ligation. In 
vitro-generated 3C products are labeled as controls; primers B13 were used 
to assess the amount of starting material. Significant interactions, present 




This observation was in line with the above mentioned observation that the 
SERPINB5 gene was up-regulated in clone 28. In particular, the levels of 
Figure 2.23  Dpn II 3C analysis on HaCaT clone 28 cells. 
Same as is 3.22, with representation for Dpn II restriction sites and primers. 
In the lower part of the figure, Dpn II 3C analysis in HaCaT clone 28 cells 
using 18D2 primer in combination with one of the other Dpn II primers is 
indicated. Common PCR primers are shown above the figure, with the 
second primer shown above each lane. 3C analysis was conducted both on 
cross-linked and not cross-linked chromatin, before and after ligation. In 
vitro-generated 3C products are labeled as controls; primers B13 were used 
to assess the amount of starting material. Significant interactions, present 
only in cross-linked and ligated chromatin, are marked by a star. 
the SERPINB5 mRNA was 3.5 fold higher than the mean expression levels 
measured in untransduced HaCaT and in the other 51 analyzed HaCaT 
clones (unpublished data, personal communication by Maruggi and Mavilio, 
Figure 2.24).  
Conversely, VPS4B was not affected by retroviral integration, and indeed 








Once demonstrated that the 5’LTR is juxtaposed to the poly(A) of the over-
expressed SERPINB5, we next wondered which might be the mechanisms 
underlining this event (further discussed in Section 3.7 of this Thesis). 
Given that the vector and the SERPINB5 gene were really in close proximity 
to each other, and that they are in the same transcriptional orientation, we 
envisioned that a read-through transcription of the downstream gene might 
have occurred, consistent with the previously published literature (Zaiss et 
al., 2002). In order to gain a first insight into the eventual transcriptional 
activity in the intergenic region, we reverse-transcribed total RNA extracted 
Figure 2.24  Expression analysis of VPS4B and SERPINB5 genes in 
HaCaT clone 28. 
Expression analysis of VPS4B and SERPINB5 genes in clone 28 cells was 
compared to untransduced HaCaT cells and to other clones (51) carrying 
different retroviral integrations. Total RNA was extracted, reverse 
transcribed and finally amplified by Real Time PCR. Expression in HaCaT 
cells was set to 1, while expression in other clones was indicated as fold 
increase over HeLa cells. Expression levels were normalized to GAPDH used 
as a housekeeping gene.  
from clone 28 and from clone 27 as a control. We then amplified cDNA with 
primers located in that region (as indicated in Figure 2.25) and with those 
specific for SERPINB5 gene (between exons 2 and 3). Despite the 
observation that the region immediately 3’ to the vector (2 kbs) was 
transcribed in clone 28 up to 14 folds compared to clone 27, no differences 
between the two clones were detected further downstream (18 kbs from 
the retroviral integration site). 
In this respect, it is worth mentioning that no difference in SERPINB5 
expression in clone 28 was detected, indicating that clone 27 that we used 
to normalize our expression data is not an appropriate control (in 
accordance with Mavilio’s data). This is not surprising, since data regarding 
SERPINB5 over-expression were obtained from the analysis of a number of 
Figure 2.25  Expression analysis of intergenic region between 
retroviral vector and SERPINB5 gene in HaCaT clone 28. 
Total RNA was extracted from clones 27 and 28, retrotranscribed and 
amplified by Real Time PCR with primer sets indicated as “1”, “2” and “3”.  
Expression in HaCaT clone 27 cells was set to 1, while expression in clone 
28 was indicated as fold increase over clone 27 cells. Expression levels were 
normalized to GAPDH used as a housekeeping gene.  
 
clones (51), and the estimated 3.5 fold up-regulation was calculated with 
respect to the mean value of the whole clonal population. Thus, to gain 
further insights into the mechanisms through which aberrant looping is 
associated with gene up-regulation, analysis of other HaCaT clones as well 
as parental HaCaT cell line are currently in progress. Moreover, we will also 
exploit more sensitive experimental approaches such as Northern Blotting 




3B. DISCUSSION  
 
 
3.5 Chromosome Conformation Capture (3C) as a powerful 
technique to detect chromatin loops 
 
Inside the cell nucleus, chromatin is organized into highly dynamic and 
tightly regulated higher-order structures (Fraser and Bickmore, 2007; Zhao 
et al., 2009). The genome extensively establishes physical interactions in 
the form of chromatin loops, that bring distal elements of the chromosome 
into close physical proximity, thus contributing at various extent to the 
regulation of gene expression within the three-dimensional context of the 
nuclear architecture (Gondor and Ohlsson, 2009; Misteli, 2007). Much 
progress in this research area has been achieved thanks to the 
development of the Chromosome Conformation Capture (3C) technique 
(Dekker et al., 2002), which rapidly evolved into 4C-based assays (Simonis 
et al., 2007), and finally into the Hi-C, a striking method that permits the 
identification of all chromatin interactions across the entire genome at a 
resolution of one megabase (Lieberman-Aiden et al., 2009).  
In parallel, the 3C technique itself has also greatly improved since its 
original development, essentially increasing its resolution, that is currently 
down to a few kilobases. In this way, identification of small gene loops has 
been recently described, initially in yeast (Ansari and Hampsey, 2005; 
O'Sullivan et al., 2004; Singh and Hampsey, 2007), and later on also in 




3.6 Gene looping between the viral LTRs is a hallmark of 
transcriptionally active MoMLV proviral DNA  
 
With our work we have demonstrated for the first time that a specific gene 
loop structure is imposed on the integrated MoMLV (i), that  the regions 
involved in looping are the promoter/enhancer elements encompassing the 
5’LTR and the poly(A) site within the 3’LTR (ii), and that this LTR-LTR 
interaction is associated with gene activation (iii).  
 
(i) Taking advantage of the 3C technique we showed here that the 5’LTR 
and the 3’LTR of the MoMLV are physically juxtaposed to form a gene loop 
structure.  
A gene loop is a peculiar conformation that a gene might adopt by bringing 
the 3’ end in spatial proximity to its 5’ start site. The existence of gene loop 
structures is in accordance with the now widely accepted notion that the 
transcription machinery physically interacts with the CPF (Cleavage and 
Poly-adenylation Factor) 3’ end-processing and RNA processing factors 
(Bentley et al., 2005). The first demonstration of a gene loop conformation 
derives from the studies on yeast genes (O'Sullivan et al., 2004), which 
showed an essential roles for factors such as RNA Pol II, the Ssu72 and 
Pta1 components of the CPF 3’-end processing complex and general 
transcription factor TFIIB in gene loop formation, (Ansari and Hampsey, 
2005; Singh and Hampsey, 2007). The first evidence of gene loop 
occurrence in higher eukaryotes was described for the human 
mythocondrial heavy-strand rRNA, which was shown to require the human 
termination factor mTERF (Martin et al., 2005), followed by the 
demonstration that the BRCA1 (BReast CAncer susceptibility gene 1) gene 
also juxtaposes its 5’ and 3’ ends (Tan-Wong et al., 2008). Most relevant 
for our work, a gene loop conformation was also adopted by the HIV-1 
provirus which, upon transcriptional activation, bridges together its 
promoter and its poly(A) signal located within the 5’ and the 3’ LTR, 
respectively (Perkins et al., 2008). 
 
We analyzed four different cell clones, derived two from HeLa and two 
from HaCaT cells. These clones harboured either single (HeLa) or multiple 
(HaCaT) retroviral integrations in different chromosomes. In each cell line, 
3C was performed using two different restriction enzymes, and reliability of 
our results was confirmed by a number of critical controls. In particular, the 
specific PCR band corresponding to the interacting fragments was only 
apparent on chromatin that had been cross-linked and ligated (however not 
in cross-linked not ligated chromatin, nor in not cross-linked chromatin); a 
number of primer set combinations were tested, and proved to be 
negative, thus confirming that the detected interaction was not merely a 
false positive obtained due to the length of the region analyzed (in a range 
of only 3-10 kbs depending on the restriction enzyme); all the primers 
employed were validated for their efficiency in an in vitro-generated 
template; the amount of loaded  chromatin (cross-linked or not cross-
linked, ligated or not ligated) was normalized. 
 
(ii) The combination of several restriction enzymes used to digest 
chromatin during 3C allowed us to obtain a fine mapping of the regions 
involved in the interaction. Indeed, both Ban I (used for HeLa clone 19 and 
HaCaT clone 27) and Dpn II (used for HeLa clones 11 and 19 and for 
HaCaT clone 28) recognized restriction sites within the LTR (three or one, 
respectively), so that we could conclude that the regions responsible for 
the loop formation corresponded to the first 95 bp of the 5’LTR, where the 
Upstream Conserved Region (UCR)  of the enhancer  resides, and to the 
last 113 bp of the 3’LTR, corresponding to the R-U5 regions, including the 
bipartite poly(A) signal. Interestingly, the UCR contains binding sites for 
several cellular factors, including YY1 (acting either as a repressor or as an 
activator of transcription, as in HIV-1 LTR), and NFAT (Nuclear Factor of 
Activated T cells, an ubiquitous transcriptional activator), and has been 
identified as an important activator sequence of retroviral enhancers both 
in murine and human cell types (Wahlers et al., 2002a). Since deletion of 
these sequences has been shown to attenuate the transcriptional activity of 
retroviral vectors in hematopoietic and fibroblastic cell lines, it is plausible 
that these deletions also caused a loss of the “looping” capacity of MoMLV. 
Moreover, this is further supporting the idea that gene loops are stuctures 
involved in efficient gene transcription (as it is further discussed below).  
In addition, further insights into the determination of the sequences that 
are essential for the looping capacity might accrue from the application of 
the plasmid 3C assay, recently developed by Perkins and co-workers 
(Perkins et al., 2008). We plan to apply this technique taking advantage of 
MoMLV-based retroviral vectors carrying mutant UCRs or poly(A) signals of 
diverse origin and length, as well as mutants bearing progressive deletions 
of the LTRs. Whether factors such as YY1, ELP and NFAT, or even other 
factors are critical determinants for loop formation still remains elusive, but 
ChIP-loop assay will prove to be the ultimate technique to gain clues into 
this issue (Cai et al., 2006; Horike et al., 2005; Kumar et al., 2007).  
Finally, it is worth mentioning that many other binding motifs for activating 
factors are located within the central region of the MoMLV enhancer, 
immediately downstream of the UCR, including  basic helix-loop-helix, ETS 
(E Twenty-Six), GATA-binding factors, NF-1, and Myb (see (Wahlers et al., 
2002b) and references therein). However, according to our 3C analysis with 
Dpn II (which cuts at position 96 of the LTR), none of the binding sites for 
these factors are likely to be involved in loop formation. Moreover, we can 
also exclude the possibility that the MoMLV loop is sustained by the 
interaction between the promoter and the enhancer elements that are 
located within the U3 regions of both the LTRs, as previously demonstrated 
for the androgen receptor (Wang et al., 2005). 
 
(iii) Gene loops have been shown to be dynamic structures that are strictly 
dependent on the transcriptional status of the gene. In particular, with the 
only exception of the BRCA1 gene, in which the 5’ and the 3’ ends are 
juxtaposed when expression is repressed, and released upon estrogen-
mediated transcriptional induction (Tan-Wong et al., 2008), in general gene 
loops have been associated with transcriptional activation. This holds true 
both for several yeast genes, the “looping activity” of which dramatically 
diminishes upon inhibition of RNA Pol II (Ansari and Hampsey, 2005; 
O'Sullivan et al., 2004; Singh and Hampsey, 2007), and for the human 
heavy-strand mithocondrial DNA (Martin et al., 2005). Accordingly, 
juxtaposition of the two LTRs in the HIV-1 provirus was observed upon 
stimulation with Tat or phorbol esters, confirming the transcription-
dependence of gene looping (Perkins et al., 2008). How exactly looping 
might promote transcriptional activation or viceversa, still remains to be 
determined. CPF complex involved in RNA Pol II recycling (Ansari and 
Hampsey, 2005; Singh and Hampsey, 2007), as well as ongoing 
transcription (Perkins et al., 2008) are essential for loop formation. Hence, 
a following scenario might be envisaged: loops serve to coordinate an 
efficient co-transcriptional RNA-processing and recycling of the polymerase, 
as well as to provide scaffolds for an effective reinitiation. 
In this context, our study demonstrated that the interaction between the 
LTRs of MoMLV is linked to gene activation as well, reinforcing the view 
that looping might be a hallmark of transcriptionally active retroviral DNA. 
In fact, all the clones that we analyzed were selected for active 
transcription of the retroviral vector: namely, HeLa clones were selected for 
neomicine resistence, directly dependent on the LTR activity. HaCaT clones 
were selected by FACS (Fluorescence-Activated Cell Sorter) analysis for GFP 
expression, which is also driven by the LTR (personal communication from 
Maruggi and Mavilio). In this respect, it is worth mentioning that, since 
HaCaT cells carry multiple integrations, we still do not know whether the 
GFP is expressed effectively from the integrant that we specifically 
considered for 3C analysis. A further confirmation of the link existing 
between looping and transcriptional activation might be obtained  by 
employing RNA Pol II inhibitors, such as -amanitin (Lusic et al., 2003), 
which are predicted to abolish loop formation. Indeed, a similiar approach 
taking advantage of flavopiridol (an inhibitor of the kinase activity of CDK9)  
has already been used to confirm that looping of the HIV-1 genome is a 
transcriptionally-dependent phenomenon (Perkins et al., 2008). 
 
 
3.7 Aberrant looping as a potential mechanism for insertional 
mutagenesis 
 
As we already mentioned above, both MoMLV and HIV-1 contain poly(A) 
signals entirely located within the R region of the 5’ and 3’ LTRs. While 
HIV-1 has evolved active mechanisms to suppress the proximal 5’ poly(A) 
since this provides a very strong signal (Ashe et al., 1995; Ashe et al., 
1997), MoMLV has a much weaker poly(A) (Furger et al., 2001; Zaiss et al., 
2002). A leaky 3’ poly(A) signal has the potential to mobilize cellular 
sequences due to the frequent 3’ poly(A) read-through. This could raise 
increased risk of activating or capturing cellular oncogenes both upstream 
and downstream to the viral integration site by means of long-range 
chromosomal interactions, and this is exactly what we addressed in our 
work.  
Despite the vast amount of data on the insertion sites of retroviral vectors 
performed in several studies and in different cell lines (Bushman et al., 
2005; Cattoglio et al., 2007; Mitchell et al., 2004; Recchia et al., 2006; Wu 
et al., 2003), the molecular basis connecting retroviral integration to 
aberrant cellular gene expression - insertional mutagenesis - is still almost 
completely obscure. Hence, our observations suggest for the first time that 
a physical interaction between the retroviral promoter and cellular 
regulatory elements of the de-regulated gene, namely the poly(A) signal, 
might play a critical role. 
In summary, for each of the four MoMLV integrations, we have assessed 
the expression levels of six genes encompassing a window of 100 kbs 
centered on the integration site (50 kb upstream and 50 kb downstream), 
namely IGF1R (HeLa clone 11), ADA (HeLa clone 19), WISP2 (HeLa clone 
19), LRRC28 (HaCaT clone 27), VPS4B (HaCaT clone 28) and SERPINB5 
(HaCaT clone 28). All these genes were expressed in HeLa or in HaCaT 
cells, but only the SERPINB5 gene was found to be significantly 
upregulated (3.5 folds). Our findings are consistent with several large-scale 
studies that extimated the de-regulation of cellular genes activation upon 
retroviral integration as 20% of cases in T cells (Maruggi et al., 2009; 
Recchia et al., 2006). In this respect, a bioinformatic analysis recently 
demonstrated that retroviral vectors integrate preferentially in genomic 
regions enriched in cell-type specific subsets of transcription factor-binding 
sites, indicating that the gene expression program of the target cell is 
instrumental in directing retroviral integration (Felice et al., 2009). We 
therefore envisioned that cell-type specific transcription factors might be 
involved in loop formation as well, and this might contribute to explain why 
gene de-deregulation and aberrant looping is not observed in not all the 
cases and the cell types. 
Notably, SERPINB5 is a tumor suppressor gene, shown to block the growth, 
invasion, and metastatic properties of mammary tumors (Zou et al., 1994) 
and this is in line with the observation that retroviral vectors have a high 
propensity to target genes involved in cell proliferation and signaling as 
well as proto-oncogenes (Baum et al., 2003; Cattoglio et al., 2007; Wu et 
al., 2006). 
However, the molecular mechanisms connecting aberrant looping to altered 
gene expression is still not completely understood. We can just speculate 
that a read-through activity of the down-stream gene might have occurred, 
generating chimeric transcripts that include all or part of the coding 
sequences of the downstream gene (namely, SERPINB5), a possibility 
which would be consistent with the weak MoMLV poly(A) signal (Zaiss et 
al., 2002). In our work, we initially investigated this possibility, basically 
assessing the levels of transcription of the intergenic region between the 
MoMLV integration and the SERPINB5 gene by RT-PCR. Apparently, an 
enhanced read-through activity of the RNA Pol II in  HaCaT clone 28 (in 
which SERPINB5 had been up-regulated), compared to clone 27, was 
detected in a region located immediately downstream of the retroviral 
integration site. However, when transcription was measured further 
downstream from insertion site (immediatly upstream of SERPINB5), no 
differences were appreciated between the two clones, indicating that 
chimeric transcripts are not generated. Nevertheless, these findings are 
preliminary, and clone 27 did not prove to be a good negative control (as 
previously discussed in the section 2.14 of this Thesis). Thus, we cannot 
rule out the possibility that the 3’LTR-read-through activity is indeed critical 
in the aberrant looping involving SERPINB5, and crucial information might 
be obtained by Northern Blotting or Run-On assays that allow a better 
charachterization and quantification of transcripts deriving from the 
analyzed region, as well as by ChIP experiments to check the distribution of 
RNA Pol II on this region of chromatin.  
Another possible mechanism underlining insertional mutagenesis is that a 
retrovirus integrated in any orientation upstream, within, or downstream of 
a gene might increase the level of expression by virtue of interactions 
between an enhancer in one of the LTRs and the cellular promoter of the 
gene. Should this be the case, a physical juxtaposition of the MoMLV and 
the promoter of the over-expressed gene would have been expected to 
take place which, conversely, we did not detect. 
 
 
3.8 The relevance of retroviral gene loops for gene therapy 
 
In four out of five patients in which gene therapy for SCID-X1 caused the 
development of leukemia, the MoMLV-based retroviral vector was inserted 
within (or close to) the LMO2 T cell proto-oncogene, causing its activation 
(Check, 2005; Hacein-Bey-Abina et al., 2008; Hacein-Bey-Abina et al., 
2003; Howe et al., 2008).   
Based on the findings obtained so far in our cellular models of retroviral 
integration, we can reasonably predict that aberrant looping between the 
retroviral vector and regulatory elements of LMO2 might have occurred in 
the leukemic patients; to demonstrate this will indeed be our ultimate goal.  
Interestingly, Dean and co-workers have recently shown that the NLI/Ldb 1 
complex (Nuclear LIM Interactor, acting as a protein-binding interface that 
facilitates multiple interactions) together with GATA-1/SCL/LMO2 binds the 
-globin locus control region (LCR) as well as the promoter region after the 
transcriptional activation of -globin gene. These associations coincide with 
loop formation, between the LCR and the gene (Song et al., 2007). GATA-1 
binding motifs have also been found in the MoMLV LTRs (according to 
TESS (Transcription Element Search System) in silico analysis, 
http://www.cbil.upenn.edu/cgi-bin/tess/tess). This observation intriguingly 
suggests that LMO2 itself might play a role as a bridging molecule in loop 
formation, causing its own up-regulation. A ChIP-loop assay entailing the 
use of an anti-LMO2 antibody will allow us to directly test this hypothesis. 
 
Overall, a comprehensive understanding of the mechanisms involved in 
insertional mutagenesis is still far to be achieved. Many questions still 
remain unanswered, such as the role of clonal selection in vivo, as well as 
to which extent disease- , vector-, or transgene-specific factors might 
cooperate with insertional gene activation in inducing malignant or pre-
malignant transformation (Bushman, 2007). Our analysis will provide 
critical insights into this field, and hopefully will give important clues for the 
development of safer vectors in order to further exploit the enormous 














4B.  MATERIALS AND METHODS 
 
 
4.10 Cell cultures and plasmids  
 
HeLa, HEK 293T and the amphotropic HEK 293T-derived cells were 
cultured in Dulbecco’s modified Eagle’s medium with Glutamax (Life 
Technologies, Inc.) supplemented with 10% fetal bovine serum (Life 
Technologies, Inc.) and gentamicin (100 g/ ml) at 37°C in a humidified 
95% air-5% CO2 incubator. HeLa clones transduced with the MoMLV 
vectors were cultured in the same conditions described above, but medium 
was added with G418 (Sigma) at a concentration of 800 g/ml. HaCaT cells 
were cultured in Dulbecco’s modified Eagle’s medium supplemented with 
8% fetal bovine serum, penicillin (25 U/l), streptomicin (25 U/l), and 
glutamin (2mM). 
pLXN plasmid was obtained upon sequential digestion with Hind III and 
Ban I, filling in of sticky ends with DNA Polymerase I (Klenow) (New 
England BioLabs), followed by ligation with T4 DNA ligase (New England 
BioLabs). The resulting plasmid was then checked by sequencing. 
 
 
4.11 Vector production and clone selection 
 
To produce MoMLV-based retroviral vectors, amphotropic HEK 293T 
packaging cells were transfected with pLXN plasmid with the standard 
calcium phosphate co-precipitation method. Cloroquine at a final 
concentration of 25 M was added to the medium at the same time when 
the DNA complexes were added, to enhance transfection efficiency.  
Supernatant was collected 48 hours after the beginning of transfections, 
centrifugated and filtered with a 45 m siringe, and finally used to 
transduce HeLa cells. 36 hours after transduction, HeLa cells were splitted 
1:10 and put in selection with 800 g/ml G418. Isolated colonies were 
maintained in selection for 4-6 weeks. 
 
 
4.12 Inverse PCR 
 
Chromosomal regions flanking the retroviral vector in transduced HeLa 
clones were defined by inverse PCR as previously described by Chun and 
co-workers (Chun et al., 1997). DNA was extracted from HeLa clones with 
DNeasy Blood and Tissue kit (Qiagen), according to manufacturer’s 
protocol. After EcoR I digestion (overnight at 37°C), DNA was 
phenol:chloroform extracted and ethanol precipitated, and subsequently 
properly diluted and ligated with 2000 U of T4 DNA Ligase (New England 
BioLabs), overnight at 16°C. A first PCR was performed on 20 ng of ligated 
DNA using the following outwards primers annealing on pLXN plasmid: 
inverse FW: 5’ GTAGGAGACGAGAACCTAA 3’; inverse RV: 5’ 
ATCGAGACATAGACCGCCT 3’. Herculase Enhanced DNA Polymerase 
(Stratagene) was used in a PCR reaction of 40 cycles of 92°C for 10 s, 52°C 
for 30 s, 72°C for 15 min and final extension for 5 min at 72°C. The 
resulting amplification products were purified using QIAquick PCR 
Purification kit (Qiagen, according to manufacturer’s protocol), and 1 l of 
the purified DNA was used as template for a second nested PCR with the 
following primers: 5’ TTGAACCTCCTCGTTCGAC 3’ and nested RV new 5’ 
TCCTGACCTTGATCTGAAC 3’. Herculase Enhanced DNA Polymerase was 
used in a PCR reaction of 40 cycles of 92°C for 1 min, 56°C for 30 s, 72°C 
for 15 min and a final extension of 10 min at 72°C. PCR products were then 
run on 1% agarose gel, and the resulting band was purified with QIAquick 




4.13 Southern Blotting 
 
DNA was extracted as previously described in (Giacca et al., 1994) 
Approximately 30 g of DNA were digested with EcoR I overnight at 37°C 
(New England BioLabs) and fractionated on a 0.8% agarose gel. After 
running, gel was subjected to a acid hydrolysis in 0.2 N HCl and, denatured 
in 1.5 M NaCl and 0.5 M NaOH and blotted overnight in 20X SSC transfer 
buffer. Membrane was neutralized in 1.5 M NaCl and 0.5 M Tris-HCl pH 7.0, 
air-dried and UV-crosslinked (0.5 J) before being subjected to pre-
hybridation in Denhardts’s buffer added with saumon sperm DNA at a final 
concentration of 150 g/ml, 4 hours at 65°C. The 32P-labeled probe was 
obtained upon EcoR I and Nhe I (New England BioLabs) digestion of pLXN 
plasmid, using Ready-To-Go DNA Labelling Beads (minus dCTP) 
(Amersham Biosciences, according to manufacturer’s protocol). For the 
hybridation reaction, 106   cpm/ml were used, overnight at 65°C. After 
several washings in decreasing SSC concentrations, membranes were 
exposed to a phosphor storage screen (Cyclone, Packard).  
 
 
4.14 Chromosome Conformation Capture (3C) 
 
3C was performed as previously described by Perkins and collaborators 
(Perkins et al., 2008) with some modifications. Approximately 8x107 cells 
were crosslinked with 1% formaldehyde for 10 min at room temperature. 
The reaction was quenched by the addition of glycine to 0.125 M. Cells 
were collected and cell pellets were resuspended in lysis buffer (10mM Tris-
HCl pH 8, 10 mM NaCl, 0.2% NP-40 plus protease inhibitors, 2ml/107 cells) 
for 10 min at 4°C. Cell lysis was completed with 20 strokes in Dounce 
homogeniser, then nuclei were washed in the appropriate restriction buffer 
and resuspended in a suitable volume of restriction buffer containing 0.1% 
SDS and incubated for 30 min at 37°C while shacking. Triton-X-100 was 
added to 1% and nuclei were further incubated for 15 min at 37°C to 
sequester SDS. The crosslinked DNA was digested overnight with the 
appropriate restriction enzyme (800 U). The enzyme was inactivated by the 
addition of SDS at a concentration of 2% and incubation at 65°C for 20 
min. The extent of digestion was verified by quantitative real-time PCR 
using Sybr Green detection (BioRad) across the restriction sites. Digested 
chromatin was properly diluted (depending on the restriction enzyme used) 
in 800 l ligation buffer (New England BioLabs) added with 1% Triton-X-
100 and 0.1 mg/ml BSA and 4000 U of T4 DNA ligase (New England 
BioLabs). Ligation conditions were specific for each restriction enzyme, but 
generally ligation was for 4 hours at 16°C, followed by 30 min at room 
temperature and overnight at 4°C. Proteinase K was added, and the 
chromatin mixture was then incubated overnight at 65°C to reverse the 
crosslinks. The following day, DNA was purified by phenol:chloroform 
extraction and ethanol precipitation. One microliter of input was used in a 
PCR reaction of 30, 35 or 40 cycles (depending on the restriction enzyme)  
of 95°C for 30 s, 62°C for 30 s, 72°C for I min, and final extension for 5 
min at 72°C. Primers used for PCR reactions were indicated in Table 4.1. 
The control template was generated by PCR amplifying sequences spanning 
individual restriction sites to be analyzed, mixing them in equal molar 
amounts, followed by restriction digestion and ligation to include all 
possible ligation products.  
 




























































































B13 fw GCCAGCTGGGTGGTGATAGA 
B13 rv CCTCAGAACCCAGCTGTGGA 
 




Total cellular RNA was extracted from HeLa and HaCaT clones with an 
RNeasy Minikit (Qiagen), according to the manufacturer’s protocol. RNA (3 
μg) was treated with RNase-free DNase I (30 U, Roche) for one hour at 
room temperature, and then reverse-transcribed using 20 U MoMLV RT 
(Gibco-BRL), and 1 mM of random hexameric primers (Invitrogen). cDNA 
was amplified by quantitative real-time PCR using Sybr Green detection 
(BioRad). Primers were used at a final concentration of 400 nM and their 
sequences is indicated in Table 4.2. 
Primer name Primer sequence 
IGF1R ex2 fw TGTGAGAAGACCACCATCAACAA
IGF1R ex3 rv CGCTTCCCACACGTGCTT
ADA ex3 fw TCCTGGCCAAGTTTGACTACTACA
ADA ex4 rv GCCCTCTTTGGCCTTCATCT
WISP2 ex1 fw CATGAGAGGCACACCGAAGA
WISP2 eX2 rv ACATGGTGTCGGGCACAG
SERP ex2 fw ACTTGCTCAAGTGGGTGCTAAAG
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Abstract
Background: Despite the large amount of data available on the molecular mechanisms that
regulate HIV-1 transcription, crucial information is still lacking about the interplay between
chromatin conformation and the events that regulate initiation and elongation of viral transcription.
During transcriptional activation, histone acetyltransferases and ATP-dependent chromatin
remodeling complexes cooperate with histone chaperones in altering chromatin structure. In
particular, human Nucleosome Assembly Protein-1 (hNAP-1) is known to act as a histone
chaperone that shuttles histones H2A/H2B into the nucleus, assembles nucleosomes and promotes
chromatin fluidity, thereby affecting transcription of several cellular genes.
Results: Using a proteomic screening, we identified hNAP-1 as a novel cellular protein interacting
with HIV-1 Tat. We observed that Tat specifically binds hNAP1, but not other members of the
same family of factors. Binding between the two proteins required the integrity of the basic domain
of Tat and of two separable domains of hNAP-1 (aa 162–290 and 290–391). Overexpression of
hNAP-1 significantly enhanced Tat-mediated activation of the LTR. Conversely, silencing of the
protein decreased viral promoter activity. To explore the effects of hNAP-1 on viral infection, a
reporter HIV-1 virus was used to infect cells in which hNAP-1 had been either overexpressed or
knocked-down. Consistent with the gene expression results, these two treatments were found to
increase and inhibit viral infection, respectively. Finally, we also observed that the overexpression
of p300, a known co-activator of both Tat and hNAP-1, enhanced hNAP-1-mediated transcriptional
activation as well as its interaction with Tat.
Conclusion: Our study reveals that HIV-1 Tat binds the histone chaperone hNAP-1 both in vitro
and in vivo and shows that this interaction participates in the regulation of Tat-mediated activation
of viral gene expression.
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Background
Efficient packaging of DNA in a highly organized chroma-
tin structure inside the cell is one of the most remarkable
characteristics of all eukaryotic organisms. Chromatin
assembly and disassembly are dynamic biological proc-
esses that increase chromatin fluidity and regulate the
accessibility of the genome to all DNA transactions,
including transcription, DNA replication and DNA repair.
The basic structural unit of eukaryotic chromatin is the
nucleosome, formed by the wrapping of DNA around an
octamer of core histone proteins. By restricting the access
to DNA-binding factors and impeding elongation by RNA
polymerase II (RNAPII), the nucleosome is not only a
structural unit of the chromosome, but perhaps the most
important regulator of gene expression (for recent
reviews, see refs. [1,2]). Chromatin structure is modulated
by the covalent modifications of the N-termini of the core
histones in nucleosomes and by the action of ATP-
dependent chromatin remodeling complexes. In particu-
lar, histone acetylation at the promoter of genes, mediated
by histone acetyltransferases (HATs), has been shown to
be necessary, albeit not sufficient, for transcriptional acti-
vation [2,3].
Chromatin assembly is a stepwise process which requires
histone chaperones to deposit histones on forming nucle-
osomes (reviewed in refs. [4-7]). The Nucleosome Assem-
bly Protein-1 (NAP-1) is one of the major histone
chaperones involved in this process. This factor belongs to
the NAP family of proteins, which is characterized by the
presence of a NAP domain [8]. NAP-1 is conserved in all
eukaryotes from yeast to humans [9-12], and is responsi-
ble for the incorporation of two histone H2A-H2B dimers
to complete the nucleosome (reviewed in ref. [7]). The
protein acts as a nucleo-cytoplasmic shuttling factor that
delivers H2A-H2B dimers from cytoplasm to the chroma-
tin assembly machinery in the nucleus [13]. In addition,
NAP-1 has been involved in the regulation of cell-cycle
progression [14-16], incorporation and exchange of his-
tone variants [17-19], and promotion of nucleosome slid-
ing [20].
Most relevant to the regulation of gene expression, the
chromatin-modifying activity of histone chaperones also
facilitates transcription. In particular, recent information
suggests that HAT complexes as well as ATP-dependent
chromatin remodeling complexes cooperate with histone
chaperones in altering chromatin structure during tran-
scriptional activation [21-24]. In addition, NAP proteins
have been reported to interact with the histone acetyl-
transferase (HAT) and transcriptional coactivator p300/
CBP [25-27], suggesting that NAPs may augment activa-
tion by all the transcription factors that use p300/CBP as
a co-activator. Accordingly, a yeast two-hybrid screen
revealed that hNAP-1 forms a complex with the HPV E2
transcription factor, and a complex formed by hNAP-1, E2
and p300 proved able to activate transcription in vitro
[28].
One of the promoters that show exquisite sensitivity to
regulation by chromatin structure and its modifications is
the long terminal repeat (LTR) of the Human Immunode-
ficiency Virus type 1 (HIV-1) (reviewed in ref. [29]). Fol-
lowing infection of susceptible cells, the HIV-1 provirus
becomes integrated into the host genome and, for still
poorly understood reasons, the LTR promoter enters a
latent state and becomes silenced by chromatin confor-
mation [29,30]. Independent of the site of integration,
two distinct nucleosomes are precisely positioned in the 5'
LTR, separated by a nuclease-hypersensitivity region con-
taining the enhancer and basal promoter elements [31-
34]. Genomic footprinting experiments performed in
either activated or latently infected cells have revealed that
most of the critical protein-DNA interactions in the pro-
moter region are preserved, independent from the LTR
activation state [35,36]. This observation first indicated
that the transcriptional activation of the integrated LTR is
not primarily restricted by DNA target site accessibility,
but occurs through the modulation of chromatin confor-
mation. Indeed, Nuc-1, which is positioned near the viral
mRNA start site, appears to exert a repressive role on tran-
scription; this nucleosome becomes remodelled when
HIV-1 transcription is activated [37,38]. Which are the fac-
tors involved in chromatin remodelling during transcrip-
tional activation, besides the recruitment of several HATs
[39], is a still poorly addressed question.
One of the key factors involved in transcriptional activa-
tion of the provirus is the HIV-1 Tat protein, a highly unu-
sual transactivator that binds an RNA element (TAR)
positioned at the 5' end of the primary proviral transcript
[40]. Tat activates HIV-1 transcription by promoting the
assembly of transcriptionally active complexes at the LTR
by multiple protein-protein interactions. Over the last few
years, a number of cellular proteins have been reported to
interact with Tat and to mediate or modulate its activity.
Among these interacting partners, a major role can be
ascribed to the P-TEFb complex [41-43] and to several cel-
lular HATs, including p300/CBP, P/CAF and GCN5 [44-
47]. P-TEFb promotes processive transcription by phos-
phorylating the RNAPII carboxy-terminal domain (CTD)
[48,49], while HATs induce the activation of chromati-
nized HIV-1 LTR through the acetylation of histones [39].
Of interest, optimal Tat-mediated activation of viral gene
expression also requires the function of ATP-dependent
chromatin-remodelling complexes [50].
In this work we address the issue of identifying novel cel-
lular interactors of Tat through a proteomic screening. We
identify human NAP-1 as a major Tat partner and show
that the interaction between the two proteins is important
for Tat-mediated transcriptional activation and for effi-
cient viral infection.
Results
Identification of cellular factors binding to HIV-1 Tat by 
proteomic analysis
With the aim of identifying cellular partners of HIV-1 Tat
through a proteomic approach, we used an expression
vector encoding the open reading frame of full length Tat
(101 aa) fused with a C-terminal Flag tag. This epitope-
tagged version of Tat was active in HIV-1 LTR transactiva-
tion similar to the wild type protein (data not shown).
Extracts from HEK 293T cells transfected with Flag-
Tat101, as well as from mock-transfected cells, were
immunoprecipitated with M2 Flag antibody conjugated
to agarose beads. Affinity purified Tat-Flag protein and co-
purifying cellular factors were subsequently eluted with
an excess of Flag peptide, run on a 6–15% gradient SDS-
PAGE gel and stained with silver stain (Figure 1). Individ-
ual bands that were apparent only in the sample from Tat-
Flag transfected cells were excised and their identification
attempted by ESI-MS/MS (Electrospray tandem Mass
Spectrometry) analysis of peptides obtained after trypsin
digestion. Five bands were unequivocally identified, as
shown in Figure 1. One corresponding to Tat-Flag itself;
B23/nucleophosmin, a nucleolar protein possibly associ-
ated with ribosome assembly and/or transport [51]; the
p32 protein, an inhibitor of the ASF/SF2 splicing regulator
[52], also known as Tat-associated protein (TAP) [53,54];
ribosomal protein S4 and the histone chaperone NAP-1
(Nucleosome Assembly Protein-1). The proteomic analy-
sis was repeated and the results were also confirmed by
sequencing proteins directly from the Flag beads, rather
than from gel-excised bands.
Since overexpressed Tat is known to accumulate in the
nucleoli, probably due to its unspecific RNA binding
capacity, and given the observation that the same pro-
teomic assay resulted in the identification of a number of
other ribosomal proteins when performed in the absence
of RNase (data not shown), no further work was per-
formed on the B23/nucleophosmin and ribosomal S4
proteins. In this respect, other investigators have already
shown that Tat binds B23/nucleophosmin when both
proteins are overexpressed [55] and that B23/nucleophos-
min protein is required for Tat nucleolar localization but
not for promoter transactivation [56]. The rest of our
research was therefore focused on the characterization of
the hNAP-1/Tat interaction.
HIV-1 Tat interacts with hNAP-1 in vivo
A schematic representation of hNAP-1 is shown in Figure
2A. The protein has 391 amino acids, contains three acidic
domains and has a long KIX-binding domain. This
domain and the C-terminal acidic domain are very con-
served in other members of the NAP family of histone
chaperones, including SET-TAF-I (47% and 68% amino
acid homology in the two regions respectively [57,58];
Identification of Tat-interacting proteins by mass spectrome-tryFigure 1
Identification of Tat-interacting proteins by mass 
spectrometry. A. Flag-immunoprecipitated material from 
Tat-Flag- and mock-transfected HEK 293T cells was resolved 
by 6–10% gradient SDS-PAGE gel, followed by silver staining. 
Protein bands present exclusively in the sample transfected 
with Tat-Flag were excised from the gel and their identifica-
tion attempted by ESI-MS/MS. The identified proteins, in 
addition to hNAP-1 and Tat-Flag, are indicated (1: B23/nucle-
ophosmin; 2: pre-mRNA splicing factor SF2p32 – Tat-associ-
ated protein TAP; 3: ribosomal protein S4). B. Amino acid 
sequence of the human NAP-1 protein (locus NP_631946) – 
391 aa. The underlined amino acid sequences correspond to 
peptides obtained from MS/MS analysis of three independent 
preparations (P = 7.8 × 10-19).
Figure 2B).
The interaction between HIV-1 Tat and hNAP-1 was con-
firmed by co-immunoprecipitation analysis. When
expression vectors for Tat-Flag and for an N-terminal HA-
tagged version of hNAP-1 (HA-NAP-1) were transfected
into HEK 293T, HA-NAP-1 was co-immunoprecipitated
with Tat using anti-Flag antibody (Figure 2C). The specif-
icity of interaction of the two proteins is underlined by the
observation that no co-immunoprecipitation was
observed when Tat was co-expressed with HA-hSET/TAF-I,
despite its sequence homology with hNAP-1 (Figure 2C).
Tat was also found to bind endogenous hNAP-1. As
shown in Figure 2D, an anti-GFP antibody was able to
precipitate endogenous hNAP-1, as detected with an anti-
hNAP-1 antibody, from extracts of cells transfected with
GFP-Tat but not from extracts of cells transfected with
control GFP.
Finally, a bacterially expressed and purified GST-Tat
recombinant protein was also able to pull-down endog-
enous hNAP-1 from a HEK 293T cell extract (Figure 2E).
Binding domain analysis
The domains within hNAP-1 and HIV-1 Tat that were
responsible for the interaction were defined by in vitro
GST-pulldown assays. A series of N- and C-terminal dele-
tion mutants of hNAP-1 (Figure 3A) was expressed after
fusion to GST, and incubated with 35S-labeled full-length
HIV-1 Tat obtained by in vitro translation. All deletants
lacking the N-terminus of the protein up to aa 161 bound
Tat as efficiently as the full length protein; in contrast,
binding was impaired when the hNAP-1 domain from
residues 163 to 289 as well as the C-terminal region from
Co-immunoprecipitation of Tat with transfected and endogenous hNAP-1Figure 2
Co-immunoprecipitation of Tat with transfected and endogenous hNAP-1. A. Schematic representation of hNAP-1 
structure. The acidic domains of the protein are shown by black boxes, with the indication of their boundary amino acids. The 
localization of nuclear export and nuclear localization signals (NES and NLS respectively) are indicated. B. Schematic represen-
tation of the regions of amino acid homology between hNAP-1 and hSET/TAF-I. C. Co-immunoprecipitation of transfected 
hNAP-1 with Tat. The plasmids indicated on top of the figure were transfected into HEK 293T cells. The upper two panels 
show western blots with the indicated antibodies after immunoprecipitation using an anti-Flag antibody; the lower two panels 
show western blotting controls from whole cell lysates (WCL) from transfected cells to show the levels of expression of the 
transfected proteins. D. Co-immunoprecipitation of endogenous hNAP-1 with Tat. The experiment was performed by trans-
fecting HEK 293T cells with plasmids encoding GFP-Tat or GFP alone, followed by co-immunoprecipitation with anti-GFP anti-
body. GFP-Tat retains full transcriptional and trafficking capacities as wt Tat [69, 74, 75]. E. GST-pulldown experiment using 
GST-Tat and HEK 293T whole cell lysates. GST-Tat, but not control GST protein, pulled down endogenous hNAP-1.
residues 290 to 391 were deleted (Figure 3B). These
results indicate that Tat binds two separable domains
within hNAP-1, one internal from amino acids 162 to 290
and one C-terminal from residues 290 to 391.
Next we analyzed the domains of Tat responsible for the
interaction with hNAP-1. GST pull-down experiments
were performed using wild type Tat (101 aa), Tat72 (lack-
ing the second exon), Tat86 (HXB2 clone), and mutated
derivatives of Tat86 carrying cysteine to alanine mutations
at positions 22, 25 and 27 in the cysteine-rich domain or
arginine to alanine mutations at positions 49, 52, 53, 55,
56 and 57 in the basic domain (Tat86 C(22–27)A and
R(49–57)A respectively); Figure 3C. These proteins,
obtained as C-terminal fusions to GST, were used to pull-
down 35S-methionine-labelled hNAP-1 obtained by in
Mapping of hNAP-1 and Tat interacting domainsFigure 3
Mapping of hNAP-1 and Tat interacting domains. A. Schematic representation of hNAP-1 protein and of its deletion 
mutants obtained as GST fusion proteins. The capacity of binding to Tat – see experiment in panel B – is indicated on the right 
side of each mutant. The two dotted boxes indicate the hNAP-1 domains interacting with Tat. B. Representative GST pull-
down experiment using the indicated hNAP-1 mutants and radiolabelled Tat101 protein. The autoradiography shows the 
amount of Tat binding to each mutant; the histogram on top shows densitometric quantification of data, expressed as fold bind-
ing with respect to background binding to GST alone (set as 1). The lower panel shows the Coomassie stained gel at the end 
of the binding experiment. The experiment was repeated at least three times with similar results. C. Schematic representation 
of HIV-1 Tat protein and of its mutants obtained as GST fusion proteins. The capacity of binding to hNAP-1 – see experiment 
in panel D – is indicated on the right side of each mutant. The dotted box corresponds to the basic domain of Tat, which binds 
hNAP-1. D. Representative GST pulldown experiment using the indicated Tat mutants (obtained as GST fusion proteins) and 
in vitro transcribed and translated hNAP-1 protein. The autoradiography shows the amount of hNAP-1 binding to each 
mutant; the histogram on top shows densitometric quantification of data, expressed as fold binding with respect to background 
binding to GST alone (set as 1). The lower panel shows the Coomassie stained gel at the end of the binding experiment. The 
experiment was repeated at least three times with similar results.
vitro transcription/translation. The results obtained dem-
onstrated that hNAP-1 bound the basic domain of HIV-1
Tat (Figure 3D).
hNAP-1 and Tat cooperate in the activation of HIV-1 gene 
expression
One of the essential molecular events that parallel Tat-
driven transcriptional activation is the modification of
chromatin structure at the HIV-1 promoter [34,39]. We
therefore investigated whether NAP-1 might contribute to
Tat transactivation. A reporter construct containing the U3
and R sequences of the HIV-1 LTR upstream of the luci-
ferase gene was co-transfected into HeLa cells, together
with vectors for HA-tagged hNAP-1 and HIV-1 Tat. As
shown in Figure 4A, hNAP-1, when co-transfected with
Tat, significantly enhanced Tat-mediated transactivation
of the LTR; hNAP-1 alone had no effect on promoter activ-
ity.
To test the requirement for endogenous hNAP-1 protein
in Tat-mediated HIV-1 LTR transactivation, luciferase
assays were performed with HeLa cells in which expres-
sion of hNAP-1 was down-regulated by RNAi. A specific
siRNA oligonucleotide was designed which was able to
silence ~80% of the expression of its target from 48 hours
after transfection onward, as assessed by western blot
analysis (Figure 4B). In hNAP-1-knock down cells, Tat
transactivation of the HIV-1 LTR was significantly
impaired, compared to cells treated with a control siRNA.
Collectively, the results of these experiments indicate that
hNAP-1 participates in Tat-mediated control of HIV-1
gene expression.
p300, hNAP-1 and Tat synergistically activate HIV-1 
transcription
Previous work has indicated that NAP-1 interacts with the
cellular transcriptional co-activator and histone acetyl-
transferase p300 [25-27]. Since p300 is also an essential
co-factor for Tat transactivation, we investigated the
effects of hNAP-1 and p300 on Tat-mediated transactiva-
tion. For this purpose, HeLa cells were transfected with an
LTR-luciferase reporter plasmid and expression vectors for
p300 and hNAP-1 together with Tat. As previously
described [47], p300 enhanced Tat-driven transcriptional
activation; when hNAP-1 was co-transfected, transcrip-
tion was further increased (~3.5 fold Tat+hNAP-1+p300
over Tat alone; Figure 4C).
As shown in the co-immunoprecipitation experiment in
Figure 4D, the overexpression of p300 in the same exper-
imental conditions did not affect the levels of expression
of NAP-1 or Tat proteins (as shown in the anti-Flag immu-
noblot). However, in cells overexpressing p300, the
amount of hNAP-1 protein co-immunoprecipitating with
Tat was markedly increased, a result that is consistent with
the possibility that p300 might stabilize the formation of
the Tat-hNAP-1 complex in vivo.
Effect of hNAP-1 on HIV-1 infection
To further examine the effect of hNAP-1 on viral replica-
tion, we used an HIV vector in which a portion of nef had
been replaced by the firefly luciferase gene; two frame-
shifts inactivate vpr and env in this clone, thus blocking
subsequent rounds of viral replication. Infectious virus,
pseudotyped with VSV-G, was produced by transfections
of HEK 293T cells, and used to infect HeLa cells in which
hNAP-1 had been earlier either overexpressed or knocked
down by RNAi. As shown in Figure 5A, the overexpression
of hNAP-1 (as assessed by western blot analysis) resulted
in a 5-fold increase of luciferase activity in HA-hNAP-1-
transfected cells compared to mock-transfected cells. Con-
versely, in cells in which the levels of hNAP-1 had been
reduced to <20% by RNAi, viral luciferase activity was
reduced 3-fold compared to control-treated cells (Figure
5B).
Taken together, these results support the conclusion that
hNAP-1 also plays an important activating role in the con-
text of HIV-1 infection.
Discussion
Activation of the HIV-1 LTR is a complex event involving
the coordinated function of several cellular proteins act-
ing by both releasing the negative inhibition that chroma-
tin imposes on the promoter and inducing the
recruitment of elongation-competent RNPII-containing
complexes. Tat appears to exert an essential activating
function for both these processes. In the last decade, a
number of laboratories have reported the identification of
various cellular factors that mediate Tat function. These
factors fall in several broad categories, including members
of the basal transcriptional machinery, among which
RNAPII itself, ubiquitous transcription factors, transcrip-
tional co-activators, histone-acetyltransferases, and others
[29,59,60]. Our proteomic screening led to the identifica-
tion of yet another cellular partner, hNAP-1, that appears
to be essentially involved in mediating Tat function. We
could confirm the interaction between Tat and hNAP-1
both in vitro and inside the cells, and demonstrate its spe-
cificity by showing that Tat was not able to co-precipitate
hSET/TAF I, another member of the NAP family of pro-
teins. The relevance of the detected interaction between
Tat and hNAP-1 was further reinforced by the observa-
tions that the overexpression of hNAP-1 stimulated Tat-
mediated transactivation of the LTR as well as increased
HIV-1 infection. Conversely, the down-regulation of the
protein by RNAi impaired both transcription and viral
infection. To our knowledge, this is the first demonstra-
tion of an interaction between Tat and a histone chaper-
hNAP-1 cooperates with Tat in LTR transactivationFigure 4
hNAP-1 cooperates with Tat in LTR transactivation. A. hNAP-1 synergizes with Tat in transcriptional activation. HeLa 
cells were cotransfected with a reporter construct containing the HIV-1 LTR upstream of the luciferase gene, and with vectors 
for HA-tagged hNAP-1 (100 ng) and HIV-1 Tat (5 and 25 ng), as indicated. The histogram shows mean ± s.d. of at least three 
independent experiments; the results are shown as fold transactivation over LTR-luciferase reporter alone. The co-expression 
of hNAP-1 significantly increased Tat transactivation of the LTR promoter. The western blot at the bottom shows the levels of 
transfected hNAP-1 protein in a representative experiment. B. hNAP-1 knock down decreases Tat transactivation. HeLa cells 
were transfected with a specific siRNA against hNAP-1 or a control siRNA, and then transfected with the LTR-luciferase 
reporter together with Tat (5 and 25 ng). The histogram shows mean ± s.d. of at least three independent experiments; the 
results are shown as fold transactivation over LTR-luciferase reporter alone. The western blot at the bottom shows the levels 
of endogenous hNAP-1 protein and of tubulin as a control in a representative experiment. C. hNAP-1, Tat and the acetyltrans-
ferase p300 synergistically activate viral transcription. HeLa cells were transfected with LTR-luciferase reporter plasmid and 
with vectors for HIV-1 Tat (5 ng), HA-hNAP-1 (100 ng) and p300 (100 ng), as indicated. After 24 h from transfection, luciferase 
assays were performed. The histogram shows mean ± s.d. of at least three independent experiments; the results are shown as 
fold transactivation over LTR-luciferase reporter alone. D. p300 enhances Tat-hNAP-1 interaction in vivo. The plasmids indi-
cated on top of the figure were transfected into HEK 293T cells. The upper panel shows western blots with the indicated anti-
bodies after immunoprecipitation using an anti-Flag antibody; the lower three panels show western blotting controls from 
whole cell lysates (WCL) from transfected cells to show the levels of expression of the transfected proteins.
one and a first proof of the involvement of this class of
proteins in the regulation of proviral transcription.
Of notice, and in contrast to our expectations, our pro-
teomic screening did not detect several of the cellular pro-
teins previously reported to associate with Tat and to
mediate some of its functions. There are several possible
explanations for this outcome. Our proteomic screening
was conducted by immunoprecipitating a Flag epitope-
tagged version of Tat (which was fully active transcription-
ally) followed by RNase/DNase treatment, elution with a
Flag peptide and resolution of Tat-associated proteins by
gradient gel electrophoresis. In particular, we found that
RNase treatment was essential to avoid the purification of
a vast number of RNA-binding proteins unspecifically co-
immunoprecipitating with Tat (data not shown). It might
well be envisaged, however, that this clearing step might
also affect the binding of Tat to some of its known part-
ners, the interaction of which is strengthened by RNA
bridging. In addition, RNA removal also frees the basic
domain of Tat, thus rendering this region available for the
interaction with hNAP-1. An additional explanation for
the lack of other known Tat partners in our screening
relates to the relative abundance of hNAP-1 in the cells,
compared to other proteins such as p300 and P/CAF
HATs, or Cyclin T1. Since our method relied on the iden-
tification of protein bands in silver-stained gels, a likely
possibility is that we missed the detection of lower abun-
dance proteins. Finally, it is worth however noting that
other proteomic screenings aimed at the identification of
cellular partners to other proteins also failed in identify-
ing obvious candidates, while successfully discovering
new factors essential for the function of the investigated
proteins (see, among others, refs. [53,61]).
The basic region of Tat was found to bind two separable
domains within hNAP-1, one internal from amino acids
162 to 290 and one C-terminal from residues 290 to 391.
These domains correspond to a series of alternate  helix/
 sheet regions known to be involved in the interaction
with histones and other cellular proteins (see ref. [8,62]
and citations therein). Of notice, the observation that Tat
does not bind the highly acidic protein hSET/TAF I,
another member of the NAP family with high structural
and functional homology to hNAP-1 [57,58], argues in
favor of a specific interaction between Tat and hNAP-1
which is not merely based on electrostatic interactions.
There is growing evidence that hNAP-1 plays important
roles during transcriptional activation [21-24]. In particu-
lar, hNAP-1 and other histone chaperones both cooperate
with ATP-dependent chromatin remodeling complexes
[25,63] and participate in the formation of protein com-
plexes also containing p300/CBP [25-28]. Taken together,
these observations clearly suggest that hNAP-1 may serve
as an interaction hub between transcriptional coactivators
and chromatin. As far as p300/CBP is specifically con-
cerned, p300 has been shown to directly bind the C-termi-
nus of hNAP-1, namely the same region that is also
involved in binding to Tat. Since the basic domain of Tat
is also involved in binding to p300 [47], we cannot rule
out the possibility that p300 might act as a scaffold for the
simultaneous interaction with the two proteins. While
further biochemical studies are clearly needed to ascertain
this possibility, it is of interest to observe that the overex-
pression of all the three proteins together determined an
increase in the levels of LTR transcription that is higher
Effect of hNAP-1 on HIV-1 infectionFigure 5
Effect of hNAP-1 on HIV-1 infection. A. Overexpres-
sion of hNAP-1 enhances LTR transcription upon HIV-1 
infection. HeLa cells were transfected with an expression 
vector for HA-hNAP-1 or with a control vector, and then 
infected with VSG-luciferase HIV-1 vector. Luciferase activity 
was measured after 24 h post-infection. The mean ± s.d. of at 
least three different experiments is shown. The panel on the 
right side shows anti-HA western blottings to assess HA-
hNAP-1 expression in a representative experiment. B. 
Silencing of hNAP-1 impairs LTR transcription upon HIV-1 
infection. HeLa cells were treated with an siRNA directed 
against hNAP-1 or a control siRNA. Forty-eight hours after 
the beginning of siRNA treatment, cells were infected with 
the luciferase reported virus, and luciferase assays were per-
formed on cell lysates 24 hours later. The mean ± s.d. of at 
least three different experiments is shown. The panel on the 
right side shows anti-hNAP-1 western blottings to assess the 
levels of endogenous hNAP-1 and tubulin expression in a 
representative experiment.
than those obtained by overexpression of either p300 or
hNAP-1 alone together with Tat. In addition, expression
of p300 did not affect the levels hNAP-1 or Tat proteins,
but markedly increased their binding in vivo. This obser-
vation is again in favor of the possibility that p300 might
exert a stabilizing role on the Tat-hNAP-1 interaction. This
possibility would be consistent with the proposed func-
tion for hNAP-1 in regulating transcription in all p300-
dependent promoters [27,28].
What might be the actual mechanism by which hNAP-1
might facilitate Tat transactivation? First, overexpression
of hNAP-1 significantly increases the overall levels of Tat
inside the cells. This result is consistent with the possibil-
ity that the interaction with hNAP-1 might increase the
stability of Tat. Second, and more relevant to a specific
and direct role of hNAP-1 on the LTR promoter, previous
results have indicated that the acetylation of histones by
p300 helps transfer histones H2A and H2B from nucleo-
somes to hNAP-1 [26], and that, at least in vitro, the
absence of these histones correlates with increased gene
activity, probably by decreasing the level of chromatin
folding [64,65]. On the basis of these observations, we
can speculate that hNAP-1 and p300, brought to the LTR
promoter through their interaction with Tat, might coop-
erate in the creation of an open-chromatin environment,
favorable for gene expression. Of interest, a recent
genome-wide analysis in fission yeast has revealed that
chromatin remodeling factors and NAP-1 colocalize
within promoter regions, where they disassemble nucleo-
somes near the transcriptional start site, an event that is
linked to changes in the levels of histone acetylation [24].
Conclusion
In conclusion, this proteomic study reveals that the his-
tone chaperone hNAP-1 is an important cellular factor
specifically binding HIV-1 Tat. The interaction between
the two proteins is involved in the regulation of Tat-medi-
ated activation of viral gene expression, exerting a positive
role on transcription. In particular, our findings indicate
that HIV-1 Tat, hNAP-1 and p300 functionally cooperate
to induce transcriptional activation of the HIV-1 LTR pro-
moter.
Methods
Protein purification and identification
Twenty-four hours after transfection, 2 × 108 HEK 293T
cells were washed once in phosphate-buffered saline
(PBS) and lysed on ice in lysis buffer (150 mM NaCl/20
mM HEPES pH 7.9/0.5% NP-40/1 mM EDTA/1 mM DTT/
protease inhibitor cocktail-Roche). The cell extract was
sonicated once and then centrifuged for 15' at 14,000 rpm
at 4°C. An aliquot of the cleared extract was kept as input,
while the rest was incubated with 100 l of packed and
pre-equilibrated Flag M2 agarose beads overnight at 4°C.
Beads were rinsed twice in lysis buffer, before treatment
with DNAse I (Invitrogen, according to manufacturer's
instructions) and RNAse A (150 mM NaCl/10 mM Tris
HCl pH 7.5/5 mM EDTA/10 units RNAse A, for 30' at
37°C) and then washed in the same buffer three times.
Immunocomplexes were eluted by adding 500 g/ml Flag
peptide (Sigma) in lysis buffer. The eluate was concen-
trated by standard trichloroacetic acid precipitation and
resuspended in 1X sodium dodecylsulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) protein loading buffer.
Proteins were then subjected to 6–15% gradient SDS-
PAGE and then stained with silver stain. Stained proteins
were excised and processed for in-gel trypsin digestion fol-
lowing standard protocols. The resulting peptides were
extracted and purified on C18-Ziptips (Millipore) accord-
ing to the manufacturer's protocol and resuspended in 10
l of 30% methanol, 0.5% acetic acid. Protein identifica-
tion was performed by the ICGEB Proteomics Facility by
analyzing the purified peptides by MALDI-TOF mass spec-
trometry using an ABI 4800 TOF/TOF instrument
(Applied Biosystems). The remaining sample was ana-
lyzed by LC-MS/MS using an LCQDeca mass spectrometer
(Thermo-Finnigan).
Cell cultures, plasmids and siRNAs
HeLa and HEK 293T cells were cultured in Dulbecco's
modified Eagle's medium with Glutamax (Life Technolo-
gies, Inc.) supplemented with 10% fetal bovine serum
(Life Technologies, Inc.) and gentamicin (100 g/ml) at
37°C in a humidified 95% air-5% CO2 incubator.
All hNAP-1 encoding plasmids (wild type and mutants)
were a kind gift by G. Steger [28]. All other plasmids used
have already been described elsewhere [47,66-69].
RNA interference (RNAi) with hNAP-1 was performed
against the target sequence 5' AAGGAACACGAUGAACC
UAUU 3'. An siRNA targeted against the GFP RNA was
used as a control (5' GGCTACGTCCAGGAGCGCACC 3').
Synthetic double-stranded RNA oligonucleotides were
purchased by Dharmacon.
Co-immunoprecipitation
For co-immunoprecipitation analyses, HEK 293T cells
where transfected with the indicated plasmids using the
standard calcium phosphate coprecipitation method.
Twenty-four hours after transfection cells were washed
once in PBS and lysed on ice in 1 ml/dish lysis buffer (150
mM NaCl/20 mM HEPES pH 7.9/0.5% NP-40/1 mM
EDTA/1 mM DTT/protease inhibitor cocktail-Roche).
After sonication, cleared cell extracts were incubated with
pre-equilibrated Flag M2 agarose beads on a rotating
wheel for 4 hours at 4°C. Beads were washed twice with 1
ml of lysis buffer, treated with DNase I (Invitrogen,
according to manufacturer's instructions) and RNAse A
(150 mM NaCl/10 mM Tris HCl pH 7.5/5 mM EDTA/10
units RNAse A, for 30' at 37°C) and then washed in the
same buffer three times.
Antibodies
Anti-hNAP-1 mouse monoclonal antiserum was a kind
gift from Y. Ishimi [70]. Mouse monoclonal anti-Flag M2
antibody, mouse monoclonal anti-tubulin, and mouse
monoclonal anti-Flag M2 agarose-conjugated beads were
purchased from Sigma. Rat monoclonal anti-HA high
affinity (3F10) antibody was purchased from Roche diag-
nostics. Rabbit polyclonal anti-GFP antibody SC8334 was
purchased from Santa Cruz Biotechnology.
Recombinant proteins
Glutathione S-transferase (GST), GST-Tat, GST-hNAP-1,
GST-Tat mutants and GST-hNAP-1 mutants were prepared
as already described [71]. Plasmids pcDNA3-Tat101 and
pcDNA3-HA-NAP-1 were used as templates to produce
the in vitro 35S-labeled Tat and hNAP-1 proteins, respec-
tively, by using the TNT Reticulocyte Lysate System
(Promega) according to the manufacturer's protocol.
GST pull-down assay
GST and GST-Tat recombinant proteins immobilized on
agarose beads were pre-treated with nucleases (see
below). HEK293T cells were lysed in 150 mM NaCl/20
mM HEPES pH 7.9/0.5% NP-40/1 mM EDTA/1 mM DTT/
protease inhibitors (Roche). Recombinant proteins and
cell extracts were incubated 1 hour and 30 minutes at 4°C,
and washed four times in lysis buffer.
In vitro binding assay
To remove contaminant bacterial nucleic acids, recom-
binant proteins were pretreated with nucleases (0.25 U/ l
DNase I and 0.2 g/ l RNase) for 1 hour at 25°C in 50
mM Tris HCl, pH 8.0/5 mM MgCl2/2.5 mM CaCl2/100
mM NaCl/5% glycerol/1 mM DTT. Subsequently, GST
fusion proteins immobilized on agarose beads were
washed and resuspended in NETN buffer (20 mM Tris
HCl, pH 7.5/100 mM NaCl/1 mM EDTA/0.5% NP-40/1
mM DTT/1 mM PMSF) supplemented with 0.2 mg/ml
ethidium bromide to block the possible formation of
non-specific interactions between residual DNA and pro-
teins. 35S-labeled hNAP-1 or Tat101 proteins (400 cpm)
were added and incubated at 4°C on a rotating wheel.
After 90 min, bound proteins were washed twice with 0.3
ml of NETN with ethidium bromide, three times with 0.3
ml of NETN without ethidium bromide and once with 0.3
ml of 10 mM Tris HCl pH 8.0/100 mM NaCl. Finally,
bound proteins were separated by electrophoresis on a
12% SDS-polyacrylamide gel. Gels were stained and fixed
for 1 hour with 10% acetic acid/40% methanol/0.1%
Coomassie Brilliant blue G250, and destained with 10%
acetic acid/40% methanol. Dried gels were quantitated by
Instant Imager (Packard).
Luciferase assay
Reporter gene assays were performed using pLTR-luci-
ferase plasmid as a reporter and pcDNA3-Tat101 as an
effector in the presence or absence of plasmids pcDNA3-
hNAP-1 and pCMV-p300. HeLa cells were transfected
using Effectene Reagent (Quiagen, according to manufac-
turer's protocol), with 100 ng of pLTR-luciferase, 50 ng of
pcDNA3-hNAP-1 and 5 or 25 ng of pcDNA3-Tat101. A
Renilla luciferase expression plasmid, in which reporter
gene expression was driven by the CMV promoter, was
cotransfected to standardize each experiment for the effi-
ciency of gene transfer. Cells were harvested 48 hours post
transfection, and luciferase activity was measured with
Luciferase assay kit (Promega). The measured activities
were standardized by the activities of Renilla, and transac-
tivation was expressed as fold activation compared with
the basal activity of LTR-luciferase without effectors. All
experiments were performed in duplicate and repeated at
least three times.
For the transactivation experiments following RNAi, siR-
NAs were transfected using Oligofectamin Reagent (Invit-
rogen, according to manufacturer's protocol). After 36
hours from the beginning of siRNA treatment, cells were
transfected with LTR-luciferase and CMV-Renilla plasmids
and increasing amounts of pcDNA3-Tat101. Thirty-six
hours later luciferase assays were performed on cell
lysates.
In the case of infection with VSV-G-luciferase vectors, luci-
ferase assays were performed 24 hours after the beginning
of infection. For the gene-silencing experiments, cells were
infected 48 hours after siRNA transfection. To normalize
luciferase measures, protein concentrations in the lysates
were determined with Bradford reagent (BioRad, accord-
ing to manufacturer's protocol).
Virus production and infections
To produce VSV-G-luciferase vectors, HEK 293T cells were
transfected with pNL4.3-luciferase plasmid [72,73] and
VSV-G encoding plasmid at a ratio 3:1, according to a
standard calcium phosphate coprecipitation method.
Supernatants were collected 48 hours after the beginning
of transfections, centrifuged and filtered with a 45 m
syringe.
Infections with viral supernatants was carried out for 6
hours in the presence of polybrene (Sigma) at a final con-
centration of 5 g/ml.
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Abstract
Background: The human immunodeficiency virus type 1 (HIV-1) favors integration in active genes
of host chromatin. It is believed that transcriptional interference of the viral promoter over the
endogenous gene or vice versa might occur with implications in HIV-1 post-integrative
transcriptional latency.
Results: In this work a cell line has been transduced with a HIV-based vector and selected for Tat-
inducible expression. These cells were found to carry a single silent integration in sense orientation
within the second intron of the HMBOX1 gene. The HIV-1 Tat transactivator induced the viral LTR
and repressed HMBOX1 expression independently of vector integration. Instead, single-cell
quantitative in situ hybridization revealed that allele-specific transcription of HMBOX1 carrying the
integrated provirus was not affected by the transactivation of the viral LTR in cis.
Conclusion: A major observation of the work is that the HIV-1 genome has inserted in genes that
are also repressed by Tat and this could be an advantage for the virus during transcriptional
reactivation. In addition, it has also been observed that transcription of the provirus and of the
endogenous gene in which it is integrated may coexist at the same time in the same genomic
location.
Background
Retroviruses, such as human immunodeficiency virus type
1 (HIV-1) require reverse transcription and integration
into host chromatin to establish a provirus as an obliga-
tory replication step. The choice of the integration site is a
crucial intermediate of the virus life cycle. The chromatin
context determines the efficiency of viral transcription and
is involved in the establishment of post-integrative
latency that is the major obstacle to HIV-1 eradication
with current antiviral therapies [1-3]. In addition, inser-
tion of a provirus in the human genome can cause several
adverse effects [4]. For example, insertion of the retrovirus
Published: 4 November 2008
Retrovirology 2008, 5:98 doi:10.1186/1742-4690-5-98
Received: 6 October 2008
Accepted: 4 November 2008
This article is available from: http://www.retrovirology.com/content/5/1/98
© 2008 De Marco et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
close to a proto-oncogene may induce transformation of
the cell. Gene therapy approaches suffer most from these
effects and recently it has been demonstrated that the acti-
vation of an oncogene caused transformation in several
children treated with a therapeutic retroviral vector [5]. In
principle, insertion of an ectopic transcription unit within
a gene may also result either in disruption of exonic
sequences, introduction of alternative splicing or tran-
scriptional interference. Clearly, these negative effects
would increase in importance relative to the increasing
unbalance of the endogenous gene expression between
alleles.
Integration site selection by retroviruses is not sequence-
specific but also not random. HIV-1 favors integration
within active transcription units [6-8]. Additional features
are the requirement of host factors such as the lens epithe-
lium-derived growth factor LEDGF/p75 for efficient tar-
geting of active transcription units [9] and a DNA
substrate wrapped around nucleosomes. Indeed, integra-
tion of HIV-1 is linked to nucleosomal markers of active
transcription (H3/H4 acetylation, H3K4 methylation)
and negatively correlated with inhibitory modifications
(H3K27 trimethylation and DNA CpG methylation) [10].
Subtle differences in the integration site choice exist
among retroviruses. Murine leukemia virus (MLV) inte-
grates within highly active promoters at ± 5 kb from the
transcription start sites [7,11]. HIV-1 instead, although
also favoring active genes, does not show a preference for
promoter-proximal integration. Rather, the virus inserts
throughout the transcriptional unit with a bias towards
intronic sequences: this is the likely result of the greater
size of introns compared to exons within a gene [6].
A crucial aspect of HIV-1 pathogenesis is the control of
provirus transcription. In particular the ability of the virus
to maintain a reservoir of transcriptionally silent provi-
ruses in resting memory T cells for long periods of time.
Multiple mechanisms have been postulated to concur in
these processes. Host factors, for example, may be limiting
the activity of the Tat transactivator. Tat interacts with a
cis-acting RNA element (trans-activation-responsive
region; TAR) present at the 5' end of each viral transcript
[12]. Through this interaction, the protein activates HIV-1
transcription by promoting the assembly of transcription-
ally active complexes at the LTR through multiple protein-
RNA and protein-protein interactions [13]. Tat interacts
with the core RNA polymerase II [14,15], the TATA-bind-
ing protein associated factor (TAFII) [16], TFIIH [17], cyc-
lin-dependent protein kinase 7 [18], SP1 [19], nuclear
factor of activated T cells (NFAT) [20], several histone
acetyltransferases [21-23] and cyclin T1 [24]. On the other
hand, the chromatin context at the site of integration
should determine whether the provirus is transcription-
ally active, poised for activation or inactive [25]. Early
studies showed that latency involved integration into
regions of heterochromatin [26,27]. More recent system-
atic genome-wide analysis of the chromosomal features
negatively associated to HIV-1 transcription revealed that
low levels of LTR-driven expression correlated with inte-
gration in gene deserts and in centromeric heterochroma-
tin, but also in highly expressed cellular genes [28].
Furthermore, HIV-1 has been found in intronic regions of
actively transcribed genes in resting memory CD4+ cells
derived from patient on highly active antiretroviral treat-
ment [29]. The paradox of HIV-1 integration in active
genes while being transcriptionally silent requires molec-
ular investigation of the phenomenon. Unfortunately
most cellular models of HIV-1 post-integrative latency
harbor the provirus outside of transcribed genes [3]. In
this work a cell-line that carries a single repressed provirus
integrated within the active transcription unit of the
HMBOX1 gene has been generated. Tat-mediated induc-
tion of provirus transcription resulted in the inhibition of
HMBOX1 expression. However, this effect could be
ascribed to Tat expression and not to activation of the viral
LTR. Indeed, a subset of activated cells showed bi-allelic
expression of HMBOX1 together with expression of the
provirus within one of the alleles. These results are dis-
cussed in light both of HIV-1 pathogenesis and of the
potential use of lentiviral vectors for gene therapy applica-
tions.
Results
Generation and characterization of a cell line carrying a 
stably integrated lentiviral vector
The HIV-Intro-MS2 × 24-ECFPskl-IRES-TK lentiviral vec-
tor (for simplicity: HIV-Intro) has been engineered to con-
tain the elements required for RNA production: the 5'
LTR, the major splice donor (SD1), the packaging signal
, the RRE, the splice acceptor A7 and the 3' LTR that
drives 3'-end formation (Figure 1). The construct carries
also an array of 24 repeats of the MS2 phage coat protein
within the intron, to increase specific detection of nascent
mRNA, a reporter of gene expression (ECFP) fused to the
peroxisome localization signal Ser-Lys-Leu (skl) and the
selectable marker thymidine kinase (TK) of herpes sim-
plex type 1.
In order to characterize this construct extensively before
transduction, HeLa cells were transfected with plasmid
HIV-Intro together with a plasmid expressing a mono-
meric DsRed-tagged Tat Figure 2A, top panels). As
expected from previous studies showing transcribed nas-
cent RNA by MS2-tagging [30,31], bright yellow spots
appeared within the nucleus. Each spot corresponds to
several plasmids clustered together that express viral RNA
[32]. As expected, Tat was found at transcription sites
because it binds the 5'-end of each transcript. The reporter
of gene expression ECFPskl was found in the cytoplasm.
When a plasmid expressing a DsRed-tagged Rev was co-
transfected together with Tat (without tag), the unspliced
RNA was found in the cytoplasm, consistent with its Rev-
mediated export (Figure 2A, bottom panels). These results
are mirrored by the behavior in RT-PCR using a set of
primers that distinguish pre-mRNA from spliced RNA. As
shown in figure 2B, basal transcription is up-regulated by
Tat with a higher proportion of spliced over unspliced
RNA. Co-transfection of a plasmid encoding pEYFP-
MS2nls does not affect the splicing reaction, ruling out
perturbation of the system by such a strong RNA binding
protein. Expression of Rev instead increased the propor-
tion of unspliced RNA, consistent with its role in RRE-
containing RNA stabilization and export.
A key question that arose while doing these experiments
was the real nature of these yellow spots in the nucleus
(Figure 2A, top panels). To confirm that these where sites
of HIV-Intro transcription we incubated the cells with
inhibitors such as Actinomicin D, -Amanitin or Fla-
vopiridol. As shown in Figure 2C, a rapid decrease of the
number of transcription spots was observed with all three
inhibitors. Hence, RNA-dependent accumulation of RNA
at these sites was dependent on RNAPII activity.
Next a strategy was designed to express the HIV-Intro con-
struct from a single chromatinized location in a Tat-induc-
ible way. Osteosarcoma HOS_143b cells, that are negative
for thymidine kinase activity (TK-), were transduced with
the HIV-Intro vector pseudotyped with the VSV-G enve-
lope. To select for clones that carry an inducible integrated
provirus, cells that constitutively expressed high levels of
HSV-TK were selected against by treatment with 50 g/ml
ganciclovir. Surviving cells, that were either non-trans-
duced, or transduced but with a low level of TK expres-
sion, were treated with GST-Tat and briefly selected for
inducible HSV-TK expression in hypoxanthine, aminop-
terin and thymidine (HAT) medium. Clonal populations
were obtained by limiting dilutions and colonies were vis-
ually scored for low basal level of ECFP expression in the
cytoplasm and to be highly inducible by GST-Tat by fluo-
rescence microscopy. The HOS_A4 cell clone showed a
robust and homogenous induction of ECFPskl in the cyto-
plasm upon treatment with GST-Tat (Figure 3A). These
Genomic organization of the HMBOX1 gene and of the HIV-intro construct in HOS_A4 cellsFigure 1
Genomic organization of the HMBOX1 gene and of the HIV-intro construct in HOS_A4 cells. Position of the RT-
PCR primers are indicated by black arrows. Positions of the FISH probes are indicated by red bars.
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A) HeLa cells were cotransfected with pHIV-Intro, pEYFP-MS2nls and either mDsRed tagged Tat (top) or Tat and mDsRed tagged Rev (bottom)Fi ure 2
A) HeLa cells were cotransfected with pHIV-Intro, pEYFP-MS2nls and either mDsRed tagged Tat (top) or Tat 
and mDsRed tagged Rev (bottom). Yellow spots in the nucleus correspond to nascent RNA from transfected plasmids. 
Cyan spots in the cytoplasm correspond to ECFPskl localized to peroxisomes. B) RT-PCR on HeLa cells transfected as indi-
cated. Three primers were used, their position is shown in Figure 1. Resulting bands correspond to the unspliced and spliced 
HIV-Intro RNAs. Bottom panels: -actin loading control (M = molecular weight marker). C) Effect of RNAPII inhibitors on 
HIV-Intro transcription in transfected HeLa cells transfected as indicated in Figure 2A, top panels. Nuclei showing transcription 
spots were scored 1 hour (gray bars) an 6 hours (black bars) after treatment with Actinomicin D (10 g/ml), -Amanitin (10 
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A) Generation of HOS_A4 cells by transduction with HIV-Intro and selection as described in the textFigure 3
A) Generation of HOS_A4 cells by transduction with HIV-Intro and selection as described in the text. Tat induc-
tion induced the expression of ECFPskl in the cytoplasm. Top panels: phase contrast. Bottom panels: ECFP channel. B) South-
ern blot analysis of HOS_A4 cells shows the presence of a single integration event. Genomic DNA was digested with XhoI or 
SpeI and hybridized with a probe encompassing ECFP. C) Effect of Tat-mDsRed on HOS_A4 cells. Co-localization of Tat and 
HIV-Intro RNA is shown on the single transcription spot present in HOS_A4 cells. Correct gene expression is demonstrated 
by the ECPFskl signal in the cytoplasm. D) Co-localization of RNAPII and Cyclin T1 on HOS_A4 transcription spots. Cells 
were transfected with pEYFP-MS2nls and Tat, fixed and Cyclin T1 (top panels) or RNAPII (bottom panels) detected by immun-
ofluorescence as described in [30].























cells were transfected with plasmids encoding EYFP-
MS2nls and Tat-mDsRed. As shown in figure 3C, HOS_A4
showed ECFPskl in the cytoplasm and presented one sin-
gle bright yellow spot in the nucleus compatible with a
single site of HIV-Intro transcription that co-localized
with Tat-mDsRed. Immuonfluorescence with antisera
against Cyclin T1, the P-TEFb component recruited
directly by Tat on the viral RNA, or RNAPII demonstrated
enrichment of such factors at these sites (Figure 3D).
These results are compatible with one integration event of
the HIV vector in HOS_A4 cells. Indeed, analysis by
southern blotting (Figure 3B) and cloning of the integra-
tion sites by inverse PCR revealed that the provirus lay
within the HMBOX1 (homeobox containing 1) cellular
gene.
Allele-specific expression of HMBOX1 following HIV-
Intro-MS2 × 24-ECFPskl-IRES-TK transactivation
Human HMBOX1 is composed of 11 exons, spanning
about 160 kb within chromosome 8 p21.1 (Figure 1).
HMBOX1 is believed to encode for a transcription factor
involved in the transcriptional regulation of key eukaryo-
tic developmental processes. HMBOX1 is widely
expressed in pancreas and the expression of this gene can
also be detected in pallium, hippocampus and hypothala-
mus [33]. In HOS_A4 cells the HIV-Intro lentiviral vector
integrated within the second giant intron of HMBOX1
(Figure 1). In order to assess expression of HMBOX1 in
HOS cells RT-PCR was performed with primers specific for
Exon3 or encompassing Exon2/Exon3 junction (Figure
4A). Both parental HOS 143b and HOS_A4 expressed
HMBOX1 at similar levels. However, this assay was nei-
ther quantitative nor specific for the HMBOX1 allele car-
rying the integrated vector. A similar approach was also
employed for the HIV-Intro transcript. As shown in Figure
4B, a basal level of HIV-Intro expression was detected in
HOS_A4 that could be up regulated by Tat transfection.
In order to detect allele-specific transcription in the
HMBOX1 locus carrying the integrated provirus a quanti-
tative RT-PCR was developed according to the protocol of
Han and collaborators [29]. As shown in the diagram of
Figure 1, RT-PCR primers were designed to detect also
HMBOX1 transcripts containing HIV sequences upstream
of the viral transcription start site. RNA from HOS_A4
cells was reverse-transcribed and the resulting cDNA was
amplified with two primers that share the HIV_RT primer.
HIV_UP5 amplifies only HIV-Intro sequences produced
as a result of transcription of HMBOX1 reading through
the HIV-Intro genome that is inserted into the gene.
Because the forward primer is located upstream of the
transcription start site and the reverse primer is located
downstream of the LTR, only RNA species initiating
upstream of the HIV-1 transcription start site could be
amplified. HIV_START instead is able to amplify any HIV-
Intro transcript that has initiated at the viral start site. To
prevent amplification from HIV-1 DNA, isolated RNA was
treated with DNase before RT-PCR. In addition, control
reactions from which RT was omitted were included in
each experiment and were invariably negative. A positive
control of HIV transactivation involved a set of primers for
the HIV-1 spliced RNA product (primers HIV_nuc and
HIV_spliced). PCR amplification was conducted in the
presence of the dye CyberGreen for relative quantification
of PCR products. Transfection of Tat induced HIV-1 tran-
scripts several folds with both primer sets detecting HIV-1
transcripts (Figure 4C and Figure 4D). This result is per-
fectly in line with the well-known Tat-transactivation of
the viral LTR and with RT PCR data shown in Figure
4B[34]. Allele-specific detection of HMBOX1 RNA instead
showed a marked decrease in response to Tat (Figure 4E).
This result would be explained by negative interference
with the expression of HMBOX1 due to activation of a
strong promoter embedded within the gene. However,
when the analysis was conducted on two primer sets spe-
cific for the HMBOX1 gene both in HOS_A4 and the
parental HOS_143b we realized that expression of
HMBOX1 was affected by the presence of Tat per se and
not by the activation of the viral LTR (Figure 4F and Figure
4G). This effect was not a general effect on transcription
since the GAPDH gene was not affected (Figure 4H).
Single-cell analysis of HMBOX1 and HIV-1 expression
Ensemble-averaged analysis such as RT-PCR that relies on
the evaluation of a number of cells does not allow distinc-
tion between expression of each HMBOX1 allele. In fact,
although we analyzed allele-specific expression of the
allele carrying the provirus, still we don't know whether
HMBOX1 expression was balanced between alleles or not.
In order to evaluate the simultaneous expression of both
HMBOX1 alleles and of the integrated provirus, tran-
scripts were detected by quantitative fluorescent in situ
RNA hybridization (FISH). The amount of RNA on the
transcription spot is determined by the rate of transcrip-
tion and the rate of RNA processing. At steady state it
could be derived from the intensity of the fluorescence sig-
nal compared with the intensity of the signal from a
known reference as described previously [30]. For this
purpose for each probe and each acquisition we prepared
a calibration curve spotting different amounts of probe on
a coverslip in a constant volume. The probes were
acquired and deconvoluted using the same conditions
used for the samples (see Methods). The z-projection sum
of all planes was averaged and this value represent the sig-
nal emitted by each amount of probe. Therefore, the
number of probes for each voxel (a volume pixel in a
three-dimensional image) could be calculated for each
point of the calibration curve. In the case of HIV-Intro
A) RT-PCR analysis of HMBOX1 expression in parental HOS_143b and clone HOS_A4 using primers for HMBOX1 Exon 3 (79 bp, top panel) nd Exon 2/Exon 3 s licing (86 bp, middle panel)Figure 4
A) RT-PCR analysis of HMBOX1 expression in parental HOS_143b and clone HOS_A4 using primers for 
HMBOX1 Exon 3 (79 bp, top panel) and Exon 2/Exon 3 splicing (86 bp, middle panel). Bottom panel: -actin con-
trol (230 bp). B) RT-PCR analysis of HIV-Intro expression (280 bp top panel) in parental HOS_143b and clone HOS_A4 using 
primers HIV_SPLICED and HIV_NUC (Table 1). Bottom panel: -actin control (M = molecular weight marker; T = hours after 
Tat induction). C-H) Quantitative RT PCR for HIV-Intro, HMBOX1 and GAPDH expression using the indicated primers shown 
in Figure 1 and Table 1. Each histogram is the mean of three experiments normalized for -actin expression and corrected for 























































































































































































transcripts, the number of RNAs on the transcription spot
in the presence of Tat was calculated to be 17 ± 4.
HMBOX1 expression was low and could not be detected
by a single probe. Therefore a mixture of eight oligonucle-
otides, distributed in the first and fourth exon and in the
second intron before and after the integration (Figure 1),
were designed to detect the nascent unprocessed RNA
transcripts of HMBOX1 (Table 1). As shown in figure 5A,
in parental HOS-143b two spots of equal intensity were
clearly visible in 37.2% of nuclei indicating that the
HMBOX1 gene is expressed from both alleles, but only in
a fraction of the asynchronous population of cells. This is
not surprising since there is ample variation of the
number of alleles/nucleus detected by this method,
depending on how robust is gene expression and how effi-
cient is the processing of the RNA; both contribute to the
level of RNA at the site of transcription at steady state [35].
It is however unlikely that detection was lowered by scarce
accessibility of the probe to the RNA since positive cells
showed invariably two alleles of equal intensity, where in
the case of technical problems there would be a higher
proportion of single-allele expressing cells. The same was
observed in derivative HOS_A4 cells where 36.8% of
nuclei showed biallelic expression of the HMBOX1 gene
(Figure 5C). The number of nascent RNAs present on the
transcription site at steady-state was calculated to be sig-
nificantly similar in both cell lines: 4.13 ± 1.02 for
HOS_143b and 4.11 ± 0.91 for HOS_A4 (p value = 0.18)
(Figure 6B). Most importantly, the ratio between the
intensity of the signal of the two loci was invariably close
to 1 in both cell lines demonstrating bi-allelic expression
of the HMBOX1 gene with comparable levels (Figure 6C).
Next we investigated the effect of Tat transfection. Consist-
ently with what has been observed with RT PCR analysis,
the number of Tat-transfected nuclei showing expression
of the two HMBOX1 loci decreased (Figure 6A). This dif-
ference was significant in both cell lines (p value = 1.34 ×
10-23 for HOS_143b and p value = 2.63 × 10-4 for
HOS_A4). Interestingly, in those cells where both spots
were detected, the number of RNAs and the ratio of the
HMBOX1 alleles were not affected (Figure 6B and Figure
6C). HIV transcripts instead were present in most (93%)
of Tat-EGFP transfected cells, consistent with transactiva-
tion of the viral LTR in the clonal population (Figure 7).
Interestingly, most cells that express the vector do not
show expression of HMBOX1 in both alleles, indicating
that the effect on the expression of HMBOX1 was depend-
ent on the expression of Tat and not on the transactivation
of the provirus. Even more strikingly, in 11% of Tat-EGFP
transfected nuclei both HMBOX1 alleles and the proviral
transcript were active (Figure 7). In this subset of cells the
ratio between HMBOX1 alleles was also close to 1 and the
intensity of the proviral signal comparable to that of cells
where there was no HMBOX1 expression. In fact, as
shown in figure 6D, transcription of HIV-1 was not signif-
icantly affected by allele-specific HMBOX1 transcription
(p value = 0.91). Hence, there are conditions where intra-
genic transcription of HIV-1 can occur in the presence of
transcription of the host gene.
Discussion
Integration of HIV-1 in host chromatin is a crucial event
for viral pathogenesis. Chromatin control of provirus
gene expression has been postulated to be a major deter-
minant of post-integration latency that is the cause of fail-
ure to eradicate HIV-1 infection by current antiretroviral
regimens [1-3]. In addition, development of lentiviral vec-
tors for gene therapy requires that endogenous genes
shouldn't be affected by the integration event. However,
recent evidence suggests that down-modulation of HIV-1
expression occurs also within active genes, in the absence
of a repressive chromatin context. A cell line harboring a
Tat-inducible HIV-1 vector integrated within the
HMBOX1 endogenous gene has been engineered in this
work. This allowed the detailed investigation of the recip-
rocal influence of HIV-1 and HMBOX1 expression both
with or without Tat induction.
As a result of the double selection procedure, HOS_A4
showed a basal level of HIV-1 RNA by RT PCR that could
be assigned to HMBOX1 read-through transcription
across the silent HIV-1 provirus since neither RNA was evi-
dent in FISH (Figure 5C) nor ECFPskl could be detected in
the cytoplasm (Figure 3A). Tat overexpression, while
increasing HIV-1 expression as expected, also reduced the
level of expression of HMBOX1 in both alleles. Besides its
essential role in trans-activating HIV-1 transcription, Tat is
known to regulate key host cell functions, primarily at the
level of transcription. For example, Tat down-regulates
MHC class II by preventing the interaction of cyclin T1
with the class II transactivator CIITA [36]. It is conceivable
that Tat, being able to interact with a variety of host factors
required for HIV transactivation [13,37], at the same time
pulls these factors away from specific host genes, altering
transcription from these promoters. Genome-wide
expression profiling indeed revealed that Tat overexpres-
sion resulted in down-modulation of many cellular genes,
possibly through targeting of general factors such as the
SWI/SNF chromatin remodeling complex and the p300
acetyltransferase [38,39]. Hence, HMBOX1 adds to the list
of genes being down modulated by Tat overexpression. It
is possible that during the establishment of the HOS_A4
cell line there has been a positive selection of integration
loci where Tat induced repression of transcription. If
expression of the endogenous gene interferes in cis with
the expression of the provirus, the net result of Tat induc-
tion would have been of increased LTR-driven expression
due also in part to the decrease of HMBOX1 expression.
A) FISH for HMBOX1 RNA on parental HOS_143b cellsFigure 5
A) FISH for HMBOX1 RNA on parental HOS_143b cells. Top panel: large field image (bar = 10 m). Bottom panels: 
single cell from the figure above (inset). Two distinct hybridization signals per nucleus demonstrate bi-allelic expression of the 
HMBOX1 gene. B) Same as A after transfection of Tat-EGFP. Also the signal for Tat-EGFP is shown (middle panels). Bottom 
panel: merge of HMBOX1 hybridization and Tat-EGFP expression. C) FISH for HIV-Intro RNA on HOS_A4 cells. Top panel: 
large field image (bar = 10 m). Bottom panels: single cell from the figure above (inset). Absence of the hybridization signal with 
the HIV probe is due to silencing of the gene without Tat (left panels). Two distinct hybridization signals per nucleus demon-
strate bi-allelic expression of the HMBOX1 gene (middle panels).
HMBOX1 probes DAPI
A) HOS_143b
HMBOX1 probes Tat-EGFP DAPI
EGFP/Cy3 merge
B) HOS_143b + Tat
HMBOX1 probesHIV-1 probe DAPI
C) HOS_A4
A) The number of cells expressing HMBOX1 in both loci before and after Tat-EGFP transfection is shownFigur  6
A) The number of cells expressing HMBOX1 in both loci before and after Tat-EGFP transfection is shown. B) 
The number of HMBOX1 RNAs on the transcription spots before and after Tat-EGFP transfection is shown. C) The ratio 
between the intensity of the hybridization signals on the transcription spots of the HMBOX1 alleles is shown. D) The intensity 





























































































































However, the number of HIV-1 nascent RNAs in Tat-trans-
fected HOS_A4 cells that were negative for HMBOX1
expression was similar to the number of those where
instead HMBOX1 was active (Figure 6D).
Another important finding of this work was that in some
cells expression of the endogenous HMBOX1 gene and of
the provirus coexisted at the same transcription site. This
finding could not be anticipated since it was believed that
transcriptional interference should have occurred. Tran-
scriptional interference is the suppressive influence of one
transcriptional process directly and in cis, on a second
transcriptional process [40,41]. Several combinations of
the disposition of the two transcription units produce dif-
ferent effects [42]. For example, two promoters firing in
opposite orientation would end up in collision of the two
converging transcription elongation complexes. In
HOS_A4 cells instead, the two promoters elongate in the
same direction allowing a possible transcriptional inter-
ference through occlusion of the downstream promoter.
In such model transcription from the upstream HMBOX1
promoter should transiently preclude the occupation by
RNAPII and/or associated transcription factors of the
downstream LTR promoter. Alternatively, the LTR could
pose a roadblock to the progress of the transcription-elon-
gation complex firing from the HMBOX1 promoter result-
ing in its inhibition of expression from one allele.
The observation that in the absence of Tat transcription
both HMBOX1 alleles were equally expressed while
expression from the viral LTR remained undetectable
might indicate that transcription elongation of RNAPII
across the HMBOX1 gene occluded the viral LTR. The sit-
uation changed dramatically in the presence of Tat. Tran-
scription from the viral LTR is switched on as shown in RT
PCR as well as demonstrated by the appearance of the
viral transcript in RNA FISH. As discussed previously, Tat
repressed HMBOX1 expression while allowing provirus
transcription. However, in a subset of cells, expression of
both genes coexisted. Recent data also analyzed HIV pro-
viral gene expression from within a cellular gene [43].
Work by Peterlin's group showed transcriptional interfer-
ence occurring from elongating polymerase firing from
the host gene [44], whereas work from Silicano's labora-
tory showed that elongating polymerase from the host
gene could enhance HIV transcription when orientated in
the same direction [45]. It is difficult to compare directly
these data with those presented here since different cell
lines and host cell genes were studied. However the find-
ings presented in this work show an alternative situation
that will require further analysis to understand the molec-
ular basis of the phenomenon.
Conclusion
In this work HIV-1 gene expression was studied from
within the endogenous gene HMBOX1. Transcriptional
Tat-transactivation of the viral LTR resulted in up-regula-
tion of HIV-1 transcription while it repressed HMBOX1
gene expression in both alleles, independent of vector
integration. Hence, it could be proposed that HIV-1
Table 1: Primers for RT-PCR and probes for RNA FISH used in this work.






















Modified aminoallyl thymidines in the probes are indicated with "x". The sequence of one binding site for MS2 is underlined in the HIV_MS2 probe.
FISH for HMBOX1 and HIV-Intro RNA on HOS_A4 cells after transfection of Tat-EGFPigure 7
FISH for HMBOX1 and HIV-Intro RNA on HOS_A4 cells after transfection of Tat-EGFP. Merged images are 









genome insertion in genes repressed by Tat could be an
advantage for the virus allowing its transactivation from a
low-transcribing endogenous gene. It has also been
observed that both HIV-1 and HMBOX1 gene expression
may occur at the same genomic location in the same cell,




Plasmid pHIV-Intro was derived from the plasmid
pEV731 [27] by cloning 24 MS2 repeats into the NotI
restriction site. A cassette encoding for ECFP with the per-
oxisome localization signal Ser-Lys-Leu (skl) was inserted
between the ClaI and XhoI sites, the IRES from EMCV and
the thymidine kinase from HSV-1 were cloned in the XhoI
site [46]. To obtain cells transduced by the HIV-Intro len-
tiviral vector expressing the HSV-TK gene we exploited a
protocol for negative and positive selection of TK- cells.
HEK-293T cells were transfected with the vector plasmid
pHIV-Intro together with the packaging plasmids as previ-
ously described [26]. The supernatant was filtered and
used to transduce human bone osteosarcoma TK- cells
(HOS 143b, ECACC n. 91112502). Next day cells were
treated with ganciclovir at 50 g/ml. Surviving cells were
expanded and then treated with 2.5 g/ml of GST-Tat to
induce LTR expression as described previously [34,47].
The following day cells were incubated in hypoxanthine,
aminopterin and thymidine (HAT) medium and then
cloned by colony picking and expansion in complete
DMEM medium. Colonies were visually scored for low
basal level of ECFP expression and to be highly inducible
by GST-Tat by fluorescence microscopy. The number of
integrations was assessed by southern blotting with a
probe for ECFP and the cloning of the integration sites
was obtained by inverse PCR essentially as described [26].
Briefly, genomic DNA was digested with BamHI (cleavage
site within HIV-Exo-MS2 × 24), and the resulting products
were circularized with DNA ligase. The product of two
nested PCRs performed with primers pointing outwards
from the vector was cloned and sequenced.
Plasmids expressing Tat and MS2 have been described
previously [30,48]. Tat and Rev were fused to pDsRed-
Monomer-N1 (Clontech) by PCR.
Allele-specific RT-PCR
Total RNA was extracted as described by the kit (Qiagen,
RNA easy). Reverse transcription was performed with M-
MLV RT (Invitrogen) using random primers. Amplifica-
tion of the cDNA was conducted in the presence of Cyber-
Green™ (Applied Biosystems) and monitored on
AbiPrism 7000 (Applied Biosystems). Specific primers are
shown in Table 1.
Quantitative RNA fluorescent in situ hybridization (RNA 
FISH)
In situ hybridization was performed essentially as previ-
ously described [30]. Cells were fixed with 4% PFA pH7.4
and permeabilized overnight in 70% ethanol. Formamide
concentration was 40% for HMBOX1 probes and 20% for
MS2. The amino-allyl thymidine modified oligonucle-
otide probes (Table 1) have been synthesized by J-M
Escudier (Platforme de synthèse d'Oligonucléotides mod-
ifiés de l'Interface Chimie Biologie de l'ITAV, Toulouse,
France). Probes were labeled with Cy3 or Cy5 (Cyn mono-
reactive dye, Amersham). For quantitative measurements
stacks of 21 planes were acquired at bin = 2 with steps of
0.5 m in the z-axis using a wide-field Leica DMRI
inverted microscope (63× objective, NA 1.3) controlled
by Metamorph (Universal Imaging). Digital images were
collected using a CoolSnap K CCD camera (Roper scien-
tific). The three-dimensional deconvolution and recon-
struction was performed with the ImageJ plug-in "Iterative
Deconvolve 3D". The total light intensity at the transcrip-
tion site was calculated and divided for the number of
planes and the number of molecule were computed from
a calibration curve of the probes in solution [30].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ADM and CB carried out the RT-PCR, ADM and PM car-
ried out the in situ hybridization and quantitative analysis,
AK, CV and AM prepared and characterized the cell line,
AM contributed to the experimental design and coordina-
tion of the study, data analysis, as well as to writing the
manuscript. All authors have read and approved the final
manuscript.
Acknowledgements
We thank Edouard Bertrand (IGMM, Montpellier, France) for the gift of 
reagents and useful suggestions and Gianluca Pegoraro (NIH, Bethesda, US) 
for critically reading the manuscript. This work was supported in part by a 
HFSP Young Investigators Grant, by the Italian FIRB program of the "Minis-
tero dell'Istruzione, Universita' e Ricerca" of Italy and by the AIDS Program 
of the "Istituto Superiore di Sanità" of Italy.
References
1. Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF: Experi-
mental approaches to the study of HIV-1 latency.  Nat Rev
Microbiol 2007, 5:95-106.
2. Bisgrove D, Lewinski M, Bushman F, Verdin E: Molecular mecha-
nisms of HIV-1 proviral latency.  Expert Rev Anti Infect Ther 2005,
3:805-814.
3. Marcello A: Latency: the hidden HIV-1 challenge.  Retrovirology
2006, 3:7.
4. Daniel R, Smith JA: Integration site selection by retroviral vec-
tors: molecular mechanism and clinical consequences.  Hum
Gene Ther 2008, 19:557-568.
5. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulf-
fraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E,
Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexan-
der I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D,
Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macin-
tyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH,
Le Deist F, Fischer A, Cavazzana-Calvo M: LMO2-associated
clonal T cell proliferation in two patients after gene therapy
for SCID-X1.  Science 2003, 302:415-419.
6. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-
1 integration in the human genome favors active genes and
local hotspots.  Cell 2002, 110:521-529.
7. Wu X, Li Y, Crise B, Burgess SM: Transcription start regions in
the human genome are favored targets for MLV integration.
Science 2003, 300:1749-1751.
8. Mitchell RS, Beitzel BF, Schroder AR, Shinn P, Chen H, Berry CC,
Ecker JR, Bushman FD: Retroviral DNA integration: ASLV, HIV,
and MLV show distinct target site preferences.  PLoS Biol 2004,
2:E234.
9. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P, Ecker JR,
Bushman F: A role for LEDGF/p75 in targeting HIV DNA inte-
gration.  Nat Med 2005, 11:1287-1289.
10. Wang GP, Ciuffi A, Leipzig J, Berry CC, Bushman FD: HIV integra-
tion site selection: analysis by massively parallel pyrose-
quencing reveals association with epigenetic modifications.
Genome Res 2007, 17:1186-1194.
11. De Palma M, Montini E, Santoni de Sio FR, Benedicenti F, Gentile A,
Medico E, Naldini L: Promoter trapping reveals significant dif-
ferences in integration site selection between MLV and HIV
vectors in primary hematopoietic cells.  Blood 2005,
105:2307-2315.
12. Berkhout B, Silverman RH, Jeang KT: Tat trans-activates the
human immunodeficiency virus through a nascent RNA tar-
get.  Cell 1989, 59:273-282.
13. Marcello A, Zoppe M, Giacca M: Multiple modes of transcrip-
tional regulation by the HIV-1 Tat transactivator.  IUBMB Life
2001, 51:175-181.
14. Cujec TP, Cho H, Maldonado E, Meyer J, Reinberg D, Peterlin BM:
The human immunodeficiency virus transactivator Tat
interacts with the RNA polymerase II holoenzyme.  Mol Cell
Biol 1997, 17:1817-1823.
15. Mavankal G, Ignatius Ou SH, Oliver H, Sigman D, Gaynor RB:
Human immunodeficiency virus type 1 and 2 Tat proteins
specifically interact with RNA polymerase II.  Proc Natl Acad Sci
USA 1996, 93:2089-2094.
16. Chiang CM, Roeder RG: Cloning of an intrinsic human TFIID
subunit that interacts with multiple transcriptional activa-
tors.  Science 1995, 267:531-536.
17. Blau J, Xiao H, McCracken S, O'Hare P, Greenblatt J, Bentley D:
Three functional classes of transcriptional activation
domain.  Mol Cell Biol 1996, 16:2044-2055.
18. Cujec TP, Okamoto H, Fujinaga K, Meyer J, Chamberlin H, Morgan
DO, Peterlin BM: The HIV transactivator TAT binds to the
CDK-activating kinase and activates the phosphorylation of
the carboxy-terminal domain of RNA polymerase II.  Genes
Dev 1997, 11:2645-2657.
19. Jeang KT, Chun R, Lin NH, Gatignol A, Glabe CG, Fan H: In vitro
and in vivo binding of human immunodeficiency virus type 1
Tat protein and Sp1 transcription factor.  J Virol 1993,
67:6224-6233.
20. Macian F, Rao A: Reciprocal modulatory interaction between
human immunodeficiency virus type 1 Tat and transcription
factor NFAT1.  Mol Cell Biol 1999, 19:3645-3653.
21. Marzio G, Tyagi M, Gutierrez MI, Giacca M: HIV-1 tat transactiva-
tor recruits p300 and CREB-binding protein histone acetyl-
transferases to the viral promoter.  Proc Natl Acad Sci USA 1998,
95:13519-13524.
22. Benkirane M, Chun RF, Xiao H, Ogryzko VV, Howard BH, Nakatani
Y, Jeang KT: Activation of integrated provirus requires histone
acetyltransferase. p300 and P/CAF are coactivators for HIV-
1 Tat.  J Biol Chem 1998, 273:24898-24905.
23. Hottiger MO, Nabel GJ: Interaction of human immunodefi-
ciency virus type 1 Tat with the transcriptional coactivators
p300 and CREB binding protein.  J Virol 1998, 72:8252-8256.
24. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA: A novel CDK9-
associated C-type cyclin interacts directly with HIV-1 Tat
and mediates its high-affinity, loop-specific binding to TAR
RNA.  Cell 1998, 92:451-462.
25. Marcello A, Lusic M, Pegoraro G, Pellegrini V, Beltram F, Giacca M:
Nuclear organization and the control of HIV-1 transcription.
Gene 2004, 326:1-11.
26. Jordan A, Bisgrove D, Verdin E: HIV reproducibly establishes a
latent infection after acute infection of T cells in vitro.  Embo
J 2003, 22:1868-1877.
27. Jordan A, Defechereux P, Verdin E: The site of HIV-1 integration
in the human genome determines basal transcriptional
activity and response to Tat transactivation.  Embo J 2001,
20:1726-1738.
28. Lewinski MK, Bisgrove D, Shinn P, Chen H, Hoffmann C, Hannenhalli
S, Verdin E, Berry CC, Ecker JR, Bushman FD: Genome-wide anal-
ysis of chromosomal features repressing human immunode-
ficiency virus transcription.  J Virol 2005, 79:6610-6619.
29. Han Y, Lassen K, Monie D, Sedaghat AR, Shimoji S, Liu X, Pierson TC,
Margolick JB, Siliciano RF, Siliciano JD: Resting CD4+ T cells from
human immunodeficiency virus type 1 (HIV-1)-infected indi-
viduals carry integrated HIV-1 genomes within actively tran-
scribed host genes.  J Virol 2004, 78:6122-6133.
30. Boireau S, Maiuri P, Basyuk E, de la Mata M, Knezevich A, Pradet-
Balade B, Backer V, Kornblihtt A, Marcello A, Bertrand E: The tran-
scriptional cycle of HIV-1 in real-time and live cells.  J Cell Biol
2007, 179:291-304.
31. Darzacq X, Shav-Tal Y, de Turris V, Brody Y, Shenoy SM, Phair RD,
Singer RH: In vivo dynamics of RNA polymerase II transcrip-
tion.  Nat Struct Mol Biol 2007, 14:796-806.
32. Binnie A, Castelo-Branco P, Monks J, Proudfoot NJ: Homologous
gene sequences mediate transcription-domain formation.  J
Cell Sci 2006, 119:3876-3887.
33. Chen S, Saiyin H, Zeng X, Xi J, Liu X, Li X, Yu L: Isolation and func-
tional analysis of human HMBOX1, a homeobox containing
protein with transcriptional repressor activity.  Cytogenet
Genome Res 2006, 114:131-136.
34. Lusic M, Marcello A, Cereseto A, Giacca M: Regulation of HIV-1
gene expression by histone acetylation and factor recruit-
ment at the LTR promoter.  Embo J 2003, 22:6550-6561.
35. Levsky JM, Shenoy SM, Pezo RC, Singer RH: Single-cell gene
expression profiling.  Science 2002, 297:836-840.
36. Kanazawa S, Okamoto T, Peterlin BM: Tat competes with CIITA
for the binding to P-TEFb and blocks the expression of MHC
class II genes in HIV infection.  Immunity 2000, 12:61-70.
37. Jeang KT, Xiao H, Rich EA: Multifaceted activities of the HIV-1
transactivator of transcription, Tat.  J Biol Chem 1999,
274:28837-28840.
38. de la Fuente C, Santiago F, Deng L, Eadie C, Zilberman I, Kehn K, Mad-
dukuri A, Baylor S, Wu K, Lee CG, Pumfery A, Kashanchi F: Gene
expression profile of HIV-1 Tat expressing cells: a close
interplay between proliferative and differentiation signals.
BMC Biochem 2002, 3:14.
39. Gibellini D, Re MC, La Placa M, Zauli G: Differentially expressed
genes in HIV-1 tat-expressing CD4(+) T-cell line.  Virus Res
2002, 90:337-345.
40. Mazo A, Hodgson JW, Petruk S, Sedkov Y, Brock HW: Transcrip-
tional interference: an unexpected layer of complexity in
gene regulation.  J Cell Sci 2007, 120:2755-2761.
41. Shearwin KE, Callen BP, Egan JB: Transcriptional interference – a
crash course.  Trends Genet 2005, 21:339-345.
42. Eszterhas SK, Bouhassira EE, Martin DI, Fiering S: Transcriptional
interference by independently regulated genes occurs in any
relative arrangement of the genes and is influenced by chro-
mosomal integration position.  Mol Cell Biol 2002, 22:469-479.
43. Perkins KJ, Proudfoot NJ: An ungracious host for an unwelcome
guest.  Cell Host Microbe 2008, 4:89-91.
44. Lenasi T, Contreras X, Peterlin BM: Transcriptional interference
antagonizes proviral gene expression to promote HIV
latency.  Cell Host Microbe 2008, 4:123-133.
45. Han Y, Lin YB, An W, Xu J, Yang HC, O'Connell K, Dordai D, Boeke
JD, Siliciano JD, Siliciano RF: Orientation-dependent regulation
of integrated HIV-1 expression by host gene transcriptional
readthrough.  Cell Host Microbe 2008, 4:134-146.
46. Marcello A, Giaretta I: Inducible expression of herpes simplex
virus thymidine kinase from a bicistronic HIV1 vector.  Res
Virol 1998, 149:419-431.
47. du Chéné I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia
C, Mettling C, Baillat V, Reynes J, Corbeau P, Bertrand E, Marcello A,
Emiliani S, Kiernan R, Benkirane M: Suv39H1 and HP1gamma are
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
responsible for chromatin-mediated HIV-1 transcriptional
silencing and post-integration latency.  Embo J 2007,
26:424-435.
48. Marcello A, Cinelli RA, Ferrari A, Signorelli A, Tyagi M, Pellegrini V,
Beltram F, Giacca M: Visualization of in vivo direct interaction
between HIV-1 TAT and human cyclin T1 in specific subcel-
lular compartments by fluorescence resonance energy
transfer.  J Biol Chem 2001, 276:39220-39225.
